data_2n3p_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2n3p _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.9 p . . . . . 0 N--CA 1.466 0.333 0 CA-C-O 120.699 0.285 . . . . 0.0 111.455 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.585 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.46 120.92 26.5 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.633 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.73 -156.65 0.42 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.565 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.06 112.87 18.83 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 122.68 0.392 . . . . 0.0 111.363 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.38 9.12 39.45 Favored Glycine 0 C--N 1.334 0.472 0 CA-C-N 115.417 -0.811 . . . . 0.0 112.672 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.54 159.8 21.57 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 122.625 0.37 . . . . 0.0 110.519 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.1 p -80.97 135.19 35.83 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.586 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.414 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.69 36.18 2.62 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.2 -11.5 52.3 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.798 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.405 HG11 ' N ' ' A' ' 13' ' ' TYR . 11.8 p -124.03 -38.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 O-C-N 123.423 0.452 . . . . 0.0 110.135 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.405 ' N ' HG11 ' A' ' 12' ' ' VAL . 27.1 m-85 -132.81 152.29 79.6 Favored Pre-proline 0 CA--C 1.538 0.515 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.422 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.14 -168.42 0.29 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.541 2.827 . . . . 0.0 112.85 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.9 m -83.93 175.84 9.3 Favored 'General case' 0 CA--C 1.538 0.481 0 O-C-N 123.156 0.285 . . . . 0.0 110.547 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.0 m -117.75 -55.88 2.24 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.53 12.62 6.66 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -178.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.83 35.83 7.57 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.359 -0.448 . . . . 0.0 112.41 -179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.42 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.4 mt -81.95 171.54 14.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.134 0.574 . . . . 0.0 111.197 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -117.08 144.07 25.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.456 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 m -80.8 102.1 9.78 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.32 178.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.6 m-85 -79.99 140.97 54.17 Favored Pre-proline 0 N--CA 1.456 -0.163 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.36 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.91 64.41 1.89 Allowed 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 122.957 2.438 . . . . 0.0 112.098 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.0 p -95.19 150.98 19.62 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.937 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.26 144.09 28.26 Favored Pre-proline 0 C--O 1.234 0.25 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.738 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.566 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.76 -35.17 2.97 Favored 'Cis proline' 0 C--N 1.366 1.487 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.226 0.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.566 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.66 144.96 31.32 Favored Pre-proline 0 CA--C 1.542 0.654 0 O-C-N 123.258 0.348 . . . . 0.0 111.194 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.25 157.54 53.47 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.784 2.323 . . . . 0.0 113.374 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.4 mm -124.06 152.88 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.979 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.414 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.83 118.85 28.83 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.788 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.42 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -152.88 145.62 13.31 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 116.195 -0.457 . . . . 0.0 113.368 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.448 -0.787 . . . . 0.0 111.046 179.503 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.5 p . . . . . 0 N--CA 1.466 0.331 0 CA-C-O 120.665 0.269 . . . . 0.0 111.536 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.591 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.75 120.69 26.34 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.647 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.64 -156.8 0.42 Allowed 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.54 -178.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -80.82 112.85 18.59 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.682 0.393 . . . . 0.0 111.407 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.42 9.06 39.5 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.585 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.5 159.71 21.67 Favored 'General case' 0 C--O 1.235 0.301 0 C-N-CA 122.592 0.357 . . . . 0.0 110.438 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.8 p -80.88 135.27 35.89 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.555 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.416 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.96 36.43 2.57 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.863 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.25 -11.77 51.43 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.868 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.406 HG13 ' N ' ' A' ' 13' ' ' TYR . 12.7 p -123.95 -38.46 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 123.384 0.428 . . . . 0.0 110.234 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.406 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.5 m-85 -132.6 152.46 80.0 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.396 179.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.19 -168.57 0.3 Allowed 'Trans proline' 0 C--N 1.367 1.545 0 C-N-CA 123.507 2.805 . . . . 0.0 112.937 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.591 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.1 m -83.75 175.9 9.34 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 123.148 0.28 . . . . 0.0 110.567 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.1 m -117.65 -55.9 2.25 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.913 0.709 . . . . 0.0 112.913 -178.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.59 12.58 6.81 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 -178.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.77 36.03 7.51 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 121.449 -0.405 . . . . 0.0 112.337 -179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.419 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.4 mt -81.99 171.38 14.47 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.19 0.596 . . . . 0.0 111.196 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.86 144.16 25.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.484 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.5 m -80.94 102.13 9.92 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.382 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -79.99 140.9 54.1 Favored Pre-proline 0 CA--C 1.529 0.165 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.39 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 64.45 1.85 Allowed 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.961 2.44 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.51 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.7 p -95.27 151.14 19.5 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.893 -178.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.46 144.05 28.22 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.769 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.565 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.77 -35.17 2.98 Favored 'Cis proline' 0 C--N 1.367 1.506 0 C-N-CA 124.085 -1.214 . . . . 0.0 113.253 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.565 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.69 144.92 31.25 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.291 0.37 . . . . 0.0 111.217 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -64.1 157.34 53.9 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.904 2.403 . . . . 0.0 113.343 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.51 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.2 mm -123.92 152.88 29.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.068 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.416 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.81 118.92 28.85 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.781 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.419 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -152.75 145.66 13.43 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 116.109 -0.496 . . . . 0.0 113.3 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.078 -0.963 . . . . 0.0 111.055 179.446 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.1 p . . . . . 0 N--CA 1.467 0.38 0 CA-C-O 120.74 0.305 . . . . 0.0 111.46 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.98 119.79 25.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.81 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.77 -156.28 0.38 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.456 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.34 112.77 18.94 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 122.597 0.359 . . . . 0.0 111.375 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.98 8.15 39.82 Favored Glycine 0 CA--C 1.522 0.488 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.637 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.75 159.58 21.24 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 122.604 0.362 . . . . 0.0 110.562 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.0 p -80.02 131.21 35.74 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.787 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.542 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -100.6 29.83 4.26 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.911 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.39 -10.48 56.2 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.741 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.401 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.5 p -121.96 -37.68 1.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.006 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.401 ' N ' HG13 ' A' ' 12' ' ' VAL . 25.1 m-85 -137.05 152.87 74.65 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.19 179.398 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.39 -172.72 0.56 Allowed 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 123.313 2.676 . . . . 0.0 112.757 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 48.4 m -80.9 175.41 10.71 Favored 'General case' 0 CA--C 1.539 0.526 0 O-C-N 123.026 0.204 . . . . 0.0 110.472 179.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 34.8 m -117.2 -56.01 2.28 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.91 13.07 6.35 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.18 36.7 7.47 Favored Glycine 0 C--N 1.34 0.769 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.418 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.423 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.6 mt -82.24 170.41 15.45 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.157 0.583 . . . . 0.0 111.222 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -115.48 144.44 23.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.588 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.8 m -80.87 102.74 10.25 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.276 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -80.78 140.61 50.87 Favored Pre-proline 0 CA--C 1.53 0.184 0 CA-C-N 115.296 -0.866 . . . . 0.0 111.439 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.73 64.61 1.78 Allowed 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.885 2.39 . . . . 0.0 112.175 179.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.8 p -95.31 152.33 18.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.983 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.29 144.26 28.83 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.64 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.542 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.6 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.476 0 C-N-CA 124.152 -1.187 . . . . 0.0 113.273 -0.078 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.542 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.93 145.38 32.29 Favored Pre-proline 0 CA--C 1.541 0.599 0 O-C-N 123.365 0.416 . . . . 0.0 111.203 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -63.67 156.96 54.26 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 122.884 2.389 . . . . 0.0 113.428 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.2 mm -123.12 153.46 28.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.979 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.542 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.37 119.16 29.59 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.792 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.423 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -153.44 145.78 13.52 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.261 -0.495 . . . . 0.0 113.256 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.127 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.134 179.386 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.4 p . . . . . 0 C--O 1.235 0.317 0 CA-C-O 120.677 0.275 . . . . 0.0 111.506 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.589 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.86 119.94 25.91 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.844 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.46 -156.43 0.4 Allowed 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.418 -178.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.2 112.42 18.51 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.687 0.395 . . . . 0.0 111.233 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.88 36.8 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -116.94 158.95 23.2 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.646 0.379 . . . . 0.0 110.582 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.4 p -80.13 131.75 35.8 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.855 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.564 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.5 p -100.76 31.11 3.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.89 179.758 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.411 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.26 -11.54 52.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.781 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.411 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.4 -37.77 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.134 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.407 ' N ' HG11 ' A' ' 12' ' ' VAL . 25.8 m-85 -136.6 152.97 75.59 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.13 179.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -69.35 -172.31 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.561 0 C-N-CA 123.345 2.696 . . . . 0.0 112.646 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 54.6 m -81.46 174.93 10.98 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 123.017 0.198 . . . . 0.0 110.487 179.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.5 m -115.87 -55.59 2.4 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -84.64 11.81 8.26 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.67 35.29 7.91 Favored Glycine 0 C--N 1.339 0.732 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.348 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.426 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.5 mt -80.01 166.95 21.06 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.164 0.586 . . . . 0.0 111.488 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.34 144.41 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.188 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.7 m -82.27 104.03 12.29 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.241 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -80.85 140.27 50.47 Favored Pre-proline 0 CA--C 1.53 0.19 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.13 65.16 2.02 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 122.904 2.402 . . . . 0.0 112.103 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.49 151.62 19.14 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.798 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.22 144.31 28.71 Favored Pre-proline 0 CA--C 1.532 0.282 0 O-C-N 123.511 0.507 . . . . 0.0 111.626 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -32.01 4.77 Favored 'Cis proline' 0 C--N 1.367 1.53 0 C-N-CA 124.13 -1.196 . . . . 0.0 113.179 0.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -113.98 144.33 31.34 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.025 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo -63.45 157.41 50.85 Favored 'Trans proline' 0 C--N 1.375 1.97 0 C-N-CA 123.0 2.467 . . . . 0.0 113.803 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.73 154.4 27.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.92 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.564 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.54 119.26 30.66 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.851 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.426 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.68 144.28 10.95 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.112 -0.495 . . . . 0.0 113.003 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.251 1.145 0 CA-C-O 118.474 -0.774 . . . . 0.0 111.244 179.558 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.7 p . . . . . 0 N--CA 1.466 0.328 0 CA-C-O 120.821 0.344 . . . . 0.0 111.524 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.607 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.36 116.84 24.78 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.826 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . 0.545 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.67 -154.46 0.29 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.155 -179.269 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -79.83 106.44 11.86 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.973 0.416 . . . . 0.0 111.053 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.55 9.98 24.19 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.326 -0.852 . . . . 0.0 112.407 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.545 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.9 mt-10 -112.34 156.48 22.38 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.608 0.363 . . . . 0.0 110.525 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -82.64 128.5 34.39 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.889 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.532 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.6 p -96.77 33.33 1.88 Allowed 'General case' 0 C--O 1.238 0.486 0 CA-C-O 121.295 0.569 . . . . 0.0 110.9 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.403 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -89.85 -10.83 43.88 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.407 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.416 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.8 p -123.9 -39.12 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.031 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.418 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 25.6 m-85 -134.86 152.63 77.76 Favored Pre-proline 0 CA--C 1.538 0.494 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.177 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.55 -171.76 0.49 Allowed 'Trans proline' 0 C--N 1.367 1.544 0 C-N-CA 123.308 2.672 . . . . 0.0 112.689 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.607 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.4 m -81.87 174.84 10.92 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 110.324 -0.25 . . . . 0.0 110.324 178.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 40.9 m -114.29 -55.28 2.51 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 -178.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.45 12.2 10.79 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.82 36.86 7.59 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.514 -0.374 . . . . 0.0 112.263 -179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.434 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 3.1 mt -79.96 166.85 21.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 123.254 0.622 . . . . 0.0 111.597 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.8 mt -107.7 144.85 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.195 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.9 m -82.52 104.65 12.96 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.162 178.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -81.25 139.93 48.87 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.554 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.1 65.24 2.0 Allowed 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.929 2.42 . . . . 0.0 112.079 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.505 ' OG1' HG12 ' A' ' 29' ' ' ILE . 43.8 p -95.53 151.73 19.05 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.875 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.39 144.3 28.72 Favored Pre-proline 0 CA--C 1.532 0.269 0 O-C-N 123.57 0.544 . . . . 0.0 111.563 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.58 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.367 1.519 0 C-N-CA 124.145 -1.189 . . . . 0.0 113.166 0.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -113.73 144.07 30.73 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.145 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -63.46 157.23 51.88 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.048 2.499 . . . . 0.0 113.717 -179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.505 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.9 mm -122.38 154.39 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.904 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -90.67 119.39 30.87 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.791 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.434 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.77 144.65 11.17 Favored Glycine 0 C--N 1.338 0.675 0 CA-C-N 116.101 -0.5 . . . . 0.0 113.044 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.079 -0.962 . . . . 0.0 111.199 179.564 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.0 p . . . . . 0 N--CA 1.465 0.298 0 CA-C-O 120.726 0.298 . . . . 0.0 111.476 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.599 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.79 119.03 24.84 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.8 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -88.24 -155.96 0.34 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.466 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.55 112.99 19.28 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 122.708 0.403 . . . . 0.0 111.256 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.26 7.1 41.08 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-N 115.528 -0.76 . . . . 0.0 112.733 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.12 159.25 21.1 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.561 0.345 . . . . 0.0 110.504 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 54.7 p -79.94 131.63 35.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.843 -179.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.555 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -100.73 31.23 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.865 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.407 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.58 -11.46 51.44 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.759 179.982 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.407 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.24 -37.68 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.051 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.404 ' N ' HG12 ' A' ' 12' ' ' VAL . 25.0 m-85 -136.76 153.1 75.46 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.123 179.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.53 -172.1 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.572 0 C-N-CA 123.295 2.663 . . . . 0.0 112.539 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.599 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.6 m -81.52 175.14 10.78 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 110.49 -0.189 . . . . 0.0 110.49 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.4 m -115.85 -55.3 2.43 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.21 12.36 8.14 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.15 35.36 8.16 Favored Glycine 0 C--N 1.339 0.748 0 C-N-CA 121.516 -0.374 . . . . 0.0 112.383 -179.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.431 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.5 mt -79.91 167.0 21.07 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.231 0.612 . . . . 0.0 111.576 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.46 144.33 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.268 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.8 m -82.09 104.03 12.14 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.253 178.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -81.3 140.43 48.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.501 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -70.26 64.83 2.1 Favored 'Trans proline' 0 C--N 1.364 1.393 0 C-N-CA 122.999 2.466 . . . . 0.0 112.054 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.4 p -95.31 152.52 18.31 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.897 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.52 144.18 28.72 Favored Pre-proline 0 C--O 1.236 0.374 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.565 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.3 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.485 0 C-N-CA 124.064 -1.223 . . . . 0.0 113.238 -0.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.02 145.37 32.3 Favored Pre-proline 0 CA--C 1.542 0.661 0 O-C-N 123.29 0.369 . . . . 0.0 111.197 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -63.67 156.79 55.24 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.943 2.429 . . . . 0.0 113.419 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.8 mm -122.52 153.79 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.96 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.555 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -89.92 119.16 30.05 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.939 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.431 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.35 144.04 10.73 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.985 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.073 -0.965 . . . . 0.0 111.127 179.571 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p . . . . . 0 C--O 1.235 0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.385 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.622 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.89 116.48 24.16 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.878 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . 0.544 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.14 -154.32 0.27 Allowed 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.181 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -79.82 106.86 12.15 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.082 0.468 . . . . 0.0 111.187 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.74 9.9 25.82 Favored Glycine 0 C--N 1.336 0.541 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.55 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.544 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.0 mt-10 -111.72 156.8 21.32 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 122.649 0.379 . . . . 0.0 110.499 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.4 p -82.88 132.05 35.17 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.752 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.418 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.2 p -102.05 38.1 1.72 Allowed 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.58 0.55 . . . . 0.0 111.18 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -91.46 -11.0 38.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.38 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 13' ' ' TYR . 11.9 p -124.72 -39.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.934 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.411 ' N ' HG12 ' A' ' 12' ' ' VAL . 27.2 m-85 -132.16 152.01 79.39 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 123.538 0.524 . . . . 0.0 111.51 179.367 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.5 -169.07 0.34 Allowed 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.577 2.851 . . . . 0.0 112.75 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.622 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 49.4 m -83.53 175.13 10.01 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 123.119 0.262 . . . . 0.0 110.376 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.9 m -114.84 -55.26 2.5 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.102 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 12.36 9.9 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.96 36.14 7.87 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 121.422 -0.418 . . . . 0.0 112.39 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.436 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.9 mt -79.93 168.13 19.62 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.331 0.653 . . . . 0.0 111.541 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -109.85 144.66 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.224 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.1 m -82.37 103.86 12.24 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.173 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -80.69 140.46 51.18 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.492 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -70.37 64.84 2.16 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.924 2.416 . . . . 0.0 111.978 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.509 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.5 p -95.0 150.43 20.17 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.963 -178.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -105.46 144.19 28.32 Favored Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.589 0.555 . . . . 0.0 111.724 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.87 -31.4 5.16 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.219 0.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -113.7 143.9 30.39 Favored Pre-proline 0 CA--C 1.541 0.621 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.199 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.09 157.59 52.53 Favored 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 123.016 2.477 . . . . 0.0 113.514 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.509 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.97 154.09 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.973 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.418 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.0 m -90.08 119.02 30.06 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.436 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.91 144.68 11.37 Favored Glycine 0 C--N 1.337 0.599 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.013 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.405 ' N ' HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.452 -0.785 . . . . 0.0 111.122 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.3 p . . . . . 0 N--CA 1.467 0.389 0 CA-C-O 120.667 0.27 . . . . 0.0 111.621 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.6 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.69 118.52 24.46 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.789 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.23 -156.78 0.38 Allowed 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.406 -178.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -80.74 112.03 17.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.641 0.376 . . . . 0.0 111.387 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.94 8.14 37.15 Favored Glycine 0 C--N 1.334 0.471 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.62 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -115.98 158.69 22.69 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 122.623 0.369 . . . . 0.0 110.535 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.0 p -80.11 131.67 35.79 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.808 -179.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.6 p -100.6 31.13 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.893 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.3 -11.38 52.37 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.749 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 13' ' ' TYR . 14.5 p -121.6 -38.08 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.137 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.409 ' N ' HG12 ' A' ' 12' ' ' VAL . 25.0 m-85 -136.2 152.86 76.04 Favored Pre-proline 0 CA--C 1.538 0.481 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.145 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.07 -172.04 0.47 Allowed 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 123.349 2.699 . . . . 0.0 112.605 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.6 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -81.64 175.78 10.2 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 123.123 0.264 . . . . 0.0 110.406 178.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 42.3 m -114.9 -55.99 2.42 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.425 ' OD2' HD13 ' A' ' 19' ' ' LEU . 3.3 p30 -87.47 13.18 10.55 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.87 35.98 6.97 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.395 -0.431 . . . . 0.0 112.625 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.43 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.8 mt -80.19 166.36 21.51 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.018 0.527 . . . . 0.0 111.447 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.86 143.96 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.223 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.5 m -82.13 103.55 11.82 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.238 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.8 m-85 -80.19 140.33 53.06 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.509 -179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 65.01 2.07 Favored 'Trans proline' 0 C--N 1.365 1.424 0 C-N-CA 123.055 2.503 . . . . 0.0 112.142 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.33 151.55 19.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.894 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.65 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.56 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.366 1.477 0 C-N-CA 124.055 -1.227 . . . . 0.0 113.088 0.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -113.87 144.24 31.12 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.09 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -63.34 157.62 49.28 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.023 2.482 . . . . 0.0 113.751 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.96 153.93 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.902 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.15 119.25 30.32 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.883 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.43 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.9 143.93 10.51 Favored Glycine 0 C--N 1.339 0.695 0 CA-C-N 116.071 -0.513 . . . . 0.0 113.088 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.135 -0.936 . . . . 0.0 111.142 179.567 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.467 0.392 0 CA-C-O 120.712 0.291 . . . . 0.0 111.468 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.59 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.67 120.25 26.17 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.742 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.68 -156.34 0.4 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.389 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.23 112.6 18.71 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.897 0.379 . . . . 0.0 111.373 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.31 8.8 37.63 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.566 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -116.97 158.97 23.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 122.622 0.369 . . . . 0.0 110.524 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.4 p -80.03 131.94 35.89 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.819 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.563 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -100.96 31.16 3.71 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.854 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.41 -11.21 52.57 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.721 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 13' ' ' TYR . 14.6 p -121.52 -37.89 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.07 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.406 ' N ' HG12 ' A' ' 12' ' ' VAL . 25.8 m-85 -136.72 152.95 75.36 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.179 179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.23 -172.17 0.5 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 123.342 2.695 . . . . 0.0 112.574 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.59 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -81.61 175.15 10.73 Favored 'General case' 0 CA--C 1.539 0.535 0 O-C-N 123.044 0.215 . . . . 0.0 110.449 179.075 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.8 m -116.02 -55.43 2.41 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -177.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -85.11 12.87 6.96 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -178.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.33 8.73 Favored Glycine 0 C--N 1.341 0.851 0 C-N-CA 121.478 -0.392 . . . . 0.0 112.413 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.427 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.5 mt -79.98 166.77 21.26 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.22 0.608 . . . . 0.0 111.484 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.09 144.36 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.239 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.5 m -82.3 103.93 12.24 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.5 m-85 -80.76 140.28 50.8 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.46 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.17 65.07 2.05 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.94 2.427 . . . . 0.0 112.056 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.41 151.49 19.23 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.878 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.339 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.746 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.52 -32.28 4.6 Favored 'Cis proline' 0 C--N 1.366 1.475 0 C-N-CA 124.046 -1.231 . . . . 0.0 113.142 0.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.76 144.23 31.05 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.43 157.42 50.73 Favored 'Trans proline' 0 C--N 1.375 1.931 0 C-N-CA 123.004 2.47 . . . . 0.0 113.809 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.7 mm -122.81 154.33 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.857 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.563 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -90.59 119.36 30.78 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.877 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.427 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.76 144.01 10.63 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 116.041 -0.527 . . . . 0.0 113.014 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.424 -0.798 . . . . 0.0 111.23 179.572 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p . . . . . 0 C--O 1.235 0.332 0 CA-C-O 120.691 0.281 . . . . 0.0 111.46 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.615 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.19 119.95 25.63 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.71 179.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -89.14 -156.3 0.39 Allowed 'General case' 0 CA--C 1.544 0.713 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.665 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -81.21 113.04 19.08 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 122.651 0.38 . . . . 0.0 111.384 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.76 8.36 40.01 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.334 -0.848 . . . . 0.0 112.604 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -116.16 159.67 21.45 Favored 'General case' 0 C--O 1.236 0.395 0 C-N-CA 122.493 0.317 . . . . 0.0 110.555 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.8 p -81.02 134.74 35.73 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.702 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.449 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -105.41 37.41 2.21 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.758 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -87.31 -13.36 43.83 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.885 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.409 HG13 ' N ' ' A' ' 13' ' ' TYR . 12.1 p -122.43 -38.43 1.37 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 O-C-N 123.506 0.504 . . . . 0.0 110.111 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.409 ' N ' HG13 ' A' ' 12' ' ' VAL . 26.4 m-85 -132.26 152.42 80.08 Favored Pre-proline 0 CA--C 1.538 0.511 0 O-C-N 123.609 0.568 . . . . 0.0 111.462 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.21 -168.35 0.29 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 123.426 2.751 . . . . 0.0 112.777 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.615 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -84.09 175.6 9.39 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 123.048 0.218 . . . . 0.0 110.502 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.9 m -116.53 -55.34 2.38 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -178.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -84.77 12.26 7.62 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.5 34.74 8.34 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.461 -0.399 . . . . 0.0 112.359 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.429 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.4 mt -80.04 167.79 19.98 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.223 0.609 . . . . 0.0 111.426 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.91 144.21 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.252 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.9 m -82.22 103.26 11.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.166 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.9 m-85 -80.34 140.83 52.69 Favored Pre-proline 0 CA--C 1.53 0.195 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.511 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.33 64.58 2.14 Favored 'Trans proline' 0 C--N 1.364 1.389 0 C-N-CA 122.955 2.437 . . . . 0.0 111.997 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.514 ' OG1' HG12 ' A' ' 29' ' ' ILE . 47.7 p -95.02 151.65 18.99 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.964 -178.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.76 143.95 28.09 Favored Pre-proline 0 C--O 1.234 0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.674 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -76.36 -36.61 2.44 Favored 'Cis proline' 0 C--N 1.365 1.435 0 C-N-CA 124.079 -1.217 . . . . 0.0 113.162 0.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -109.67 145.91 32.94 Favored Pre-proline 0 CA--C 1.54 0.559 0 O-C-N 123.342 0.401 . . . . 0.0 111.131 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -64.47 157.64 53.84 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.842 2.362 . . . . 0.0 113.351 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.514 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.1 mm -123.71 153.55 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.969 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.449 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.54 118.95 29.55 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.929 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.429 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -153.8 144.1 10.89 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 116.042 -0.526 . . . . 0.0 113.092 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.19 179.597 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.47 0.527 0 CA-C-O 120.707 0.289 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.78 120.16 27.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.524 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.08 -156.12 0.38 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.526 -178.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.12 113.49 19.32 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.78 0.432 . . . . 0.0 111.242 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.82 7.23 42.1 Favored Glycine 0 C--N 1.334 0.419 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.588 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.72 159.31 20.69 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.741 0.416 . . . . 0.0 110.579 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 65.1 p -79.98 131.44 35.81 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.781 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.47 28.7 5.3 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.971 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.4 -12.18 56.75 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.705 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.449 HG12 ' N ' ' A' ' 13' ' ' TYR . 14.5 p -121.35 -41.06 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.348 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.449 ' N ' HG12 ' A' ' 12' ' ' VAL . 22.5 m-85 -130.26 153.53 81.24 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.306 179.584 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.7 -174.71 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.202 2.601 . . . . 0.0 112.42 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.07 175.22 10.83 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 110.53 -0.174 . . . . 0.0 110.53 179.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.5 m -115.15 -54.88 2.52 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.31 12.95 8.9 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.68 8.65 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.415 -0.421 . . . . 0.0 112.366 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.435 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.7 mt -79.93 166.56 21.51 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.265 0.626 . . . . 0.0 111.565 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.6 144.29 17.37 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.155 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.8 m -82.21 103.98 12.2 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.214 178.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.64 140.18 51.23 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.535 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.33 65.23 2.14 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.965 2.443 . . . . 0.0 112.093 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.29 152.9 17.97 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.963 -178.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -107.05 144.23 28.7 Favored Pre-proline 0 C--O 1.236 0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.73 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.42 -32.05 4.77 Favored 'Cis proline' 0 C--N 1.365 1.419 0 C-N-CA 124.084 -1.215 . . . . 0.0 113.196 0.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.27 144.49 31.8 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.089 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -63.21 157.52 49.27 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 123.02 2.48 . . . . 0.0 113.75 -179.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.89 154.38 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.864 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.42 119.5 30.76 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.948 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.435 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.44 144.32 10.86 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 116.083 -0.508 . . . . 0.0 113.117 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.065 -0.969 . . . . 0.0 111.108 179.633 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.7 p . . . . . 0 N--CA 1.471 0.584 0 CA-C-O 120.681 0.277 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.565 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.9 120.03 27.74 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.0 -156.11 0.37 Allowed 'General case' 0 CA--C 1.543 0.696 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.533 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.09 113.47 19.29 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.986 0.422 . . . . 0.0 111.238 -179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.04 6.94 41.99 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.546 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.56 159.39 20.47 Favored 'General case' 0 C--O 1.234 0.275 0 C-N-CA 122.547 0.339 . . . . 0.0 110.481 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.2 p -79.94 131.27 35.79 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.811 -179.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.567 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.11 28.62 5.2 Favored 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.969 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.423 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.59 -12.1 56.5 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.661 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.4 p -121.38 -41.31 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.217 -179.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.452 ' N ' HG13 ' A' ' 12' ' ' VAL . 22.5 m-85 -130.26 153.44 81.23 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.326 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.62 -174.82 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.472 0 C-N-CA 123.202 2.601 . . . . 0.0 112.348 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.565 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -79.87 175.28 10.77 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -115.16 -54.86 2.52 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -178.019 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.55 13.08 9.05 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.26 35.88 8.53 Favored Glycine 0 C--N 1.34 0.764 0 C-N-CA 121.495 -0.384 . . . . 0.0 112.293 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.436 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.8 mt -79.97 166.58 21.45 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.159 0.584 . . . . 0.0 111.649 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -108.4 144.36 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.141 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.2 m -82.24 103.89 12.16 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -80.38 140.13 52.22 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.538 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.24 65.22 2.09 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.05 2.5 . . . . 0.0 112.079 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.36 152.74 18.13 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.889 -178.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -107.0 144.23 28.68 Favored Pre-proline 0 C--O 1.234 0.268 0 O-C-N 123.541 0.526 . . . . 0.0 111.683 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.55 -31.93 4.84 Favored 'Cis proline' 0 C--N 1.367 1.505 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.22 0.06 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.15 144.6 31.95 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.525 0.516 . . . . 0.0 111.127 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -63.28 157.53 49.53 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.962 2.441 . . . . 0.0 113.793 -179.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.83 154.31 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.871 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.567 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.31 119.44 30.61 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.91 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.436 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.56 144.36 10.88 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 116.114 -0.494 . . . . 0.0 113.016 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.126 -0.94 . . . . 0.0 111.257 179.512 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.469 0.505 0 CA-C-O 120.666 0.27 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.56 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.92 120.37 28.12 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.465 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.26 -155.96 0.37 Allowed 'General case' 0 CA--C 1.545 0.768 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.622 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.37 113.65 19.6 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.312 0.382 . . . . 0.0 111.225 -179.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.78 7.31 42.06 Favored Glycine 0 CA--C 1.521 0.453 0 CA-C-N 115.378 -0.828 . . . . 0.0 112.511 -179.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -114.95 159.51 20.65 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 122.62 0.368 . . . . 0.0 110.526 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.4 p -80.1 131.44 35.75 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.804 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.41 28.66 5.31 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.033 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.427 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.43 -12.05 56.84 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.712 179.971 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.446 HG12 ' N ' ' A' ' 13' ' ' TYR . 14.4 p -121.46 -41.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 O-C-N 123.583 0.552 . . . . 0.0 110.298 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.446 ' N ' HG12 ' A' ' 12' ' ' VAL . 22.6 m-85 -130.41 153.45 81.34 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 179.683 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -70.69 -174.65 1.14 Allowed 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 123.188 2.592 . . . . 0.0 112.357 179.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.56 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.06 175.21 10.84 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.6 m -115.29 -54.84 2.51 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 112.906 0.706 . . . . 0.0 112.906 -178.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -86.11 12.73 9.01 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.62 8.56 Favored Glycine 0 C--N 1.34 0.792 0 C-N-CA 121.517 -0.373 . . . . 0.0 112.291 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.433 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.7 mt -79.9 166.61 21.48 Favored 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 123.254 0.621 . . . . 0.0 111.51 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.57 144.42 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.175 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.6 m -82.38 103.97 12.34 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.155 178.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -80.68 140.17 51.08 Favored Pre-proline 0 CA--C 1.53 0.199 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.32 65.25 2.13 Favored 'Trans proline' 0 C--N 1.366 1.455 0 C-N-CA 122.975 2.45 . . . . 0.0 111.993 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.3 152.49 18.33 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.9 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.84 144.29 28.77 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.688 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -31.85 4.88 Favored 'Cis proline' 0 C--N 1.367 1.521 0 C-N-CA 124.024 -1.24 . . . . 0.0 113.116 0.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.31 144.6 32.03 Favored Pre-proline 0 CA--C 1.542 0.665 0 O-C-N 123.481 0.488 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -63.25 157.51 49.52 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 122.894 2.396 . . . . 0.0 113.845 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.93 154.37 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.819 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.42 30.62 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.901 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.433 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.35 144.24 10.78 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 116.048 -0.524 . . . . 0.0 113.001 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.252 1.236 0 CA-C-O 118.375 -0.822 . . . . 0.0 111.189 179.612 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p . . . . . 0 N--CA 1.47 0.555 0 CA-C-O 120.698 0.285 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.59 119.49 26.9 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.539 179.304 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.06 -156.2 0.35 Allowed 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.634 -178.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.27 113.63 19.53 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 122.765 0.426 . . . . 0.0 111.315 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.4 5.43 42.86 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.624 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.37 159.5 19.37 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.526 0.331 . . . . 0.0 110.52 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.9 131.67 35.9 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.805 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.563 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.19 4.84 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.002 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.426 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -84.02 -12.36 55.33 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.584 -0.734 . . . . 0.0 111.704 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.448 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.7 p -120.96 -41.01 1.79 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.268 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.448 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.1 m-85 -130.59 153.5 81.49 Favored Pre-proline 0 CA--C 1.536 0.44 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.305 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.8 -174.48 1.12 Allowed 'Trans proline' 0 C--N 1.365 1.436 0 C-N-CA 123.167 2.578 . . . . 0.0 112.35 179.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.561 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.0 175.38 10.69 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.135 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -115.06 -54.69 2.54 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.69 13.07 9.3 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.71 8.62 Favored Glycine 0 C--N 1.341 0.831 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.34 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.436 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.8 mt -79.83 166.81 21.32 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.187 0.595 . . . . 0.0 111.577 -179.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.54 144.4 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.195 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.8 m -82.43 104.11 12.47 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.162 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.06 140.33 49.71 Favored Pre-proline 0 CA--C 1.53 0.188 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.514 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.32 64.87 2.14 Favored 'Trans proline' 0 C--N 1.366 1.464 0 C-N-CA 122.995 2.463 . . . . 0.0 112.063 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.52 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.8 p -95.17 152.74 18.09 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.982 -178.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.68 144.16 28.73 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.57 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.31 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.025 -1.239 . . . . 0.0 113.22 0.003 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.07 145.54 32.67 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 123.34 0.4 . . . . 0.0 111.197 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -63.58 156.8 54.77 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 122.988 2.459 . . . . 0.0 113.465 -179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.52 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -122.67 153.9 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.868 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.563 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.46 30.22 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.436 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.26 144.35 10.93 Favored Glycine 0 C--N 1.341 0.81 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.979 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.049 -0.977 . . . . 0.0 111.192 179.547 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 p . . . . . 0 N--CA 1.469 0.485 0 CA-C-O 120.643 0.258 . . . . 0.0 110.879 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.557 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.38 121.32 28.78 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.417 179.265 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -89.59 -156.58 0.41 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.636 -178.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.59 113.59 19.71 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 122.742 0.417 . . . . 0.0 111.295 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.73 7.4 42.01 Favored Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.565 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -115.05 160.34 19.75 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 122.548 0.339 . . . . 0.0 110.444 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.4 p -79.86 135.36 36.43 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.525 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.511 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -107.59 34.86 3.31 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.148 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -86.59 -14.89 41.49 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.761 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 13' ' ' TYR . 11.6 p -118.76 -41.53 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 O-C-N 123.399 0.437 . . . . 0.0 110.2 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.454 ' N ' HG13 ' A' ' 12' ' ' VAL . 22.1 m-85 -127.68 153.6 77.76 Favored Pre-proline 0 CA--C 1.537 0.474 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.34 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.69 -170.25 0.51 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 123.298 2.665 . . . . 0.0 112.384 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.557 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -83.25 175.78 9.66 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.81 -54.57 2.49 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 112.875 0.695 . . . . 0.0 112.875 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 13.14 8.3 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.23 35.17 8.99 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.486 -0.388 . . . . 0.0 112.382 -179.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.436 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.6 mt -80.05 167.47 20.38 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.169 0.587 . . . . 0.0 111.489 -179.378 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.07 144.14 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.277 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.8 m -82.06 103.58 11.79 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.236 178.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -80.82 140.62 50.72 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.285 -0.87 . . . . 0.0 111.49 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.45 64.86 2.21 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.92 2.413 . . . . 0.0 112.045 179.583 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.0 p -95.02 151.01 19.54 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.948 -178.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.74 144.4 28.79 Favored Pre-proline 0 C--O 1.234 0.279 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.692 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.67 -30.99 5.47 Favored 'Cis proline' 0 C--N 1.366 1.499 0 C-N-CA 124.053 -1.228 . . . . 0.0 113.161 0.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -114.64 144.4 31.8 Favored Pre-proline 0 CA--C 1.542 0.659 0 O-C-N 123.509 0.506 . . . . 0.0 111.118 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.76 157.61 51.04 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.865 2.377 . . . . 0.0 113.572 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.0 mm -124.39 153.66 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.943 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.511 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.1 m -89.41 119.13 29.6 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.804 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.436 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.61 144.45 11.16 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.078 -0.51 . . . . 0.0 113.016 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.083 -0.96 . . . . 0.0 111.265 179.537 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p . . . . . 0 N--CA 1.47 0.546 0 CA-C-O 120.6 0.238 . . . . 0.0 110.949 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.543 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.6 120.76 27.4 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.511 179.146 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . 0.504 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 12.0 pt-20 -89.11 -155.87 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.609 -178.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.504 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.65 113.74 19.86 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.961 0.41 . . . . 0.0 111.316 -179.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.48 7.19 43.14 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.635 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.78 159.97 19.97 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 122.538 0.335 . . . . 0.0 110.395 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 59.1 p -79.97 131.31 35.79 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.798 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.549 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 32.0 p -101.33 27.49 6.18 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.042 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.404 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -82.46 -11.36 58.56 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.685 179.95 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.445 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.8 p -121.8 -40.75 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.268 -179.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.445 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.3 m-85 -130.8 153.47 81.64 Favored Pre-proline 0 CA--C 1.536 0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.377 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.92 -174.74 1.21 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.245 2.63 . . . . 0.0 112.297 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.5 m -80.01 175.53 10.55 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 110.508 -0.182 . . . . 0.0 110.508 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.4 m -116.71 -55.51 2.36 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -177.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.23 13.78 7.46 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.51 37.04 7.69 Favored Glycine 0 C--N 1.339 0.716 0 C-N-CA 121.43 -0.414 . . . . 0.0 112.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.43 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.7 mt -82.28 169.65 16.28 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.239 0.616 . . . . 0.0 111.131 -179.531 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -114.81 144.22 22.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.54 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 m -80.61 102.88 10.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.379 178.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -80.74 140.49 50.98 Favored Pre-proline 0 N--CA 1.457 -0.111 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.415 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.7 64.64 1.77 Allowed 'Trans proline' 0 C--N 1.364 1.376 0 C-N-CA 123.009 2.473 . . . . 0.0 112.22 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.52 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.7 p -95.47 152.46 18.39 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.971 -178.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.42 144.13 28.59 Favored Pre-proline 0 C--O 1.235 0.341 0 O-C-N 123.506 0.504 . . . . 0.0 111.632 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.542 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.47 -35.52 2.85 Favored 'Cis proline' 0 C--N 1.368 1.557 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.266 0.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.542 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -111.05 145.39 32.34 Favored Pre-proline 0 CA--C 1.542 0.649 0 O-C-N 123.299 0.374 . . . . 0.0 111.166 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -63.71 156.91 54.64 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 122.9 2.4 . . . . 0.0 113.365 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.52 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -123.12 153.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.977 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -88.85 119.21 29.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.72 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.43 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.01 146.08 13.96 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.342 -0.456 . . . . 0.0 113.323 -179.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.414 -0.803 . . . . 0.0 111.08 179.437 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.469 0.489 0 CA-C-O 120.658 0.266 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.57 121.89 28.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.691 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.34 -155.7 0.33 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.484 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -83.03 115.82 22.02 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 122.605 0.362 . . . . 0.0 110.509 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.65 6.63 49.7 Favored Glycine 0 CA--C 1.523 0.539 0 CA-C-N 115.468 -0.787 . . . . 0.0 112.69 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -113.35 160.05 18.78 Favored 'General case' 0 C--O 1.234 0.266 0 C-N-CA 122.494 0.318 . . . . 0.0 110.54 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.3 p -79.81 132.03 36.03 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.992 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -101.99 29.15 5.2 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.033 179.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.448 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.8 -13.58 53.46 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.713 179.97 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.45 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.3 p -119.99 -41.18 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.165 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.45 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.5 m-85 -130.47 153.38 81.36 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.291 179.637 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.12 -174.52 1.2 Allowed 'Trans proline' 0 C--N 1.365 1.442 0 C-N-CA 123.307 2.671 . . . . 0.0 112.31 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 58.7 m -79.91 176.22 9.93 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.1 m -117.72 -55.68 2.26 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -178.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.8 12.85 8.21 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.24 36.1 7.74 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 121.439 -0.41 . . . . 0.0 112.356 -179.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.443 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.5 mt -80.12 166.25 21.67 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.13 0.572 . . . . 0.0 111.464 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -109.4 143.53 19.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.097 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.9 m -81.67 103.65 11.52 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.4 m-85 -80.52 140.18 51.71 Favored Pre-proline 0 CA--C 1.529 0.167 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.542 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.3 65.31 2.12 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.998 2.466 . . . . 0.0 112.007 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.51 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.64 152.04 18.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.927 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.49 144.22 28.57 Favored Pre-proline 0 C--O 1.234 0.249 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.673 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -32.06 4.73 Favored 'Cis proline' 0 C--N 1.366 1.493 0 C-N-CA 124.074 -1.219 . . . . 0.0 113.083 0.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.96 144.46 31.6 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.502 0.501 . . . . 0.0 111.101 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.34 157.74 48.66 Favored 'Trans proline' 0 C--N 1.375 1.932 0 C-N-CA 122.938 2.425 . . . . 0.0 113.85 -179.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.51 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.15 152.88 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.967 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.13 118.78 29.08 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.703 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.443 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -153.35 142.53 9.29 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 116.206 -0.452 . . . . 0.0 113.182 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.289 179.62 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.8 p . . . . . 0 N--CA 1.469 0.515 0 CA-C-O 120.715 0.293 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.71 119.47 26.97 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.486 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . 0.501 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 11.9 pt-20 -88.07 -156.22 0.35 Allowed 'General case' 0 CA--C 1.545 0.77 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.598 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.501 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.35 113.8 19.69 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 122.714 0.406 . . . . 0.0 111.287 -179.572 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.23 5.53 43.24 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.435 -0.802 . . . . 0.0 112.628 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.39 159.47 19.41 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.638 0.375 . . . . 0.0 110.454 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.92 131.68 35.89 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.866 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.04 4.92 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.98 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.95 -12.35 55.47 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.702 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.449 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.5 p -121.12 -40.83 1.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.262 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.449 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.3 m-85 -130.66 153.43 81.52 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 123.682 0.614 . . . . 0.0 111.317 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -70.61 -174.46 1.08 Allowed 'Trans proline' 0 C--N 1.365 1.417 0 C-N-CA 123.277 2.651 . . . . 0.0 112.331 179.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -80.06 175.39 10.68 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.03 -54.59 2.55 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.821 0.675 . . . . 0.0 112.821 -177.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.77 12.91 9.76 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.36 35.81 8.51 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.509 -0.377 . . . . 0.0 112.335 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.435 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.8 mt -79.89 166.89 21.2 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.208 0.603 . . . . 0.0 111.62 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.55 144.41 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.204 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.3 m -82.28 104.11 12.36 Favored 'General case' 0 C--O 1.239 0.525 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.206 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.22 140.33 49.13 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.506 -179.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.21 64.9 2.07 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 123.003 2.469 . . . . 0.0 112.028 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.522 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.2 152.73 18.1 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.032 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.64 144.19 28.78 Favored Pre-proline 0 C--O 1.234 0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.634 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.25 -35.51 2.86 Favored 'Cis proline' 0 C--N 1.367 1.552 0 C-N-CA 123.986 -1.256 . . . . 0.0 113.333 -0.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.15 145.53 32.67 Favored Pre-proline 0 CA--C 1.543 0.677 0 O-C-N 123.303 0.377 . . . . 0.0 111.211 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -63.65 156.71 55.6 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.867 2.378 . . . . 0.0 113.489 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.522 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.2 mm -122.42 153.92 27.16 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.002 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.38 30.15 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.896 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.435 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.2 144.35 10.94 Favored Glycine 0 C--N 1.338 0.688 0 CA-C-N 116.167 -0.469 . . . . 0.0 113.096 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.146 179.606 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.1 p . . . . . 0 N--CA 1.469 0.52 0 CA-C-O 120.629 0.252 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.8 120.43 28.09 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.528 179.269 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.28 -156.09 0.38 Allowed 'General case' 0 CA--C 1.544 0.72 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.62 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.29 113.69 19.57 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.948 0.404 . . . . 0.0 111.29 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.85 7.08 42.3 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.492 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.77 159.4 20.64 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 122.71 0.404 . . . . 0.0 110.479 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.6 p -79.98 131.43 35.81 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.053 -0.522 . . . . 0.0 111.856 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 30.9 p -101.47 28.69 5.31 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.004 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.46 -11.94 56.92 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.663 179.926 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.45 HG11 ' N ' ' A' ' 13' ' ' TYR . 14.4 p -121.57 -41.17 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 O-C-N 123.543 0.527 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.45 ' N ' HG11 ' A' ' 12' ' ' VAL . 22.8 m-85 -130.24 153.58 81.23 Favored Pre-proline 0 CA--C 1.536 0.425 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.285 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.79 -174.74 1.18 Allowed 'Trans proline' 0 C--N 1.365 1.437 0 C-N-CA 123.214 2.61 . . . . 0.0 112.338 179.157 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.561 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.07 175.2 10.86 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 110.579 -0.156 . . . . 0.0 110.579 179.089 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 53.4 m -115.31 -54.81 2.51 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -177.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -86.33 13.85 7.49 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.2 35.78 9.4 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 121.428 -0.415 . . . . 0.0 112.47 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.432 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.7 mt -80.03 166.63 21.37 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 123.163 0.585 . . . . 0.0 111.602 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.41 144.36 17.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.211 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.1 m -82.28 104.05 12.31 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.272 178.7 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.68 140.21 51.1 Favored Pre-proline 0 CA--C 1.531 0.222 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.484 -179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.31 65.21 2.12 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.964 2.443 . . . . 0.0 112.101 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.27 152.56 18.27 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.899 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.86 144.21 28.62 Favored Pre-proline 0 C--O 1.233 0.233 0 O-C-N 123.512 0.507 . . . . 0.0 111.645 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.47 -32.08 4.74 Favored 'Cis proline' 0 C--N 1.368 1.578 0 C-N-CA 123.961 -1.266 . . . . 0.0 113.137 0.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.12 144.49 31.73 Favored Pre-proline 0 CA--C 1.542 0.652 0 O-C-N 123.515 0.509 . . . . 0.0 111.099 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -63.21 157.47 49.55 Favored 'Trans proline' 0 C--N 1.374 1.871 0 C-N-CA 123.015 2.476 . . . . 0.0 113.859 -179.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.98 154.41 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.863 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.55 30.73 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.873 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.432 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.48 144.27 10.79 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 116.013 -0.54 . . . . 0.0 113.046 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.094 -0.955 . . . . 0.0 111.182 179.568 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p . . . . . 0 N--CA 1.469 0.512 0 CA-C-O 120.671 0.272 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.73 122.74 30.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.659 179.298 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.62 -155.74 0.34 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.556 -178.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -83.59 116.26 22.52 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 120.926 0.393 . . . . 0.0 110.527 -179.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.14 6.4 51.62 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.71 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -112.93 160.81 17.69 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.562 0.345 . . . . 0.0 110.646 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.8 p -79.72 136.18 36.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.677 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.506 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.7 p -108.38 34.48 3.61 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.18 -179.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -86.67 -15.35 39.89 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.753 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 13' ' ' TYR . 11.4 p -118.06 -41.59 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 O-C-N 123.42 0.45 . . . . 0.0 110.086 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.452 ' N ' HG13 ' A' ' 12' ' ' VAL . 22.3 m-85 -128.14 153.58 78.64 Favored Pre-proline 0 CA--C 1.537 0.464 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.189 179.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.22 -171.19 0.66 Allowed 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 123.31 2.674 . . . . 0.0 112.424 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.49 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 59.4 m -82.05 176.79 9.24 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 123.132 0.27 . . . . 0.0 110.402 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.3 m -118.23 -55.46 2.23 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.1 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -85.73 13.0 7.78 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.2 35.57 8.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.432 -0.413 . . . . 0.0 112.391 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.447 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.3 mt -80.07 166.68 21.29 Favored 'General case' 0 C--O 1.236 0.379 0 C-N-CA 123.178 0.591 . . . . 0.0 111.51 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -110.48 143.33 20.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.091 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.7 m -81.37 103.3 11.03 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.223 178.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -80.45 140.42 52.06 Favored Pre-proline 0 CA--C 1.529 0.153 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.546 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.38 65.09 2.17 Favored 'Trans proline' 0 C--N 1.366 1.483 0 C-N-CA 122.955 2.437 . . . . 0.0 112.041 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.513 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.7 p -95.46 151.52 19.22 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.863 -178.689 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.97 144.25 28.54 Favored Pre-proline 0 C--O 1.235 0.298 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.716 -179.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -31.33 5.24 Favored 'Cis proline' 0 C--N 1.367 1.523 0 C-N-CA 123.99 -1.254 . . . . 0.0 113.115 0.142 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -114.44 144.56 32.02 Favored Pre-proline 0 CA--C 1.541 0.617 0 O-C-N 123.487 0.492 . . . . 0.0 111.172 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -63.5 157.78 49.06 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.877 2.385 . . . . 0.0 113.565 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.513 HG12 ' OG1' ' A' ' 24' ' ' THR . 16.4 mm -124.35 152.59 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.97 -179.795 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.506 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -88.67 118.54 28.41 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.782 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.447 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -152.78 142.76 9.58 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 116.138 -0.483 . . . . 0.0 113.101 -179.696 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.475 -0.774 . . . . 0.0 111.228 179.617 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 114.384 1.253 . . . . 0.0 114.384 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -98.09 -26.58 14.55 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.552 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.9 p -82.23 155.92 24.65 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 122.705 0.402 . . . . 0.0 111.455 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.585 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.46 120.92 26.5 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.633 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.73 -156.65 0.42 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.565 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.06 112.87 18.83 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 122.68 0.392 . . . . 0.0 111.363 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.38 9.12 39.45 Favored Glycine 0 C--N 1.334 0.472 0 CA-C-N 115.417 -0.811 . . . . 0.0 112.672 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.54 159.8 21.57 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 122.625 0.37 . . . . 0.0 110.519 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.1 p -80.97 135.19 35.83 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.586 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.414 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.69 36.18 2.62 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.2 -11.5 52.3 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.798 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.405 HG11 ' N ' ' A' ' 13' ' ' TYR . 11.8 p -124.03 -38.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 O-C-N 123.423 0.452 . . . . 0.0 110.135 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.405 ' N ' HG11 ' A' ' 12' ' ' VAL . 27.1 m-85 -132.81 152.29 79.6 Favored Pre-proline 0 CA--C 1.538 0.515 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.422 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.14 -168.42 0.29 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.541 2.827 . . . . 0.0 112.85 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.9 m -83.93 175.84 9.3 Favored 'General case' 0 CA--C 1.538 0.481 0 O-C-N 123.156 0.285 . . . . 0.0 110.547 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.0 m -117.75 -55.88 2.24 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.53 12.62 6.66 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -178.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.83 35.83 7.57 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.359 -0.448 . . . . 0.0 112.41 -179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.42 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.4 mt -81.95 171.54 14.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.134 0.574 . . . . 0.0 111.197 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -117.08 144.07 25.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.456 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 m -80.8 102.1 9.78 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.32 178.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.6 m-85 -79.99 140.97 54.17 Favored Pre-proline 0 N--CA 1.456 -0.163 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.36 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.91 64.41 1.89 Allowed 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 122.957 2.438 . . . . 0.0 112.098 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.0 p -95.19 150.98 19.62 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.937 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.26 144.09 28.26 Favored Pre-proline 0 C--O 1.234 0.25 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.738 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.566 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.76 -35.17 2.97 Favored 'Cis proline' 0 C--N 1.366 1.487 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.226 0.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.566 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.66 144.96 31.32 Favored Pre-proline 0 CA--C 1.542 0.654 0 O-C-N 123.258 0.348 . . . . 0.0 111.194 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.25 157.54 53.47 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.784 2.323 . . . . 0.0 113.374 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.4 mm -124.06 152.88 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.979 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.414 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.83 118.85 28.83 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.788 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.42 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -152.88 145.62 13.31 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 116.195 -0.457 . . . . 0.0 113.368 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.448 -0.787 . . . . 0.0 111.046 179.503 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 114.409 1.263 . . . . 0.0 114.409 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 94.1 m95 -105.39 -35.58 7.46 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.417 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.5 p -82.75 155.89 24.02 Favored 'General case' 0 N--CA 1.466 0.331 0 O-C-N 123.559 0.537 . . . . 0.0 111.536 -179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.591 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.75 120.69 26.34 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.647 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.64 -156.8 0.42 Allowed 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.54 -178.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -80.82 112.85 18.59 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.682 0.393 . . . . 0.0 111.407 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.42 9.06 39.5 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.585 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.5 159.71 21.67 Favored 'General case' 0 C--O 1.235 0.301 0 C-N-CA 122.592 0.357 . . . . 0.0 110.438 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.8 p -80.88 135.27 35.89 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.555 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.416 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.96 36.43 2.57 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.863 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.25 -11.77 51.43 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.868 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.406 HG13 ' N ' ' A' ' 13' ' ' TYR . 12.7 p -123.95 -38.46 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 123.384 0.428 . . . . 0.0 110.234 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.406 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.5 m-85 -132.6 152.46 80.0 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.396 179.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.19 -168.57 0.3 Allowed 'Trans proline' 0 C--N 1.367 1.545 0 C-N-CA 123.507 2.805 . . . . 0.0 112.937 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.591 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.1 m -83.75 175.9 9.34 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 123.148 0.28 . . . . 0.0 110.567 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.1 m -117.65 -55.9 2.25 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.913 0.709 . . . . 0.0 112.913 -178.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.59 12.58 6.81 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 -178.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.77 36.03 7.51 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 121.449 -0.405 . . . . 0.0 112.337 -179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.419 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.4 mt -81.99 171.38 14.47 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.19 0.596 . . . . 0.0 111.196 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.86 144.16 25.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.484 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.5 m -80.94 102.13 9.92 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.382 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -79.99 140.9 54.1 Favored Pre-proline 0 CA--C 1.529 0.165 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.39 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 64.45 1.85 Allowed 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.961 2.44 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.51 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.7 p -95.27 151.14 19.5 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.893 -178.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.46 144.05 28.22 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.769 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.565 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.77 -35.17 2.98 Favored 'Cis proline' 0 C--N 1.367 1.506 0 C-N-CA 124.085 -1.214 . . . . 0.0 113.253 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.565 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.69 144.92 31.25 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.291 0.37 . . . . 0.0 111.217 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -64.1 157.34 53.9 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.904 2.403 . . . . 0.0 113.343 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.51 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.2 mm -123.92 152.88 29.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.068 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.416 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.81 118.92 28.85 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.781 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.419 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -152.75 145.66 13.43 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 116.109 -0.496 . . . . 0.0 113.3 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.078 -0.963 . . . . 0.0 111.055 179.446 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 114.816 1.413 . . . . 0.0 114.816 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 96.7 m95 -118.49 -33.2 4.39 Favored 'General case' 0 N--CA 1.466 0.372 0 O-C-N 123.449 0.468 . . . . 0.0 111.44 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.1 p -81.88 156.28 24.9 Favored 'General case' 0 N--CA 1.467 0.38 0 O-C-N 123.413 0.446 . . . . 0.0 111.46 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.98 119.79 25.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.81 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.77 -156.28 0.38 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.456 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.34 112.77 18.94 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 122.597 0.359 . . . . 0.0 111.375 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.98 8.15 39.82 Favored Glycine 0 CA--C 1.522 0.488 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.637 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.75 159.58 21.24 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 122.604 0.362 . . . . 0.0 110.562 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.0 p -80.02 131.21 35.74 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.787 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.542 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -100.6 29.83 4.26 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.911 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -85.39 -10.48 56.2 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.741 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.401 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.5 p -121.96 -37.68 1.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.006 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.401 ' N ' HG13 ' A' ' 12' ' ' VAL . 25.1 m-85 -137.05 152.87 74.65 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.19 179.398 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.39 -172.72 0.56 Allowed 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 123.313 2.676 . . . . 0.0 112.757 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 48.4 m -80.9 175.41 10.71 Favored 'General case' 0 CA--C 1.539 0.526 0 O-C-N 123.026 0.204 . . . . 0.0 110.472 179.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 34.8 m -117.2 -56.01 2.28 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.91 13.07 6.35 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.18 36.7 7.47 Favored Glycine 0 C--N 1.34 0.769 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.418 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.423 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.6 mt -82.24 170.41 15.45 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.157 0.583 . . . . 0.0 111.222 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -115.48 144.44 23.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.588 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.8 m -80.87 102.74 10.25 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.276 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -80.78 140.61 50.87 Favored Pre-proline 0 CA--C 1.53 0.184 0 CA-C-N 115.296 -0.866 . . . . 0.0 111.439 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.73 64.61 1.78 Allowed 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.885 2.39 . . . . 0.0 112.175 179.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.8 p -95.31 152.33 18.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.983 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.29 144.26 28.83 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.64 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.542 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.6 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.476 0 C-N-CA 124.152 -1.187 . . . . 0.0 113.273 -0.078 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.542 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.93 145.38 32.29 Favored Pre-proline 0 CA--C 1.541 0.599 0 O-C-N 123.365 0.416 . . . . 0.0 111.203 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -63.67 156.96 54.26 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 122.884 2.389 . . . . 0.0 113.428 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.2 mm -123.12 153.46 28.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.979 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.542 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.37 119.16 29.59 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.792 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.423 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -153.44 145.78 13.52 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.261 -0.495 . . . . 0.0 113.256 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.127 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.134 179.386 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.782 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -99.91 -16.42 18.0 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.73 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.4 p -81.39 157.25 25.05 Favored 'General case' 0 C--N 1.343 0.321 0 C-N-CA 122.747 0.419 . . . . 0.0 111.506 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.589 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.86 119.94 25.91 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.844 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.46 -156.43 0.4 Allowed 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.418 -178.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.2 112.42 18.51 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.687 0.395 . . . . 0.0 111.233 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.88 36.8 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -116.94 158.95 23.2 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.646 0.379 . . . . 0.0 110.582 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.4 p -80.13 131.75 35.8 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.855 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.564 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.5 p -100.76 31.11 3.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.89 179.758 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.411 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.26 -11.54 52.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.781 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.411 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.4 -37.77 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.134 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.407 ' N ' HG11 ' A' ' 12' ' ' VAL . 25.8 m-85 -136.6 152.97 75.59 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.13 179.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -69.35 -172.31 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.561 0 C-N-CA 123.345 2.696 . . . . 0.0 112.646 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 54.6 m -81.46 174.93 10.98 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 123.017 0.198 . . . . 0.0 110.487 179.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.5 m -115.87 -55.59 2.4 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -84.64 11.81 8.26 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.67 35.29 7.91 Favored Glycine 0 C--N 1.339 0.732 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.348 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.426 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.5 mt -80.01 166.95 21.06 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.164 0.586 . . . . 0.0 111.488 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.34 144.41 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.188 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.7 m -82.27 104.03 12.29 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.241 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -80.85 140.27 50.47 Favored Pre-proline 0 CA--C 1.53 0.19 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.13 65.16 2.02 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 122.904 2.402 . . . . 0.0 112.103 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.49 151.62 19.14 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.798 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.22 144.31 28.71 Favored Pre-proline 0 CA--C 1.532 0.282 0 O-C-N 123.511 0.507 . . . . 0.0 111.626 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -32.01 4.77 Favored 'Cis proline' 0 C--N 1.367 1.53 0 C-N-CA 124.13 -1.196 . . . . 0.0 113.179 0.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -113.98 144.33 31.34 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.025 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo -63.45 157.41 50.85 Favored 'Trans proline' 0 C--N 1.375 1.97 0 C-N-CA 123.0 2.467 . . . . 0.0 113.803 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.73 154.4 27.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.92 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.564 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.54 119.26 30.66 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.851 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.426 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.68 144.28 10.95 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.112 -0.495 . . . . 0.0 113.003 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.251 1.145 0 CA-C-O 118.474 -0.774 . . . . 0.0 111.244 179.558 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.799 0 N-CA-C 114.944 1.461 . . . . 0.0 114.944 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 m95 -122.7 -35.54 3.05 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.433 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.7 p -81.6 157.61 24.65 Favored 'General case' 0 N--CA 1.466 0.328 0 O-C-N 123.535 0.522 . . . . 0.0 111.524 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.607 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.36 116.84 24.78 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.826 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . 0.545 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.67 -154.46 0.29 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.155 -179.269 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -79.83 106.44 11.86 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.973 0.416 . . . . 0.0 111.053 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.55 9.98 24.19 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.326 -0.852 . . . . 0.0 112.407 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.545 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.9 mt-10 -112.34 156.48 22.38 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.608 0.363 . . . . 0.0 110.525 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -82.64 128.5 34.39 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.889 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.532 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.6 p -96.77 33.33 1.88 Allowed 'General case' 0 C--O 1.238 0.486 0 CA-C-O 121.295 0.569 . . . . 0.0 110.9 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.403 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -89.85 -10.83 43.88 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.407 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.416 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.8 p -123.9 -39.12 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.031 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.418 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 25.6 m-85 -134.86 152.63 77.76 Favored Pre-proline 0 CA--C 1.538 0.494 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.177 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.55 -171.76 0.49 Allowed 'Trans proline' 0 C--N 1.367 1.544 0 C-N-CA 123.308 2.672 . . . . 0.0 112.689 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.607 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.4 m -81.87 174.84 10.92 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 110.324 -0.25 . . . . 0.0 110.324 178.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 40.9 m -114.29 -55.28 2.51 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 -178.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.45 12.2 10.79 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.82 36.86 7.59 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.514 -0.374 . . . . 0.0 112.263 -179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.434 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 3.1 mt -79.96 166.85 21.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 123.254 0.622 . . . . 0.0 111.597 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.8 mt -107.7 144.85 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.195 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.9 m -82.52 104.65 12.96 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.162 178.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -81.25 139.93 48.87 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.554 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.1 65.24 2.0 Allowed 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.929 2.42 . . . . 0.0 112.079 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.505 ' OG1' HG12 ' A' ' 29' ' ' ILE . 43.8 p -95.53 151.73 19.05 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.875 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.39 144.3 28.72 Favored Pre-proline 0 CA--C 1.532 0.269 0 O-C-N 123.57 0.544 . . . . 0.0 111.563 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.58 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.367 1.519 0 C-N-CA 124.145 -1.189 . . . . 0.0 113.166 0.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -113.73 144.07 30.73 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.145 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -63.46 157.23 51.88 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.048 2.499 . . . . 0.0 113.717 -179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.505 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.9 mm -122.38 154.39 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.904 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -90.67 119.39 30.87 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.791 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.434 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.77 144.65 11.17 Favored Glycine 0 C--N 1.338 0.675 0 CA-C-N 116.101 -0.5 . . . . 0.0 113.044 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.079 -0.962 . . . . 0.0 111.199 179.564 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 114.417 1.266 . . . . 0.0 114.417 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 8.0 m-90 -89.32 -35.63 16.0 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.344 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.0 p -82.57 157.24 23.57 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.476 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.599 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.79 119.03 24.84 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.8 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -88.24 -155.96 0.34 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.466 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.55 112.99 19.28 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 122.708 0.403 . . . . 0.0 111.256 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.26 7.1 41.08 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-N 115.528 -0.76 . . . . 0.0 112.733 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.12 159.25 21.1 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.561 0.345 . . . . 0.0 110.504 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 54.7 p -79.94 131.63 35.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.843 -179.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.555 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -100.73 31.23 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.865 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.407 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.58 -11.46 51.44 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.759 179.982 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.407 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.24 -37.68 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.051 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.404 ' N ' HG12 ' A' ' 12' ' ' VAL . 25.0 m-85 -136.76 153.1 75.46 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.123 179.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.53 -172.1 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.572 0 C-N-CA 123.295 2.663 . . . . 0.0 112.539 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.599 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.6 m -81.52 175.14 10.78 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 110.49 -0.189 . . . . 0.0 110.49 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.4 m -115.85 -55.3 2.43 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.21 12.36 8.14 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.15 35.36 8.16 Favored Glycine 0 C--N 1.339 0.748 0 C-N-CA 121.516 -0.374 . . . . 0.0 112.383 -179.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.431 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.5 mt -79.91 167.0 21.07 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.231 0.612 . . . . 0.0 111.576 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.46 144.33 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.268 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.8 m -82.09 104.03 12.14 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.253 178.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -81.3 140.43 48.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.501 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -70.26 64.83 2.1 Favored 'Trans proline' 0 C--N 1.364 1.393 0 C-N-CA 122.999 2.466 . . . . 0.0 112.054 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.4 p -95.31 152.52 18.31 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.897 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.52 144.18 28.72 Favored Pre-proline 0 C--O 1.236 0.374 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.565 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.3 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.485 0 C-N-CA 124.064 -1.223 . . . . 0.0 113.238 -0.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.02 145.37 32.3 Favored Pre-proline 0 CA--C 1.542 0.661 0 O-C-N 123.29 0.369 . . . . 0.0 111.197 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -63.67 156.79 55.24 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.943 2.429 . . . . 0.0 113.419 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.8 mm -122.52 153.79 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.96 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.555 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -89.92 119.16 30.05 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.939 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.431 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.35 144.04 10.73 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.985 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.073 -0.965 . . . . 0.0 111.127 179.571 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.778 0 N-CA-C 114.427 1.269 . . . . 0.0 114.427 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -103.21 -18.95 14.68 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.609 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p -81.73 157.2 24.64 Favored 'General case' 0 C--N 1.344 0.354 0 O-C-N 123.344 0.402 . . . . 0.0 111.385 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.622 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.89 116.48 24.16 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.878 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . 0.544 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.14 -154.32 0.27 Allowed 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.181 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -79.82 106.86 12.15 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.082 0.468 . . . . 0.0 111.187 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.74 9.9 25.82 Favored Glycine 0 C--N 1.336 0.541 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.55 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.544 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.0 mt-10 -111.72 156.8 21.32 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 122.649 0.379 . . . . 0.0 110.499 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.4 p -82.88 132.05 35.17 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.752 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.418 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.2 p -102.05 38.1 1.72 Allowed 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.58 0.55 . . . . 0.0 111.18 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -91.46 -11.0 38.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.38 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 13' ' ' TYR . 11.9 p -124.72 -39.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.934 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.411 ' N ' HG12 ' A' ' 12' ' ' VAL . 27.2 m-85 -132.16 152.01 79.39 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 123.538 0.524 . . . . 0.0 111.51 179.367 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.5 -169.07 0.34 Allowed 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.577 2.851 . . . . 0.0 112.75 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.622 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 49.4 m -83.53 175.13 10.01 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 123.119 0.262 . . . . 0.0 110.376 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.9 m -114.84 -55.26 2.5 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.102 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 12.36 9.9 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.96 36.14 7.87 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 121.422 -0.418 . . . . 0.0 112.39 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.436 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.9 mt -79.93 168.13 19.62 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.331 0.653 . . . . 0.0 111.541 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -109.85 144.66 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.224 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.1 m -82.37 103.86 12.24 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.173 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -80.69 140.46 51.18 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.492 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -70.37 64.84 2.16 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.924 2.416 . . . . 0.0 111.978 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.509 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.5 p -95.0 150.43 20.17 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.963 -178.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -105.46 144.19 28.32 Favored Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.589 0.555 . . . . 0.0 111.724 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.87 -31.4 5.16 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.219 0.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -113.7 143.9 30.39 Favored Pre-proline 0 CA--C 1.541 0.621 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.199 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.09 157.59 52.53 Favored 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 123.016 2.477 . . . . 0.0 113.514 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.509 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.97 154.09 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.973 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.418 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.0 m -90.08 119.02 30.06 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.436 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.91 144.68 11.37 Favored Glycine 0 C--N 1.337 0.599 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.013 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.405 ' N ' HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.452 -0.785 . . . . 0.0 111.122 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.793 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 93.0 m95 -100.14 -34.34 10.09 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.363 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.3 p -80.95 156.34 26.02 Favored 'General case' 0 N--CA 1.467 0.389 0 O-C-N 123.435 0.46 . . . . 0.0 111.621 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.6 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.69 118.52 24.46 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.789 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.23 -156.78 0.38 Allowed 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.406 -178.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -80.74 112.03 17.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.641 0.376 . . . . 0.0 111.387 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.94 8.14 37.15 Favored Glycine 0 C--N 1.334 0.471 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.62 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -115.98 158.69 22.69 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 122.623 0.369 . . . . 0.0 110.535 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.0 p -80.11 131.67 35.79 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.808 -179.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.6 p -100.6 31.13 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.893 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.404 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.3 -11.38 52.37 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.749 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 13' ' ' TYR . 14.5 p -121.6 -38.08 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.137 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.409 ' N ' HG12 ' A' ' 12' ' ' VAL . 25.0 m-85 -136.2 152.86 76.04 Favored Pre-proline 0 CA--C 1.538 0.481 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.145 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.07 -172.04 0.47 Allowed 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 123.349 2.699 . . . . 0.0 112.605 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.6 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -81.64 175.78 10.2 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 123.123 0.264 . . . . 0.0 110.406 178.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 42.3 m -114.9 -55.99 2.42 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.425 ' OD2' HD13 ' A' ' 19' ' ' LEU . 3.3 p30 -87.47 13.18 10.55 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.87 35.98 6.97 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.395 -0.431 . . . . 0.0 112.625 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.43 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.8 mt -80.19 166.36 21.51 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.018 0.527 . . . . 0.0 111.447 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.86 143.96 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.223 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.5 m -82.13 103.55 11.82 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.238 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.8 m-85 -80.19 140.33 53.06 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.509 -179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 65.01 2.07 Favored 'Trans proline' 0 C--N 1.365 1.424 0 C-N-CA 123.055 2.503 . . . . 0.0 112.142 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.33 151.55 19.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.894 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.65 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.56 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.366 1.477 0 C-N-CA 124.055 -1.227 . . . . 0.0 113.088 0.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -113.87 144.24 31.12 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.09 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -63.34 157.62 49.28 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.023 2.482 . . . . 0.0 113.751 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.96 153.93 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.902 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.15 119.25 30.32 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.883 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.43 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.9 143.93 10.51 Favored Glycine 0 C--N 1.339 0.695 0 CA-C-N 116.071 -0.513 . . . . 0.0 113.088 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.135 -0.936 . . . . 0.0 111.142 179.567 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -98.11 -20.29 17.42 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.597 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p -81.39 157.33 25.03 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 122.709 0.404 . . . . 0.0 111.468 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.59 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.67 120.25 26.17 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.742 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.68 -156.34 0.4 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.389 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.23 112.6 18.71 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.897 0.379 . . . . 0.0 111.373 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.31 8.8 37.63 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.566 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -116.97 158.97 23.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 122.622 0.369 . . . . 0.0 110.524 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.4 p -80.03 131.94 35.89 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.819 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.563 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -100.96 31.16 3.71 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.854 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.41 -11.21 52.57 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.721 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 13' ' ' TYR . 14.6 p -121.52 -37.89 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.07 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.406 ' N ' HG12 ' A' ' 12' ' ' VAL . 25.8 m-85 -136.72 152.95 75.36 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.179 179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.23 -172.17 0.5 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 123.342 2.695 . . . . 0.0 112.574 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.59 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -81.61 175.15 10.73 Favored 'General case' 0 CA--C 1.539 0.535 0 O-C-N 123.044 0.215 . . . . 0.0 110.449 179.075 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.8 m -116.02 -55.43 2.41 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -177.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -85.11 12.87 6.96 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -178.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.33 8.73 Favored Glycine 0 C--N 1.341 0.851 0 C-N-CA 121.478 -0.392 . . . . 0.0 112.413 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.427 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.5 mt -79.98 166.77 21.26 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.22 0.608 . . . . 0.0 111.484 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.09 144.36 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.239 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.5 m -82.3 103.93 12.24 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.5 m-85 -80.76 140.28 50.8 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.46 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.17 65.07 2.05 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.94 2.427 . . . . 0.0 112.056 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.41 151.49 19.23 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.878 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.339 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.746 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.52 -32.28 4.6 Favored 'Cis proline' 0 C--N 1.366 1.475 0 C-N-CA 124.046 -1.231 . . . . 0.0 113.142 0.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.76 144.23 31.05 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.43 157.42 50.73 Favored 'Trans proline' 0 C--N 1.375 1.931 0 C-N-CA 123.004 2.47 . . . . 0.0 113.809 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.7 mm -122.81 154.33 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.857 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.563 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -90.59 119.36 30.78 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.877 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.427 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.76 144.01 10.63 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 116.041 -0.527 . . . . 0.0 113.014 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.424 -0.798 . . . . 0.0 111.23 179.572 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -98.14 -18.7 18.34 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.697 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p -82.65 156.14 24.02 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 122.754 0.422 . . . . 0.0 111.46 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.615 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.19 119.95 25.63 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.71 179.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -89.14 -156.3 0.39 Allowed 'General case' 0 CA--C 1.544 0.713 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.665 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -81.21 113.04 19.08 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 122.651 0.38 . . . . 0.0 111.384 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.76 8.36 40.01 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.334 -0.848 . . . . 0.0 112.604 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -116.16 159.67 21.45 Favored 'General case' 0 C--O 1.236 0.395 0 C-N-CA 122.493 0.317 . . . . 0.0 110.555 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.8 p -81.02 134.74 35.73 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.702 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.449 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -105.41 37.41 2.21 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.758 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -87.31 -13.36 43.83 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.885 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.409 HG13 ' N ' ' A' ' 13' ' ' TYR . 12.1 p -122.43 -38.43 1.37 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 O-C-N 123.506 0.504 . . . . 0.0 110.111 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.409 ' N ' HG13 ' A' ' 12' ' ' VAL . 26.4 m-85 -132.26 152.42 80.08 Favored Pre-proline 0 CA--C 1.538 0.511 0 O-C-N 123.609 0.568 . . . . 0.0 111.462 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.21 -168.35 0.29 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 123.426 2.751 . . . . 0.0 112.777 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.615 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -84.09 175.6 9.39 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 123.048 0.218 . . . . 0.0 110.502 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.9 m -116.53 -55.34 2.38 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -178.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -84.77 12.26 7.62 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.5 34.74 8.34 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.461 -0.399 . . . . 0.0 112.359 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.429 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.4 mt -80.04 167.79 19.98 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.223 0.609 . . . . 0.0 111.426 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.91 144.21 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.252 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.9 m -82.22 103.26 11.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.166 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.9 m-85 -80.34 140.83 52.69 Favored Pre-proline 0 CA--C 1.53 0.195 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.511 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.33 64.58 2.14 Favored 'Trans proline' 0 C--N 1.364 1.389 0 C-N-CA 122.955 2.437 . . . . 0.0 111.997 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.514 ' OG1' HG12 ' A' ' 29' ' ' ILE . 47.7 p -95.02 151.65 18.99 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.964 -178.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.76 143.95 28.09 Favored Pre-proline 0 C--O 1.234 0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.674 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -76.36 -36.61 2.44 Favored 'Cis proline' 0 C--N 1.365 1.435 0 C-N-CA 124.079 -1.217 . . . . 0.0 113.162 0.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -109.67 145.91 32.94 Favored Pre-proline 0 CA--C 1.54 0.559 0 O-C-N 123.342 0.401 . . . . 0.0 111.131 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -64.47 157.64 53.84 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.842 2.362 . . . . 0.0 113.351 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.514 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.1 mm -123.71 153.55 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.969 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.449 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.54 118.95 29.55 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.929 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.429 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -153.8 144.1 10.89 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 116.042 -0.526 . . . . 0.0 113.092 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.19 179.597 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.795 0 N-CA-C 114.319 1.229 . . . . 0.0 114.319 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.8 m95 -139.57 96.33 3.07 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.848 179.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p -156.08 160.68 40.18 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.963 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.78 120.16 27.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.524 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.08 -156.12 0.38 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.526 -178.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.12 113.49 19.32 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.78 0.432 . . . . 0.0 111.242 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.82 7.23 42.1 Favored Glycine 0 C--N 1.334 0.419 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.588 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.72 159.31 20.69 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.741 0.416 . . . . 0.0 110.579 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 65.1 p -79.98 131.44 35.81 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.781 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.47 28.7 5.3 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.971 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.4 -12.18 56.75 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.705 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.449 HG12 ' N ' ' A' ' 13' ' ' TYR . 14.5 p -121.35 -41.06 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.348 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.449 ' N ' HG12 ' A' ' 12' ' ' VAL . 22.5 m-85 -130.26 153.53 81.24 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.306 179.584 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.7 -174.71 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.202 2.601 . . . . 0.0 112.42 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.07 175.22 10.83 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 110.53 -0.174 . . . . 0.0 110.53 179.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.5 m -115.15 -54.88 2.52 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.31 12.95 8.9 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.68 8.65 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.415 -0.421 . . . . 0.0 112.366 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.435 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.7 mt -79.93 166.56 21.51 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.265 0.626 . . . . 0.0 111.565 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.6 144.29 17.37 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.155 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.8 m -82.21 103.98 12.2 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.214 178.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.64 140.18 51.23 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.535 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.33 65.23 2.14 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.965 2.443 . . . . 0.0 112.093 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.29 152.9 17.97 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.963 -178.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -107.05 144.23 28.7 Favored Pre-proline 0 C--O 1.236 0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.73 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.42 -32.05 4.77 Favored 'Cis proline' 0 C--N 1.365 1.419 0 C-N-CA 124.084 -1.215 . . . . 0.0 113.196 0.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.27 144.49 31.8 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.089 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -63.21 157.52 49.27 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 123.02 2.48 . . . . 0.0 113.75 -179.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.89 154.38 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.864 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.42 119.5 30.76 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.948 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.435 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.44 144.32 10.86 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 116.083 -0.508 . . . . 0.0 113.117 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.065 -0.969 . . . . 0.0 111.108 179.633 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.828 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 82.3 m95 -139.42 96.47 3.1 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.348 0.594 . . . . 0.0 109.934 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.7 p -155.95 161.07 40.57 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.906 179.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.565 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.9 120.03 27.74 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.0 -156.11 0.37 Allowed 'General case' 0 CA--C 1.543 0.696 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.533 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.09 113.47 19.29 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.986 0.422 . . . . 0.0 111.238 -179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.04 6.94 41.99 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.546 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.56 159.39 20.47 Favored 'General case' 0 C--O 1.234 0.275 0 C-N-CA 122.547 0.339 . . . . 0.0 110.481 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.2 p -79.94 131.27 35.79 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.811 -179.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.567 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.11 28.62 5.2 Favored 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.969 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.423 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.59 -12.1 56.5 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.661 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.4 p -121.38 -41.31 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.217 -179.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.452 ' N ' HG13 ' A' ' 12' ' ' VAL . 22.5 m-85 -130.26 153.44 81.23 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.326 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.62 -174.82 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.472 0 C-N-CA 123.202 2.601 . . . . 0.0 112.348 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.565 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -79.87 175.28 10.77 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -115.16 -54.86 2.52 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -178.019 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.55 13.08 9.05 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.26 35.88 8.53 Favored Glycine 0 C--N 1.34 0.764 0 C-N-CA 121.495 -0.384 . . . . 0.0 112.293 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.436 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.8 mt -79.97 166.58 21.45 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.159 0.584 . . . . 0.0 111.649 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -108.4 144.36 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.141 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.2 m -82.24 103.89 12.16 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -80.38 140.13 52.22 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.538 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.24 65.22 2.09 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.05 2.5 . . . . 0.0 112.079 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.36 152.74 18.13 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.889 -178.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -107.0 144.23 28.68 Favored Pre-proline 0 C--O 1.234 0.268 0 O-C-N 123.541 0.526 . . . . 0.0 111.683 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.55 -31.93 4.84 Favored 'Cis proline' 0 C--N 1.367 1.505 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.22 0.06 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.15 144.6 31.95 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.525 0.516 . . . . 0.0 111.127 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -63.28 157.53 49.53 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.962 2.441 . . . . 0.0 113.793 -179.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.83 154.31 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.871 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.567 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.31 119.44 30.61 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.91 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.436 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.56 144.36 10.88 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 116.114 -0.494 . . . . 0.0 113.016 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.126 -0.94 . . . . 0.0 111.257 179.512 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.875 0 N-CA-C 114.357 1.243 . . . . 0.0 114.357 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.5 m95 -139.39 96.51 3.11 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.928 179.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p -156.13 160.89 40.31 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.88 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.56 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.92 120.37 28.12 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.465 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.26 -155.96 0.37 Allowed 'General case' 0 CA--C 1.545 0.768 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.622 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.37 113.65 19.6 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.312 0.382 . . . . 0.0 111.225 -179.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.78 7.31 42.06 Favored Glycine 0 CA--C 1.521 0.453 0 CA-C-N 115.378 -0.828 . . . . 0.0 112.511 -179.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -114.95 159.51 20.65 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 122.62 0.368 . . . . 0.0 110.526 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.4 p -80.1 131.44 35.75 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.804 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.41 28.66 5.31 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.033 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.427 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.43 -12.05 56.84 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.712 179.971 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.446 HG12 ' N ' ' A' ' 13' ' ' TYR . 14.4 p -121.46 -41.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 O-C-N 123.583 0.552 . . . . 0.0 110.298 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.446 ' N ' HG12 ' A' ' 12' ' ' VAL . 22.6 m-85 -130.41 153.45 81.34 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 179.683 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -70.69 -174.65 1.14 Allowed 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 123.188 2.592 . . . . 0.0 112.357 179.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.56 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.06 175.21 10.84 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.6 m -115.29 -54.84 2.51 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 112.906 0.706 . . . . 0.0 112.906 -178.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -86.11 12.73 9.01 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.62 8.56 Favored Glycine 0 C--N 1.34 0.792 0 C-N-CA 121.517 -0.373 . . . . 0.0 112.291 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.433 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.7 mt -79.9 166.61 21.48 Favored 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 123.254 0.621 . . . . 0.0 111.51 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.57 144.42 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.175 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.6 m -82.38 103.97 12.34 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.155 178.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -80.68 140.17 51.08 Favored Pre-proline 0 CA--C 1.53 0.199 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.32 65.25 2.13 Favored 'Trans proline' 0 C--N 1.366 1.455 0 C-N-CA 122.975 2.45 . . . . 0.0 111.993 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.3 152.49 18.33 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.9 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.84 144.29 28.77 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.688 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -31.85 4.88 Favored 'Cis proline' 0 C--N 1.367 1.521 0 C-N-CA 124.024 -1.24 . . . . 0.0 113.116 0.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.31 144.6 32.03 Favored Pre-proline 0 CA--C 1.542 0.665 0 O-C-N 123.481 0.488 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -63.25 157.51 49.52 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 122.894 2.396 . . . . 0.0 113.845 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.93 154.37 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.819 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.42 30.62 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.901 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.433 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.35 144.24 10.78 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 116.048 -0.524 . . . . 0.0 113.001 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.252 1.236 0 CA-C-O 118.375 -0.822 . . . . 0.0 111.189 179.612 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 114.431 1.271 . . . . 0.0 114.431 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -139.49 96.42 3.09 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.931 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p -155.96 160.59 40.21 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.943 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.59 119.49 26.9 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.539 179.304 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.06 -156.2 0.35 Allowed 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.634 -178.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.27 113.63 19.53 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 122.765 0.426 . . . . 0.0 111.315 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.4 5.43 42.86 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.624 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.37 159.5 19.37 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.526 0.331 . . . . 0.0 110.52 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.9 131.67 35.9 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.805 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.563 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.19 4.84 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.002 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.426 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -84.02 -12.36 55.33 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.584 -0.734 . . . . 0.0 111.704 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.448 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.7 p -120.96 -41.01 1.79 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.268 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.448 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.1 m-85 -130.59 153.5 81.49 Favored Pre-proline 0 CA--C 1.536 0.44 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.305 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.8 -174.48 1.12 Allowed 'Trans proline' 0 C--N 1.365 1.436 0 C-N-CA 123.167 2.578 . . . . 0.0 112.35 179.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.561 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.0 175.38 10.69 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.135 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -115.06 -54.69 2.54 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.69 13.07 9.3 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.71 8.62 Favored Glycine 0 C--N 1.341 0.831 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.34 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.436 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.8 mt -79.83 166.81 21.32 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.187 0.595 . . . . 0.0 111.577 -179.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.54 144.4 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.195 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.8 m -82.43 104.11 12.47 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.162 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.06 140.33 49.71 Favored Pre-proline 0 CA--C 1.53 0.188 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.514 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.32 64.87 2.14 Favored 'Trans proline' 0 C--N 1.366 1.464 0 C-N-CA 122.995 2.463 . . . . 0.0 112.063 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.52 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.8 p -95.17 152.74 18.09 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.982 -178.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.68 144.16 28.73 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.57 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.31 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.025 -1.239 . . . . 0.0 113.22 0.003 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.07 145.54 32.67 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 123.34 0.4 . . . . 0.0 111.197 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -63.58 156.8 54.77 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 122.988 2.459 . . . . 0.0 113.465 -179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.52 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -122.67 153.9 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.868 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.563 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.46 30.22 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.436 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.26 144.35 10.93 Favored Glycine 0 C--N 1.341 0.81 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.979 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.049 -0.977 . . . . 0.0 111.192 179.547 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.811 0 N-CA-C 114.333 1.234 . . . . 0.0 114.333 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -139.68 96.56 3.1 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.895 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 p -156.79 161.71 39.75 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.879 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.557 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.38 121.32 28.78 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.417 179.265 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -89.59 -156.58 0.41 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.636 -178.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.59 113.59 19.71 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 122.742 0.417 . . . . 0.0 111.295 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.73 7.4 42.01 Favored Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.565 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -115.05 160.34 19.75 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 122.548 0.339 . . . . 0.0 110.444 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.4 p -79.86 135.36 36.43 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.525 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.511 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -107.59 34.86 3.31 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.148 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -86.59 -14.89 41.49 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.761 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 13' ' ' TYR . 11.6 p -118.76 -41.53 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 O-C-N 123.399 0.437 . . . . 0.0 110.2 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.454 ' N ' HG13 ' A' ' 12' ' ' VAL . 22.1 m-85 -127.68 153.6 77.76 Favored Pre-proline 0 CA--C 1.537 0.474 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.34 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.69 -170.25 0.51 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 123.298 2.665 . . . . 0.0 112.384 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.557 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -83.25 175.78 9.66 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.81 -54.57 2.49 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 112.875 0.695 . . . . 0.0 112.875 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 13.14 8.3 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.23 35.17 8.99 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.486 -0.388 . . . . 0.0 112.382 -179.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.436 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.6 mt -80.05 167.47 20.38 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.169 0.587 . . . . 0.0 111.489 -179.378 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.07 144.14 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.277 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.8 m -82.06 103.58 11.79 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.236 178.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -80.82 140.62 50.72 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.285 -0.87 . . . . 0.0 111.49 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.45 64.86 2.21 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.92 2.413 . . . . 0.0 112.045 179.583 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.0 p -95.02 151.01 19.54 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.948 -178.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.74 144.4 28.79 Favored Pre-proline 0 C--O 1.234 0.279 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.692 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.67 -30.99 5.47 Favored 'Cis proline' 0 C--N 1.366 1.499 0 C-N-CA 124.053 -1.228 . . . . 0.0 113.161 0.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -114.64 144.4 31.8 Favored Pre-proline 0 CA--C 1.542 0.659 0 O-C-N 123.509 0.506 . . . . 0.0 111.118 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.76 157.61 51.04 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.865 2.377 . . . . 0.0 113.572 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.0 mm -124.39 153.66 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.943 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.511 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.1 m -89.41 119.13 29.6 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.804 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.436 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.61 144.45 11.16 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.078 -0.51 . . . . 0.0 113.016 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.083 -0.96 . . . . 0.0 111.265 179.537 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.822 0 N-CA-C 114.408 1.262 . . . . 0.0 114.408 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 82.3 m95 -139.56 96.54 3.1 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.928 179.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p -155.79 160.31 40.15 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.949 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.543 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.6 120.76 27.4 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.511 179.146 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . 0.504 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 12.0 pt-20 -89.11 -155.87 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.609 -178.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.504 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.65 113.74 19.86 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.961 0.41 . . . . 0.0 111.316 -179.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.48 7.19 43.14 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.635 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.78 159.97 19.97 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 122.538 0.335 . . . . 0.0 110.395 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 59.1 p -79.97 131.31 35.79 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.798 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.549 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 32.0 p -101.33 27.49 6.18 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.042 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.404 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -82.46 -11.36 58.56 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.685 179.95 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.445 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.8 p -121.8 -40.75 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.268 -179.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.445 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.3 m-85 -130.8 153.47 81.64 Favored Pre-proline 0 CA--C 1.536 0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.377 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.92 -174.74 1.21 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.245 2.63 . . . . 0.0 112.297 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.5 m -80.01 175.53 10.55 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 110.508 -0.182 . . . . 0.0 110.508 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.4 m -116.71 -55.51 2.36 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -177.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.23 13.78 7.46 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.51 37.04 7.69 Favored Glycine 0 C--N 1.339 0.716 0 C-N-CA 121.43 -0.414 . . . . 0.0 112.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.43 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.7 mt -82.28 169.65 16.28 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.239 0.616 . . . . 0.0 111.131 -179.531 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -114.81 144.22 22.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.54 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 m -80.61 102.88 10.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.379 178.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -80.74 140.49 50.98 Favored Pre-proline 0 N--CA 1.457 -0.111 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.415 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.7 64.64 1.77 Allowed 'Trans proline' 0 C--N 1.364 1.376 0 C-N-CA 123.009 2.473 . . . . 0.0 112.22 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.52 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.7 p -95.47 152.46 18.39 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.971 -178.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.42 144.13 28.59 Favored Pre-proline 0 C--O 1.235 0.341 0 O-C-N 123.506 0.504 . . . . 0.0 111.632 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.542 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.47 -35.52 2.85 Favored 'Cis proline' 0 C--N 1.368 1.557 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.266 0.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.542 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -111.05 145.39 32.34 Favored Pre-proline 0 CA--C 1.542 0.649 0 O-C-N 123.299 0.374 . . . . 0.0 111.166 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -63.71 156.91 54.64 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 122.9 2.4 . . . . 0.0 113.365 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.52 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -123.12 153.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.977 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.549 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -88.85 119.21 29.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.72 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.43 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -154.01 146.08 13.96 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.342 -0.456 . . . . 0.0 113.323 -179.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.414 -0.803 . . . . 0.0 111.08 179.437 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 114.461 1.282 . . . . 0.0 114.461 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -139.54 96.48 3.09 Favored 'General case' 0 C--O 1.237 0.401 0 O-C-N 123.619 0.574 . . . . 0.0 109.903 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p -156.05 161.55 40.41 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.146 -0.933 . . . . 0.0 110.917 179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.57 121.89 28.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.691 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.34 -155.7 0.33 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.484 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -83.03 115.82 22.02 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 122.605 0.362 . . . . 0.0 110.509 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.65 6.63 49.7 Favored Glycine 0 CA--C 1.523 0.539 0 CA-C-N 115.468 -0.787 . . . . 0.0 112.69 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -113.35 160.05 18.78 Favored 'General case' 0 C--O 1.234 0.266 0 C-N-CA 122.494 0.318 . . . . 0.0 110.54 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.3 p -79.81 132.03 36.03 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.992 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -101.99 29.15 5.2 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.033 179.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.448 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.8 -13.58 53.46 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.713 179.97 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.45 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.3 p -119.99 -41.18 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.165 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.45 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.5 m-85 -130.47 153.38 81.36 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.291 179.637 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.12 -174.52 1.2 Allowed 'Trans proline' 0 C--N 1.365 1.442 0 C-N-CA 123.307 2.671 . . . . 0.0 112.31 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.493 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 58.7 m -79.91 176.22 9.93 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.1 m -117.72 -55.68 2.26 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -178.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.8 12.85 8.21 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.24 36.1 7.74 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 121.439 -0.41 . . . . 0.0 112.356 -179.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.443 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.5 mt -80.12 166.25 21.67 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.13 0.572 . . . . 0.0 111.464 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -109.4 143.53 19.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.097 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.9 m -81.67 103.65 11.52 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.4 m-85 -80.52 140.18 51.71 Favored Pre-proline 0 CA--C 1.529 0.167 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.542 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.3 65.31 2.12 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.998 2.466 . . . . 0.0 112.007 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.51 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.64 152.04 18.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.927 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.49 144.22 28.57 Favored Pre-proline 0 C--O 1.234 0.249 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.673 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -32.06 4.73 Favored 'Cis proline' 0 C--N 1.366 1.493 0 C-N-CA 124.074 -1.219 . . . . 0.0 113.083 0.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.96 144.46 31.6 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.502 0.501 . . . . 0.0 111.101 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.34 157.74 48.66 Favored 'Trans proline' 0 C--N 1.375 1.932 0 C-N-CA 122.938 2.425 . . . . 0.0 113.85 -179.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.51 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.15 152.88 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.967 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.13 118.78 29.08 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.703 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.443 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -153.35 142.53 9.29 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 116.206 -0.452 . . . . 0.0 113.182 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.289 179.62 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.845 0 N-CA-C 114.37 1.248 . . . . 0.0 114.37 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.9 m95 -139.47 96.29 3.07 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.906 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.8 p -156.06 160.42 39.97 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.959 179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.71 119.47 26.97 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.486 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . 0.501 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 11.9 pt-20 -88.07 -156.22 0.35 Allowed 'General case' 0 CA--C 1.545 0.77 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.598 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.501 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.35 113.8 19.69 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 122.714 0.406 . . . . 0.0 111.287 -179.572 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.23 5.53 43.24 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.435 -0.802 . . . . 0.0 112.628 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.39 159.47 19.41 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.638 0.375 . . . . 0.0 110.454 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.92 131.68 35.89 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.866 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.04 4.92 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.98 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.431 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.95 -12.35 55.47 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.702 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.449 HG13 ' N ' ' A' ' 13' ' ' TYR . 14.5 p -121.12 -40.83 1.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.262 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.449 ' N ' HG13 ' A' ' 12' ' ' VAL . 23.3 m-85 -130.66 153.43 81.52 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 123.682 0.614 . . . . 0.0 111.317 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -70.61 -174.46 1.08 Allowed 'Trans proline' 0 C--N 1.365 1.417 0 C-N-CA 123.277 2.651 . . . . 0.0 112.331 179.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -80.06 175.39 10.68 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.03 -54.59 2.55 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.821 0.675 . . . . 0.0 112.821 -177.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.77 12.91 9.76 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.36 35.81 8.51 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.509 -0.377 . . . . 0.0 112.335 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.435 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.8 mt -79.89 166.89 21.2 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.208 0.603 . . . . 0.0 111.62 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.55 144.41 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.204 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.3 m -82.28 104.11 12.36 Favored 'General case' 0 C--O 1.239 0.525 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.206 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.22 140.33 49.13 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.506 -179.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.21 64.9 2.07 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 123.003 2.469 . . . . 0.0 112.028 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.522 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.2 152.73 18.1 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.032 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.64 144.19 28.78 Favored Pre-proline 0 C--O 1.234 0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.634 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.25 -35.51 2.86 Favored 'Cis proline' 0 C--N 1.367 1.552 0 C-N-CA 123.986 -1.256 . . . . 0.0 113.333 -0.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.15 145.53 32.67 Favored Pre-proline 0 CA--C 1.543 0.677 0 O-C-N 123.303 0.377 . . . . 0.0 111.211 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -63.65 156.71 55.6 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.867 2.378 . . . . 0.0 113.489 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.522 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.2 mm -122.42 153.92 27.16 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.002 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.38 30.15 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.896 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.435 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.2 144.35 10.94 Favored Glycine 0 C--N 1.338 0.688 0 CA-C-N 116.167 -0.469 . . . . 0.0 113.096 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.146 179.606 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.789 0 N-CA-C 114.373 1.249 . . . . 0.0 114.373 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.3 m95 -139.52 96.39 3.08 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.912 179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.1 p -156.11 160.81 40.26 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.985 179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.8 120.43 28.09 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.528 179.269 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.28 -156.09 0.38 Allowed 'General case' 0 CA--C 1.544 0.72 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.62 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.29 113.69 19.57 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.948 0.404 . . . . 0.0 111.29 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.85 7.08 42.3 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.492 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.77 159.4 20.64 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 122.71 0.404 . . . . 0.0 110.479 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.6 p -79.98 131.43 35.81 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.053 -0.522 . . . . 0.0 111.856 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 30.9 p -101.47 28.69 5.31 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.004 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.46 -11.94 56.92 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.663 179.926 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.45 HG11 ' N ' ' A' ' 13' ' ' TYR . 14.4 p -121.57 -41.17 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 O-C-N 123.543 0.527 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.45 ' N ' HG11 ' A' ' 12' ' ' VAL . 22.8 m-85 -130.24 153.58 81.23 Favored Pre-proline 0 CA--C 1.536 0.425 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.285 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.79 -174.74 1.18 Allowed 'Trans proline' 0 C--N 1.365 1.437 0 C-N-CA 123.214 2.61 . . . . 0.0 112.338 179.157 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.561 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.07 175.2 10.86 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 110.579 -0.156 . . . . 0.0 110.579 179.089 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 53.4 m -115.31 -54.81 2.51 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -177.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -86.33 13.85 7.49 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.2 35.78 9.4 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 121.428 -0.415 . . . . 0.0 112.47 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.432 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.7 mt -80.03 166.63 21.37 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 123.163 0.585 . . . . 0.0 111.602 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.41 144.36 17.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.211 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.1 m -82.28 104.05 12.31 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.272 178.7 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.68 140.21 51.1 Favored Pre-proline 0 CA--C 1.531 0.222 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.484 -179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.31 65.21 2.12 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.964 2.443 . . . . 0.0 112.101 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.27 152.56 18.27 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.899 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.86 144.21 28.62 Favored Pre-proline 0 C--O 1.233 0.233 0 O-C-N 123.512 0.507 . . . . 0.0 111.645 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.47 -32.08 4.74 Favored 'Cis proline' 0 C--N 1.368 1.578 0 C-N-CA 123.961 -1.266 . . . . 0.0 113.137 0.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.12 144.49 31.73 Favored Pre-proline 0 CA--C 1.542 0.652 0 O-C-N 123.515 0.509 . . . . 0.0 111.099 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -63.21 157.47 49.55 Favored 'Trans proline' 0 C--N 1.374 1.871 0 C-N-CA 123.015 2.476 . . . . 0.0 113.859 -179.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.98 154.41 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.863 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.55 30.73 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.873 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.432 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -155.48 144.27 10.79 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 116.013 -0.54 . . . . 0.0 113.046 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.094 -0.955 . . . . 0.0 111.182 179.568 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 114.35 1.241 . . . . 0.0 114.35 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -139.76 96.71 3.12 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.833 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p -156.9 162.42 39.65 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.721 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.73 122.74 30.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.659 179.298 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.62 -155.74 0.34 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.556 -178.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -83.59 116.26 22.52 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 120.926 0.393 . . . . 0.0 110.527 -179.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.14 6.4 51.62 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.71 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -112.93 160.81 17.69 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.562 0.345 . . . . 0.0 110.646 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.8 p -79.72 136.18 36.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.677 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.506 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.7 p -108.38 34.48 3.61 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.18 -179.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -86.67 -15.35 39.89 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.753 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 13' ' ' TYR . 11.4 p -118.06 -41.59 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 O-C-N 123.42 0.45 . . . . 0.0 110.086 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.452 ' N ' HG13 ' A' ' 12' ' ' VAL . 22.3 m-85 -128.14 153.58 78.64 Favored Pre-proline 0 CA--C 1.537 0.464 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.189 179.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.22 -171.19 0.66 Allowed 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 123.31 2.674 . . . . 0.0 112.424 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.49 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 59.4 m -82.05 176.79 9.24 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 123.132 0.27 . . . . 0.0 110.402 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.3 m -118.23 -55.46 2.23 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.1 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -85.73 13.0 7.78 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.2 35.57 8.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.432 -0.413 . . . . 0.0 112.391 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.447 ' HB3' ' N ' ' A' ' 31' ' ' GLY . 2.3 mt -80.07 166.68 21.29 Favored 'General case' 0 C--O 1.236 0.379 0 C-N-CA 123.178 0.591 . . . . 0.0 111.51 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -110.48 143.33 20.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.091 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.7 m -81.37 103.3 11.03 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.223 178.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -80.45 140.42 52.06 Favored Pre-proline 0 CA--C 1.529 0.153 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.546 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.38 65.09 2.17 Favored 'Trans proline' 0 C--N 1.366 1.483 0 C-N-CA 122.955 2.437 . . . . 0.0 112.041 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.513 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.7 p -95.46 151.52 19.22 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.863 -178.689 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.97 144.25 28.54 Favored Pre-proline 0 C--O 1.235 0.298 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.716 -179.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -31.33 5.24 Favored 'Cis proline' 0 C--N 1.367 1.523 0 C-N-CA 123.99 -1.254 . . . . 0.0 113.115 0.142 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -114.44 144.56 32.02 Favored Pre-proline 0 CA--C 1.541 0.617 0 O-C-N 123.487 0.492 . . . . 0.0 111.172 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -63.5 157.78 49.06 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.877 2.385 . . . . 0.0 113.565 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.513 HG12 ' OG1' ' A' ' 24' ' ' THR . 16.4 mm -124.35 152.59 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.97 -179.795 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.506 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -88.67 118.54 28.41 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.782 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.447 ' N ' ' HB3' ' A' ' 19' ' ' LEU . . . -152.78 142.76 9.58 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 116.138 -0.483 . . . . 0.0 113.101 -179.696 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.475 -0.774 . . . . 0.0 111.228 179.617 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.9 p . . . . . 0 N--CA 1.466 0.333 0 CA-C-O 120.699 0.285 . . . . 0.0 111.455 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.596 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.46 120.92 26.5 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.633 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.73 -156.65 0.42 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.565 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.06 112.87 18.83 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 122.68 0.392 . . . . 0.0 111.363 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.38 9.12 39.45 Favored Glycine 0 C--N 1.334 0.472 0 CA-C-N 115.417 -0.811 . . . . 0.0 112.672 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.54 159.8 21.57 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 122.625 0.37 . . . . 0.0 110.519 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.1 p -80.97 135.19 35.83 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.586 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.421 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.69 36.18 2.62 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.2 -11.5 52.3 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.798 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.03 -38.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 O-C-N 123.423 0.452 . . . . 0.0 110.135 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -132.81 152.29 79.6 Favored Pre-proline 0 CA--C 1.538 0.515 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.422 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.14 -168.42 0.29 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.541 2.827 . . . . 0.0 112.85 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.9 m -83.93 175.84 9.3 Favored 'General case' 0 CA--C 1.538 0.481 0 O-C-N 123.156 0.285 . . . . 0.0 110.547 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.0 m -117.75 -55.88 2.24 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.53 12.62 6.66 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -178.723 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.83 35.83 7.57 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.359 -0.448 . . . . 0.0 112.41 -179.66 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.512 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -81.95 171.54 14.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.134 0.574 . . . . 0.0 111.197 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -117.08 144.07 25.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.456 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 m -80.8 102.1 9.78 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.32 178.773 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.6 m-85 -79.99 140.97 54.17 Favored Pre-proline 0 N--CA 1.456 -0.163 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.36 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.91 64.41 1.89 Allowed 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 122.957 2.438 . . . . 0.0 112.098 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.521 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.0 p -95.19 150.98 19.62 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.937 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.26 144.09 28.26 Favored Pre-proline 0 C--O 1.234 0.25 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.738 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.563 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.76 -35.17 2.97 Favored 'Cis proline' 0 C--N 1.366 1.487 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.226 0.007 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.563 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.66 144.96 31.32 Favored Pre-proline 0 CA--C 1.542 0.654 0 O-C-N 123.258 0.348 . . . . 0.0 111.194 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.6 Cg_endo -64.25 157.54 53.47 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.784 2.323 . . . . 0.0 113.374 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.521 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.4 mm -124.06 152.88 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.979 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.421 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.83 118.85 28.83 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.788 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.512 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.88 145.62 13.31 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 116.195 -0.457 . . . . 0.0 113.368 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.448 -0.787 . . . . 0.0 111.046 179.503 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.5 p . . . . . 0 N--CA 1.466 0.331 0 CA-C-O 120.665 0.269 . . . . 0.0 111.536 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.604 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.75 120.69 26.34 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.647 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.64 -156.8 0.42 Allowed 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.54 -178.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -80.82 112.85 18.59 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.682 0.393 . . . . 0.0 111.407 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.42 9.06 39.5 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.585 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.5 159.71 21.67 Favored 'General case' 0 C--O 1.235 0.301 0 C-N-CA 122.592 0.357 . . . . 0.0 110.438 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.8 p -80.88 135.27 35.89 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.555 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.423 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.96 36.43 2.57 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.863 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.25 -11.77 51.43 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.868 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -123.95 -38.46 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 123.384 0.428 . . . . 0.0 110.234 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -132.6 152.46 80.0 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.396 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.19 -168.57 0.3 Allowed 'Trans proline' 0 C--N 1.367 1.545 0 C-N-CA 123.507 2.805 . . . . 0.0 112.937 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.604 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.1 m -83.75 175.9 9.34 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 123.148 0.28 . . . . 0.0 110.567 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.1 m -117.65 -55.9 2.25 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.913 0.709 . . . . 0.0 112.913 -178.058 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.59 12.58 6.81 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 -178.681 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.77 36.03 7.51 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 121.449 -0.405 . . . . 0.0 112.337 -179.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.507 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -81.99 171.38 14.47 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.19 0.596 . . . . 0.0 111.196 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.86 144.16 25.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.484 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.5 m -80.94 102.13 9.92 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.382 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -79.99 140.9 54.1 Favored Pre-proline 0 CA--C 1.529 0.165 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.39 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 64.45 1.85 Allowed 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.961 2.44 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.7 p -95.27 151.14 19.5 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.893 -178.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.46 144.05 28.22 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.769 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.562 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.77 -35.17 2.98 Favored 'Cis proline' 0 C--N 1.367 1.506 0 C-N-CA 124.085 -1.214 . . . . 0.0 113.253 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.562 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.69 144.92 31.25 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.291 0.37 . . . . 0.0 111.217 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.1 Cg_endo -64.1 157.34 53.9 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.904 2.403 . . . . 0.0 113.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.2 mm -123.92 152.88 29.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.068 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.81 118.92 28.85 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.781 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.507 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.75 145.66 13.43 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 116.109 -0.496 . . . . 0.0 113.3 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.078 -0.963 . . . . 0.0 111.055 179.446 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.1 p . . . . . 0 N--CA 1.467 0.38 0 CA-C-O 120.74 0.305 . . . . 0.0 111.46 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.588 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.98 119.79 25.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.81 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.77 -156.28 0.38 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.456 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.34 112.77 18.94 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 122.597 0.359 . . . . 0.0 111.375 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.98 8.15 39.82 Favored Glycine 0 CA--C 1.522 0.488 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.637 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.75 159.58 21.24 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 122.604 0.362 . . . . 0.0 110.562 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.0 p -80.02 131.21 35.74 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.787 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.551 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -100.6 29.83 4.26 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.911 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.405 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -85.39 -10.48 56.2 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.741 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.405 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.96 -37.68 1.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.006 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -137.05 152.87 74.65 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.19 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.39 -172.72 0.56 Allowed 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 123.313 2.676 . . . . 0.0 112.757 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.588 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 48.4 m -80.9 175.41 10.71 Favored 'General case' 0 CA--C 1.539 0.526 0 O-C-N 123.026 0.204 . . . . 0.0 110.472 179.063 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 34.8 m -117.2 -56.01 2.28 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.91 13.07 6.35 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.18 36.7 7.47 Favored Glycine 0 C--N 1.34 0.769 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.418 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.52 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.6 mt -82.24 170.41 15.45 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.157 0.583 . . . . 0.0 111.222 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -115.48 144.44 23.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.588 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.8 m -80.87 102.74 10.25 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.276 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -80.78 140.61 50.87 Favored Pre-proline 0 CA--C 1.53 0.184 0 CA-C-N 115.296 -0.866 . . . . 0.0 111.439 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.73 64.61 1.78 Allowed 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.885 2.39 . . . . 0.0 112.175 179.735 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.526 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.8 p -95.31 152.33 18.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.983 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.29 144.26 28.83 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.64 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.543 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.6 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.476 0 C-N-CA 124.152 -1.187 . . . . 0.0 113.273 -0.078 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.543 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.93 145.38 32.29 Favored Pre-proline 0 CA--C 1.541 0.599 0 O-C-N 123.365 0.416 . . . . 0.0 111.203 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.422 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.67 156.96 54.26 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 122.884 2.389 . . . . 0.0 113.428 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.526 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.2 mm -123.12 153.46 28.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.979 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.37 119.16 29.59 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.792 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.52 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.44 145.78 13.52 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.261 -0.495 . . . . 0.0 113.256 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.127 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.134 179.386 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.4 p . . . . . 0 C--O 1.235 0.317 0 CA-C-O 120.677 0.275 . . . . 0.0 111.506 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.6 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.86 119.94 25.91 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.844 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.46 -156.43 0.4 Allowed 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.418 -178.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.2 112.42 18.51 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.687 0.395 . . . . 0.0 111.233 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.88 36.8 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -116.94 158.95 23.2 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.646 0.379 . . . . 0.0 110.582 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.4 p -80.13 131.75 35.8 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.855 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.5 p -100.76 31.11 3.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.89 179.758 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.43 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.26 -11.54 52.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.781 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.43 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.4 -37.77 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.134 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -136.6 152.97 75.59 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.13 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -69.35 -172.31 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.561 0 C-N-CA 123.345 2.696 . . . . 0.0 112.646 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.6 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 54.6 m -81.46 174.93 10.98 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 123.017 0.198 . . . . 0.0 110.487 179.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.5 m -115.87 -55.59 2.4 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -84.64 11.81 8.26 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.67 35.29 7.91 Favored Glycine 0 C--N 1.339 0.732 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.348 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.545 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -80.01 166.95 21.06 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.164 0.586 . . . . 0.0 111.488 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.34 144.41 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.188 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.7 m -82.27 104.03 12.29 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.241 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -80.85 140.27 50.47 Favored Pre-proline 0 CA--C 1.53 0.19 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.13 65.16 2.02 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 122.904 2.402 . . . . 0.0 112.103 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.49 151.62 19.14 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.798 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.22 144.31 28.71 Favored Pre-proline 0 CA--C 1.532 0.282 0 O-C-N 123.511 0.507 . . . . 0.0 111.626 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -32.01 4.77 Favored 'Cis proline' 0 C--N 1.367 1.53 0 C-N-CA 124.13 -1.196 . . . . 0.0 113.179 0.044 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -113.98 144.33 31.34 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.025 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.9 Cg_endo -63.45 157.41 50.85 Favored 'Trans proline' 0 C--N 1.375 1.97 0 C-N-CA 123.0 2.467 . . . . 0.0 113.803 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.73 154.4 27.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.92 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.54 119.26 30.66 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.851 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.545 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.68 144.28 10.95 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.112 -0.495 . . . . 0.0 113.003 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.41 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.251 1.145 0 CA-C-O 118.474 -0.774 . . . . 0.0 111.244 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.7 p . . . . . 0 N--CA 1.466 0.328 0 CA-C-O 120.821 0.344 . . . . 0.0 111.524 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.621 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.36 116.84 24.78 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.826 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLU . . . . . 0.553 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.67 -154.46 0.29 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.155 -179.269 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -79.83 106.44 11.86 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.973 0.416 . . . . 0.0 111.053 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.55 9.98 24.19 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.326 -0.852 . . . . 0.0 112.407 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.553 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.9 mt-10 -112.34 156.48 22.38 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.608 0.363 . . . . 0.0 110.525 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -82.64 128.5 34.39 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.889 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.6 p -96.77 33.33 1.88 Allowed 'General case' 0 C--O 1.238 0.486 0 CA-C-O 121.295 0.569 . . . . 0.0 110.9 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -89.85 -10.83 43.88 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.407 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.8 p -123.9 -39.12 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.031 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 25.6 m-85 -134.86 152.63 77.76 Favored Pre-proline 0 CA--C 1.538 0.494 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.177 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.55 -171.76 0.49 Allowed 'Trans proline' 0 C--N 1.367 1.544 0 C-N-CA 123.308 2.672 . . . . 0.0 112.689 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.4 m -81.87 174.84 10.92 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 110.324 -0.25 . . . . 0.0 110.324 178.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 40.9 m -114.29 -55.28 2.51 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 -178.009 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.45 12.2 10.79 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.82 36.86 7.59 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.514 -0.374 . . . . 0.0 112.263 -179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.609 HD22 ' HA2' ' A' ' 31' ' ' GLY . 3.1 mt -79.96 166.85 21.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 123.254 0.622 . . . . 0.0 111.597 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.8 mt -107.7 144.85 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.195 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.9 m -82.52 104.65 12.96 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.162 178.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -81.25 139.93 48.87 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.554 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.1 65.24 2.0 Allowed 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.929 2.42 . . . . 0.0 112.079 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 43.8 p -95.53 151.73 19.05 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.875 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.39 144.3 28.72 Favored Pre-proline 0 CA--C 1.532 0.269 0 O-C-N 123.57 0.544 . . . . 0.0 111.563 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.58 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.367 1.519 0 C-N-CA 124.145 -1.189 . . . . 0.0 113.166 0.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -113.73 144.07 30.73 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.145 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.46 157.23 51.88 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.048 2.499 . . . . 0.0 113.717 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.9 mm -122.38 154.39 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.904 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -90.67 119.39 30.87 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.791 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.609 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.77 144.65 11.17 Favored Glycine 0 C--N 1.338 0.675 0 CA-C-N 116.101 -0.5 . . . . 0.0 113.044 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.484 HG13 HD23 ' A' ' 19' ' ' LEU . 1.1 m . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.079 -0.962 . . . . 0.0 111.199 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.0 p . . . . . 0 N--CA 1.465 0.298 0 CA-C-O 120.726 0.298 . . . . 0.0 111.476 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.61 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.79 119.03 24.84 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.8 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -88.24 -155.96 0.34 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.466 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.55 112.99 19.28 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 122.708 0.403 . . . . 0.0 111.256 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.26 7.1 41.08 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-N 115.528 -0.76 . . . . 0.0 112.733 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.12 159.25 21.1 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.561 0.345 . . . . 0.0 110.504 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 54.7 p -79.94 131.63 35.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.843 -179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -100.73 31.23 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.865 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.428 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.58 -11.46 51.44 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.759 179.982 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.428 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.24 -37.68 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.051 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -136.76 153.1 75.46 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.123 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.53 -172.1 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.572 0 C-N-CA 123.295 2.663 . . . . 0.0 112.539 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.61 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.6 m -81.52 175.14 10.78 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 110.49 -0.189 . . . . 0.0 110.49 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.4 m -115.85 -55.3 2.43 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.21 12.36 8.14 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.15 35.36 8.16 Favored Glycine 0 C--N 1.339 0.748 0 C-N-CA 121.516 -0.374 . . . . 0.0 112.383 -179.602 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.552 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -79.91 167.0 21.07 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.231 0.612 . . . . 0.0 111.576 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.46 144.33 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.268 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.8 m -82.09 104.03 12.14 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.253 178.679 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -81.3 140.43 48.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.501 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -70.26 64.83 2.1 Favored 'Trans proline' 0 C--N 1.364 1.393 0 C-N-CA 122.999 2.466 . . . . 0.0 112.054 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.526 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.4 p -95.31 152.52 18.31 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.897 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.52 144.18 28.72 Favored Pre-proline 0 C--O 1.236 0.374 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.565 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.3 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.485 0 C-N-CA 124.064 -1.223 . . . . 0.0 113.238 -0.019 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.02 145.37 32.3 Favored Pre-proline 0 CA--C 1.542 0.661 0 O-C-N 123.29 0.369 . . . . 0.0 111.197 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.422 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.1 Cg_endo -63.67 156.79 55.24 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.943 2.429 . . . . 0.0 113.419 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.526 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.8 mm -122.52 153.79 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.96 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -89.92 119.16 30.05 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.939 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.552 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.35 144.04 10.73 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.985 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.41 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.073 -0.965 . . . . 0.0 111.127 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p . . . . . 0 C--O 1.235 0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.385 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.635 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.89 116.48 24.16 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.878 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLU . . . . . 0.553 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.14 -154.32 0.27 Allowed 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.181 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -79.82 106.86 12.15 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.082 0.468 . . . . 0.0 111.187 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.74 9.9 25.82 Favored Glycine 0 C--N 1.336 0.541 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.55 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.553 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.0 mt-10 -111.72 156.8 21.32 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 122.649 0.379 . . . . 0.0 110.499 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.4 p -82.88 132.05 35.17 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.752 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.427 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.2 p -102.05 38.1 1.72 Allowed 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.58 0.55 . . . . 0.0 111.18 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -91.46 -11.0 38.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.38 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.9 p -124.72 -39.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.934 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 27.2 m-85 -132.16 152.01 79.39 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 123.538 0.524 . . . . 0.0 111.51 179.367 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.5 -169.07 0.34 Allowed 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.577 2.851 . . . . 0.0 112.75 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 49.4 m -83.53 175.13 10.01 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 123.119 0.262 . . . . 0.0 110.376 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.9 m -114.84 -55.26 2.5 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.102 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 12.36 9.9 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.96 36.14 7.87 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 121.422 -0.418 . . . . 0.0 112.39 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.608 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.9 mt -79.93 168.13 19.62 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.331 0.653 . . . . 0.0 111.541 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -109.85 144.66 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.224 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.1 m -82.37 103.86 12.24 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.173 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -80.69 140.46 51.18 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.492 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -70.37 64.84 2.16 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.924 2.416 . . . . 0.0 111.978 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.5 p -95.0 150.43 20.17 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.963 -178.825 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -105.46 144.19 28.32 Favored Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.589 0.555 . . . . 0.0 111.724 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.87 -31.4 5.16 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.219 0.001 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -113.7 143.9 30.39 Favored Pre-proline 0 CA--C 1.541 0.621 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.199 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.6 Cg_endo -64.09 157.59 52.53 Favored 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 123.016 2.477 . . . . 0.0 113.514 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.97 154.09 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.973 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.427 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.0 m -90.08 119.02 30.06 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.608 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.91 144.68 11.37 Favored Glycine 0 C--N 1.337 0.599 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.013 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.474 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.452 -0.785 . . . . 0.0 111.122 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.3 p . . . . . 0 N--CA 1.467 0.389 0 CA-C-O 120.667 0.27 . . . . 0.0 111.621 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.612 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.69 118.52 24.46 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.789 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.23 -156.78 0.38 Allowed 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.406 -178.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -80.74 112.03 17.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.641 0.376 . . . . 0.0 111.387 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.94 8.14 37.15 Favored Glycine 0 C--N 1.334 0.471 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.62 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -115.98 158.69 22.69 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 122.623 0.369 . . . . 0.0 110.535 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.0 p -80.11 131.67 35.79 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.808 -179.428 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.6 p -100.6 31.13 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.893 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.3 -11.38 52.37 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.749 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.6 -38.08 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.137 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -136.2 152.86 76.04 Favored Pre-proline 0 CA--C 1.538 0.481 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.145 179.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.07 -172.04 0.47 Allowed 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 123.349 2.699 . . . . 0.0 112.605 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.612 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -81.64 175.78 10.2 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 123.123 0.264 . . . . 0.0 110.406 178.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 42.3 m -114.9 -55.99 2.42 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -87.47 13.18 10.55 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.87 35.98 6.97 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.395 -0.431 . . . . 0.0 112.625 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.552 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -80.19 166.36 21.51 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.018 0.527 . . . . 0.0 111.447 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.86 143.96 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.223 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.5 m -82.13 103.55 11.82 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.238 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.8 m-85 -80.19 140.33 53.06 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.509 -179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 65.01 2.07 Favored 'Trans proline' 0 C--N 1.365 1.424 0 C-N-CA 123.055 2.503 . . . . 0.0 112.142 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.33 151.55 19.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.894 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.65 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.56 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.366 1.477 0 C-N-CA 124.055 -1.227 . . . . 0.0 113.088 0.081 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -113.87 144.24 31.12 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.09 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.0 Cg_endo -63.34 157.62 49.28 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.023 2.482 . . . . 0.0 113.751 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.96 153.93 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.902 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.15 119.25 30.32 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.883 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.552 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.9 143.93 10.51 Favored Glycine 0 C--N 1.339 0.695 0 CA-C-N 116.071 -0.513 . . . . 0.0 113.088 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.415 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.135 -0.936 . . . . 0.0 111.142 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.467 0.392 0 CA-C-O 120.712 0.291 . . . . 0.0 111.468 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.599 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.67 120.25 26.17 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.742 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.68 -156.34 0.4 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.389 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.23 112.6 18.71 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.897 0.379 . . . . 0.0 111.373 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.31 8.8 37.63 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.566 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -116.97 158.97 23.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 122.622 0.369 . . . . 0.0 110.524 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.4 p -80.03 131.94 35.89 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.819 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -100.96 31.16 3.71 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.854 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.417 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.41 -11.21 52.57 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.721 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.417 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.6 p -121.52 -37.89 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.07 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -136.72 152.95 75.36 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.179 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.23 -172.17 0.5 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 123.342 2.695 . . . . 0.0 112.574 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.599 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -81.61 175.15 10.73 Favored 'General case' 0 CA--C 1.539 0.535 0 O-C-N 123.044 0.215 . . . . 0.0 110.449 179.075 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.8 m -116.02 -55.43 2.41 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -177.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -85.11 12.87 6.96 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -178.839 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.33 8.73 Favored Glycine 0 C--N 1.341 0.851 0 C-N-CA 121.478 -0.392 . . . . 0.0 112.413 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.55 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -79.98 166.77 21.26 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.22 0.608 . . . . 0.0 111.484 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.09 144.36 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.239 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.5 m -82.3 103.93 12.24 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.5 m-85 -80.76 140.28 50.8 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.46 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.17 65.07 2.05 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.94 2.427 . . . . 0.0 112.056 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.41 151.49 19.23 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.878 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.339 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.746 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.52 -32.28 4.6 Favored 'Cis proline' 0 C--N 1.366 1.475 0 C-N-CA 124.046 -1.231 . . . . 0.0 113.142 0.077 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.76 144.23 31.05 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.43 157.42 50.73 Favored 'Trans proline' 0 C--N 1.375 1.931 0 C-N-CA 123.004 2.47 . . . . 0.0 113.809 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.7 mm -122.81 154.33 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.857 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -90.59 119.36 30.78 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.877 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.55 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.76 144.01 10.63 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 116.041 -0.527 . . . . 0.0 113.014 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.411 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.424 -0.798 . . . . 0.0 111.23 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p . . . . . 0 C--O 1.235 0.332 0 CA-C-O 120.691 0.281 . . . . 0.0 111.46 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.19 119.95 25.63 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.71 179.685 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -89.14 -156.3 0.39 Allowed 'General case' 0 CA--C 1.544 0.713 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.665 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -81.21 113.04 19.08 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 122.651 0.38 . . . . 0.0 111.384 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.76 8.36 40.01 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.334 -0.848 . . . . 0.0 112.604 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -116.16 159.67 21.45 Favored 'General case' 0 C--O 1.236 0.395 0 C-N-CA 122.493 0.317 . . . . 0.0 110.555 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.8 p -81.02 134.74 35.73 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.702 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.457 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -105.41 37.41 2.21 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.758 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -87.31 -13.36 43.83 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.885 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 p -122.43 -38.43 1.37 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 O-C-N 123.506 0.504 . . . . 0.0 110.111 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -132.26 152.42 80.08 Favored Pre-proline 0 CA--C 1.538 0.511 0 O-C-N 123.609 0.568 . . . . 0.0 111.462 179.512 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.21 -168.35 0.29 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 123.426 2.751 . . . . 0.0 112.777 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.626 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -84.09 175.6 9.39 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 123.048 0.218 . . . . 0.0 110.502 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.9 m -116.53 -55.34 2.38 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -178.016 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -84.77 12.26 7.62 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.5 34.74 8.34 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.461 -0.399 . . . . 0.0 112.359 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.539 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -80.04 167.79 19.98 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.223 0.609 . . . . 0.0 111.426 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.91 144.21 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.252 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.9 m -82.22 103.26 11.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.166 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.9 m-85 -80.34 140.83 52.69 Favored Pre-proline 0 CA--C 1.53 0.195 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.511 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.33 64.58 2.14 Favored 'Trans proline' 0 C--N 1.364 1.389 0 C-N-CA 122.955 2.437 . . . . 0.0 111.997 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.522 ' OG1' HG12 ' A' ' 29' ' ' ILE . 47.7 p -95.02 151.65 18.99 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.964 -178.834 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.76 143.95 28.09 Favored Pre-proline 0 C--O 1.234 0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.674 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -76.36 -36.61 2.44 Favored 'Cis proline' 0 C--N 1.365 1.435 0 C-N-CA 124.079 -1.217 . . . . 0.0 113.162 0.051 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -109.67 145.91 32.94 Favored Pre-proline 0 CA--C 1.54 0.559 0 O-C-N 123.342 0.401 . . . . 0.0 111.131 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.4 Cg_endo -64.47 157.64 53.84 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.842 2.362 . . . . 0.0 113.351 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.522 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.1 mm -123.71 153.55 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.969 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.457 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.54 118.95 29.55 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.929 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.539 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.8 144.1 10.89 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 116.042 -0.526 . . . . 0.0 113.092 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.407 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.19 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.47 0.527 0 CA-C-O 120.707 0.289 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.573 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.78 120.16 27.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.524 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.08 -156.12 0.38 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.526 -178.818 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.12 113.49 19.32 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.78 0.432 . . . . 0.0 111.242 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.82 7.23 42.1 Favored Glycine 0 C--N 1.334 0.419 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.588 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.72 159.31 20.69 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.741 0.416 . . . . 0.0 110.579 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 65.1 p -79.98 131.44 35.81 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.781 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.576 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.47 28.7 5.3 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.971 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.4 -12.18 56.75 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.705 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.445 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.5 p -121.35 -41.06 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.348 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -130.26 153.53 81.24 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.306 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.7 -174.71 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.202 2.601 . . . . 0.0 112.42 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.07 175.22 10.83 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 110.53 -0.174 . . . . 0.0 110.53 179.114 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.5 m -115.15 -54.88 2.52 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.31 12.95 8.9 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.68 8.65 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.415 -0.421 . . . . 0.0 112.366 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.571 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -79.93 166.56 21.51 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.265 0.626 . . . . 0.0 111.565 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.6 144.29 17.37 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.155 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.8 m -82.21 103.98 12.2 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.214 178.741 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.64 140.18 51.23 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.535 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.33 65.23 2.14 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.965 2.443 . . . . 0.0 112.093 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.29 152.9 17.97 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.963 -178.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -107.05 144.23 28.7 Favored Pre-proline 0 C--O 1.236 0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.73 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.42 -32.05 4.77 Favored 'Cis proline' 0 C--N 1.365 1.419 0 C-N-CA 124.084 -1.215 . . . . 0.0 113.196 0.047 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.27 144.49 31.8 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.089 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.2 Cg_endo -63.21 157.52 49.27 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 123.02 2.48 . . . . 0.0 113.75 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.89 154.38 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.864 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.42 119.5 30.76 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.948 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.571 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.44 144.32 10.86 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 116.083 -0.508 . . . . 0.0 113.117 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.434 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.065 -0.969 . . . . 0.0 111.108 179.633 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.7 p . . . . . 0 N--CA 1.471 0.584 0 CA-C-O 120.681 0.277 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.9 120.03 27.74 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.0 -156.11 0.37 Allowed 'General case' 0 CA--C 1.543 0.696 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.533 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.09 113.47 19.29 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.986 0.422 . . . . 0.0 111.238 -179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.04 6.94 41.99 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.546 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.56 159.39 20.47 Favored 'General case' 0 C--O 1.234 0.275 0 C-N-CA 122.547 0.339 . . . . 0.0 110.481 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.2 p -79.94 131.27 35.79 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.811 -179.321 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.578 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.11 28.62 5.2 Favored 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.969 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.446 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.59 -12.1 56.5 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.661 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.446 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.38 -41.31 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.217 -179.614 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -130.26 153.44 81.23 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.326 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.62 -174.82 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.472 0 C-N-CA 123.202 2.601 . . . . 0.0 112.348 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -79.87 175.28 10.77 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -115.16 -54.86 2.52 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -178.019 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.55 13.08 9.05 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.26 35.88 8.53 Favored Glycine 0 C--N 1.34 0.764 0 C-N-CA 121.495 -0.384 . . . . 0.0 112.293 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.576 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.97 166.58 21.45 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.159 0.584 . . . . 0.0 111.649 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -108.4 144.36 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.141 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.2 m -82.24 103.89 12.16 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -80.38 140.13 52.22 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.538 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.24 65.22 2.09 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.05 2.5 . . . . 0.0 112.079 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.36 152.74 18.13 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.889 -178.884 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -107.0 144.23 28.68 Favored Pre-proline 0 C--O 1.234 0.268 0 O-C-N 123.541 0.526 . . . . 0.0 111.683 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.55 -31.93 4.84 Favored 'Cis proline' 0 C--N 1.367 1.505 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.22 0.06 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.15 144.6 31.95 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.525 0.516 . . . . 0.0 111.127 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.2 Cg_endo -63.28 157.53 49.53 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.962 2.441 . . . . 0.0 113.793 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.83 154.31 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.871 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.31 119.44 30.61 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.91 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.576 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.56 144.36 10.88 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 116.114 -0.494 . . . . 0.0 113.016 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.433 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.126 -0.94 . . . . 0.0 111.257 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.469 0.505 0 CA-C-O 120.666 0.27 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.57 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.92 120.37 28.12 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.465 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.26 -155.96 0.37 Allowed 'General case' 0 CA--C 1.545 0.768 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.622 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.37 113.65 19.6 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.312 0.382 . . . . 0.0 111.225 -179.506 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.78 7.31 42.06 Favored Glycine 0 CA--C 1.521 0.453 0 CA-C-N 115.378 -0.828 . . . . 0.0 112.511 -179.579 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -114.95 159.51 20.65 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 122.62 0.368 . . . . 0.0 110.526 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.4 p -80.1 131.44 35.75 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.804 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.575 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.41 28.66 5.31 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.033 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.446 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.43 -12.05 56.84 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.712 179.971 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.446 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.46 -41.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 O-C-N 123.583 0.552 . . . . 0.0 110.298 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -130.41 153.45 81.34 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -70.69 -174.65 1.14 Allowed 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 123.188 2.592 . . . . 0.0 112.357 179.183 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.06 175.21 10.84 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.6 m -115.29 -54.84 2.51 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 112.906 0.706 . . . . 0.0 112.906 -178.006 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -86.11 12.73 9.01 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.62 8.56 Favored Glycine 0 C--N 1.34 0.792 0 C-N-CA 121.517 -0.373 . . . . 0.0 112.291 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.569 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -79.9 166.61 21.48 Favored 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 123.254 0.621 . . . . 0.0 111.51 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.57 144.42 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.175 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.6 m -82.38 103.97 12.34 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.155 178.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -80.68 140.17 51.08 Favored Pre-proline 0 CA--C 1.53 0.199 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.32 65.25 2.13 Favored 'Trans proline' 0 C--N 1.366 1.455 0 C-N-CA 122.975 2.45 . . . . 0.0 111.993 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.3 152.49 18.33 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.9 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.84 144.29 28.77 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.688 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -31.85 4.88 Favored 'Cis proline' 0 C--N 1.367 1.521 0 C-N-CA 124.024 -1.24 . . . . 0.0 113.116 0.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.31 144.6 32.03 Favored Pre-proline 0 CA--C 1.542 0.665 0 O-C-N 123.481 0.488 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.25 157.51 49.52 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 122.894 2.396 . . . . 0.0 113.845 -179.499 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.93 154.37 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.819 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.575 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.42 30.62 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.901 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.569 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.35 144.24 10.78 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 116.048 -0.524 . . . . 0.0 113.001 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.429 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.252 1.236 0 CA-C-O 118.375 -0.822 . . . . 0.0 111.189 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p . . . . . 0 N--CA 1.47 0.555 0 CA-C-O 120.698 0.285 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.571 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.59 119.49 26.9 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.539 179.304 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.06 -156.2 0.35 Allowed 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.634 -178.855 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.27 113.63 19.53 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 122.765 0.426 . . . . 0.0 111.315 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.4 5.43 42.86 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.624 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.37 159.5 19.37 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.526 0.331 . . . . 0.0 110.52 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.9 131.67 35.9 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.805 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.19 4.84 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.002 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.447 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -84.02 -12.36 55.33 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.584 -0.734 . . . . 0.0 111.704 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.447 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.7 p -120.96 -41.01 1.79 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.268 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -130.59 153.5 81.49 Favored Pre-proline 0 CA--C 1.536 0.44 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.305 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.8 -174.48 1.12 Allowed 'Trans proline' 0 C--N 1.365 1.436 0 C-N-CA 123.167 2.578 . . . . 0.0 112.35 179.175 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.571 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.0 175.38 10.69 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.135 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -115.06 -54.69 2.54 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.69 13.07 9.3 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.71 8.62 Favored Glycine 0 C--N 1.341 0.831 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.34 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.579 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.83 166.81 21.32 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.187 0.595 . . . . 0.0 111.577 -179.453 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.54 144.4 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.195 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.8 m -82.43 104.11 12.47 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.162 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.06 140.33 49.71 Favored Pre-proline 0 CA--C 1.53 0.188 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.514 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.32 64.87 2.14 Favored 'Trans proline' 0 C--N 1.366 1.464 0 C-N-CA 122.995 2.463 . . . . 0.0 112.063 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.527 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.8 p -95.17 152.74 18.09 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.982 -178.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.68 144.16 28.73 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.57 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.539 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.31 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.025 -1.239 . . . . 0.0 113.22 0.003 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.539 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.07 145.54 32.67 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 123.34 0.4 . . . . 0.0 111.197 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.418 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 27.9 Cg_endo -63.58 156.8 54.77 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 122.988 2.459 . . . . 0.0 113.465 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.527 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -122.67 153.9 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.868 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.46 30.22 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.579 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.26 144.35 10.93 Favored Glycine 0 C--N 1.341 0.81 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.979 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.445 HG13 HD23 ' A' ' 19' ' ' LEU . 1.1 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.049 -0.977 . . . . 0.0 111.192 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 p . . . . . 0 N--CA 1.469 0.485 0 CA-C-O 120.643 0.258 . . . . 0.0 110.879 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.38 121.32 28.78 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.417 179.265 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -89.59 -156.58 0.41 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.636 -178.734 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.59 113.59 19.71 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 122.742 0.417 . . . . 0.0 111.295 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.73 7.4 42.01 Favored Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.565 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -115.05 160.34 19.75 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 122.548 0.339 . . . . 0.0 110.444 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.4 p -79.86 135.36 36.43 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.525 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.519 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -107.59 34.86 3.31 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.148 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -86.59 -14.89 41.49 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.761 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 p -118.76 -41.53 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 O-C-N 123.399 0.437 . . . . 0.0 110.2 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -127.68 153.6 77.76 Favored Pre-proline 0 CA--C 1.537 0.474 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.34 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.69 -170.25 0.51 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 123.298 2.665 . . . . 0.0 112.384 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.567 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -83.25 175.78 9.66 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.81 -54.57 2.49 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 112.875 0.695 . . . . 0.0 112.875 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 13.14 8.3 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.23 35.17 8.99 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.486 -0.388 . . . . 0.0 112.382 -179.541 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.573 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.6 mt -80.05 167.47 20.38 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.169 0.587 . . . . 0.0 111.489 -179.378 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.07 144.14 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.277 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.8 m -82.06 103.58 11.79 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.236 178.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -80.82 140.62 50.72 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.285 -0.87 . . . . 0.0 111.49 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.45 64.86 2.21 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.92 2.413 . . . . 0.0 112.045 179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.524 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.0 p -95.02 151.01 19.54 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.948 -178.786 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.74 144.4 28.79 Favored Pre-proline 0 C--O 1.234 0.279 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.692 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.67 -30.99 5.47 Favored 'Cis proline' 0 C--N 1.366 1.499 0 C-N-CA 124.053 -1.228 . . . . 0.0 113.161 0.048 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -114.64 144.4 31.8 Favored Pre-proline 0 CA--C 1.542 0.659 0 O-C-N 123.509 0.506 . . . . 0.0 111.118 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.76 157.61 51.04 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.865 2.377 . . . . 0.0 113.572 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.524 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.0 mm -124.39 153.66 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.943 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.519 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.1 m -89.41 119.13 29.6 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.804 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.573 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.61 144.45 11.16 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.078 -0.51 . . . . 0.0 113.016 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.424 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.083 -0.96 . . . . 0.0 111.265 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p . . . . . 0 N--CA 1.47 0.546 0 CA-C-O 120.6 0.238 . . . . 0.0 110.949 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.549 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.6 120.76 27.4 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.511 179.146 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLU . . . . . 0.508 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 12.0 pt-20 -89.11 -155.87 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.609 -178.786 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.508 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.65 113.74 19.86 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.961 0.41 . . . . 0.0 111.316 -179.548 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.48 7.19 43.14 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.635 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.78 159.97 19.97 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 122.538 0.335 . . . . 0.0 110.395 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 59.1 p -79.97 131.31 35.79 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.798 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.559 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 32.0 p -101.33 27.49 6.18 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.042 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -82.46 -11.36 58.56 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.685 179.95 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.8 p -121.8 -40.75 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.268 -179.618 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -130.8 153.47 81.64 Favored Pre-proline 0 CA--C 1.536 0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.377 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.92 -174.74 1.21 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.245 2.63 . . . . 0.0 112.297 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.5 m -80.01 175.53 10.55 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 110.508 -0.182 . . . . 0.0 110.508 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.4 m -116.71 -55.51 2.36 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -177.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.23 13.78 7.46 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.625 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.51 37.04 7.69 Favored Glycine 0 C--N 1.339 0.716 0 C-N-CA 121.43 -0.414 . . . . 0.0 112.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.533 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -82.28 169.65 16.28 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.239 0.616 . . . . 0.0 111.131 -179.531 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -114.81 144.22 22.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.54 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 m -80.61 102.88 10.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.379 178.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -80.74 140.49 50.98 Favored Pre-proline 0 N--CA 1.457 -0.111 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.415 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.7 64.64 1.77 Allowed 'Trans proline' 0 C--N 1.364 1.376 0 C-N-CA 123.009 2.473 . . . . 0.0 112.22 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.527 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.7 p -95.47 152.46 18.39 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.971 -178.848 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.42 144.13 28.59 Favored Pre-proline 0 C--O 1.235 0.341 0 O-C-N 123.506 0.504 . . . . 0.0 111.632 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.543 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.47 -35.52 2.85 Favored 'Cis proline' 0 C--N 1.368 1.557 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.266 0.129 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.543 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -111.05 145.39 32.34 Favored Pre-proline 0 CA--C 1.542 0.649 0 O-C-N 123.299 0.374 . . . . 0.0 111.166 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.419 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.1 Cg_endo -63.71 156.91 54.64 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 122.9 2.4 . . . . 0.0 113.365 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.527 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -123.12 153.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.977 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -88.85 119.21 29.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.72 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.533 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.01 146.08 13.96 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.342 -0.456 . . . . 0.0 113.323 -179.742 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.4 HG13 ' HA ' ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.414 -0.803 . . . . 0.0 111.08 179.437 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.469 0.489 0 CA-C-O 120.658 0.266 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.503 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.57 121.89 28.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.691 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.34 -155.7 0.33 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.484 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.554 ' HG2' HD21 ' A' ' 19' ' ' LEU . 2.3 mt-10 -83.03 115.82 22.02 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 122.605 0.362 . . . . 0.0 110.509 -179.252 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.65 6.63 49.7 Favored Glycine 0 CA--C 1.523 0.539 0 CA-C-N 115.468 -0.787 . . . . 0.0 112.69 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -113.35 160.05 18.78 Favored 'General case' 0 C--O 1.234 0.266 0 C-N-CA 122.494 0.318 . . . . 0.0 110.54 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.3 p -79.81 132.03 36.03 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.992 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.581 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -101.99 29.15 5.2 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.033 179.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.471 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.8 -13.58 53.46 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.713 179.97 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.471 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.3 p -119.99 -41.18 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.165 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -130.47 153.38 81.36 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.291 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.12 -174.52 1.2 Allowed 'Trans proline' 0 C--N 1.365 1.442 0 C-N-CA 123.307 2.671 . . . . 0.0 112.31 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 58.7 m -79.91 176.22 9.93 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.1 m -117.72 -55.68 2.26 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -178.048 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.8 12.85 8.21 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.24 36.1 7.74 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 121.439 -0.41 . . . . 0.0 112.356 -179.63 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.554 HD21 ' HG2' ' A' ' 6' ' ' GLU . 2.5 mt -80.12 166.25 21.67 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.13 0.572 . . . . 0.0 111.464 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -109.4 143.53 19.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.097 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.9 m -81.67 103.65 11.52 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.4 m-85 -80.52 140.18 51.71 Favored Pre-proline 0 CA--C 1.529 0.167 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.542 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.3 65.31 2.12 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.998 2.466 . . . . 0.0 112.007 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.517 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.64 152.04 18.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.927 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.49 144.22 28.57 Favored Pre-proline 0 C--O 1.234 0.249 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.673 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -32.06 4.73 Favored 'Cis proline' 0 C--N 1.366 1.493 0 C-N-CA 124.074 -1.219 . . . . 0.0 113.083 0.164 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.96 144.46 31.6 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.502 0.501 . . . . 0.0 111.101 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.34 157.74 48.66 Favored 'Trans proline' 0 C--N 1.375 1.932 0 C-N-CA 122.938 2.425 . . . . 0.0 113.85 -179.499 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.517 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.15 152.88 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.967 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.581 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.13 118.78 29.08 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.703 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.512 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.35 142.53 9.29 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 116.206 -0.452 . . . . 0.0 113.182 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.425 HG13 HD23 ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.289 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.8 p . . . . . 0 N--CA 1.469 0.515 0 CA-C-O 120.715 0.293 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.71 119.47 26.97 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.486 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLU . . . . . 0.507 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 11.9 pt-20 -88.07 -156.22 0.35 Allowed 'General case' 0 CA--C 1.545 0.77 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.598 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.507 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.35 113.8 19.69 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 122.714 0.406 . . . . 0.0 111.287 -179.572 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.23 5.53 43.24 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.435 -0.802 . . . . 0.0 112.628 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.39 159.47 19.41 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.638 0.375 . . . . 0.0 110.454 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.92 131.68 35.89 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.866 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.04 4.92 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.98 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.95 -12.35 55.47 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.702 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.451 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.12 -40.83 1.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.262 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -130.66 153.43 81.52 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 123.682 0.614 . . . . 0.0 111.317 179.578 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -70.61 -174.46 1.08 Allowed 'Trans proline' 0 C--N 1.365 1.417 0 C-N-CA 123.277 2.651 . . . . 0.0 112.331 179.15 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -80.06 175.39 10.68 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.03 -54.59 2.55 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.821 0.675 . . . . 0.0 112.821 -177.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.77 12.91 9.76 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.36 35.81 8.51 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.509 -0.377 . . . . 0.0 112.335 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.583 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.89 166.89 21.2 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.208 0.603 . . . . 0.0 111.62 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.55 144.41 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.204 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.3 m -82.28 104.11 12.36 Favored 'General case' 0 C--O 1.239 0.525 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.206 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.22 140.33 49.13 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.506 -179.597 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.21 64.9 2.07 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 123.003 2.469 . . . . 0.0 112.028 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.53 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.2 152.73 18.1 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.032 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.64 144.19 28.78 Favored Pre-proline 0 C--O 1.234 0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.634 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.539 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.25 -35.51 2.86 Favored 'Cis proline' 0 C--N 1.367 1.552 0 C-N-CA 123.986 -1.256 . . . . 0.0 113.333 -0.088 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.539 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.15 145.53 32.67 Favored Pre-proline 0 CA--C 1.543 0.677 0 O-C-N 123.303 0.377 . . . . 0.0 111.211 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.3 Cg_endo -63.65 156.71 55.6 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.867 2.378 . . . . 0.0 113.489 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.53 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.2 mm -122.42 153.92 27.16 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.002 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.38 30.15 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.896 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.583 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.2 144.35 10.94 Favored Glycine 0 C--N 1.338 0.688 0 CA-C-N 116.167 -0.469 . . . . 0.0 113.096 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.443 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.146 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.1 p . . . . . 0 N--CA 1.469 0.52 0 CA-C-O 120.629 0.252 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.569 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.8 120.43 28.09 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.528 179.269 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.28 -156.09 0.38 Allowed 'General case' 0 CA--C 1.544 0.72 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.62 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.29 113.69 19.57 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.948 0.404 . . . . 0.0 111.29 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.85 7.08 42.3 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.492 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.77 159.4 20.64 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 122.71 0.404 . . . . 0.0 110.479 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.6 p -79.98 131.43 35.81 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.053 -0.522 . . . . 0.0 111.856 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.576 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 30.9 p -101.47 28.69 5.31 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.004 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.447 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.46 -11.94 56.92 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.663 179.926 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.447 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.57 -41.17 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 O-C-N 123.543 0.527 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -130.24 153.58 81.23 Favored Pre-proline 0 CA--C 1.536 0.425 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.285 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.79 -174.74 1.18 Allowed 'Trans proline' 0 C--N 1.365 1.437 0 C-N-CA 123.214 2.61 . . . . 0.0 112.338 179.157 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.569 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.07 175.2 10.86 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 110.579 -0.156 . . . . 0.0 110.579 179.089 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 53.4 m -115.31 -54.81 2.51 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -177.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -86.33 13.85 7.49 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.2 35.78 9.4 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 121.428 -0.415 . . . . 0.0 112.47 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.573 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -80.03 166.63 21.37 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 123.163 0.585 . . . . 0.0 111.602 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.41 144.36 17.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.211 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.1 m -82.28 104.05 12.31 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.272 178.7 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.68 140.21 51.1 Favored Pre-proline 0 CA--C 1.531 0.222 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.484 -179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.31 65.21 2.12 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.964 2.443 . . . . 0.0 112.101 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.27 152.56 18.27 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.899 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.86 144.21 28.62 Favored Pre-proline 0 C--O 1.233 0.233 0 O-C-N 123.512 0.507 . . . . 0.0 111.645 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.47 -32.08 4.74 Favored 'Cis proline' 0 C--N 1.368 1.578 0 C-N-CA 123.961 -1.266 . . . . 0.0 113.137 0.061 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.12 144.49 31.73 Favored Pre-proline 0 CA--C 1.542 0.652 0 O-C-N 123.515 0.509 . . . . 0.0 111.099 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.5 Cg_endo -63.21 157.47 49.55 Favored 'Trans proline' 0 C--N 1.374 1.871 0 C-N-CA 123.015 2.476 . . . . 0.0 113.859 -179.455 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.98 154.41 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.863 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.55 30.73 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.873 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.573 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.48 144.27 10.79 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 116.013 -0.54 . . . . 0.0 113.046 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.433 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.094 -0.955 . . . . 0.0 111.182 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p . . . . . 0 N--CA 1.469 0.512 0 CA-C-O 120.671 0.272 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.73 122.74 30.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.659 179.298 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.62 -155.74 0.34 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.556 -178.877 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.552 ' HG2' HD21 ' A' ' 19' ' ' LEU . 2.3 mt-10 -83.59 116.26 22.52 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 120.926 0.393 . . . . 0.0 110.527 -179.313 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.14 6.4 51.62 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.71 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -112.93 160.81 17.69 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.562 0.345 . . . . 0.0 110.646 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.8 p -79.72 136.18 36.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.677 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.515 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.7 p -108.38 34.48 3.61 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.18 -179.785 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -86.67 -15.35 39.89 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.753 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.4 p -118.06 -41.59 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 O-C-N 123.42 0.45 . . . . 0.0 110.086 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.3 m-85 -128.14 153.58 78.64 Favored Pre-proline 0 CA--C 1.537 0.464 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.189 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.22 -171.19 0.66 Allowed 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 123.31 2.674 . . . . 0.0 112.424 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 59.4 m -82.05 176.79 9.24 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 123.132 0.27 . . . . 0.0 110.402 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.3 m -118.23 -55.46 2.23 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.1 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -85.73 13.0 7.78 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.772 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.2 35.57 8.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.432 -0.413 . . . . 0.0 112.391 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.552 HD21 ' HG2' ' A' ' 6' ' ' GLU . 2.3 mt -80.07 166.68 21.29 Favored 'General case' 0 C--O 1.236 0.379 0 C-N-CA 123.178 0.591 . . . . 0.0 111.51 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -110.48 143.33 20.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.091 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.7 m -81.37 103.3 11.03 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.223 178.702 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -80.45 140.42 52.06 Favored Pre-proline 0 CA--C 1.529 0.153 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.546 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.38 65.09 2.17 Favored 'Trans proline' 0 C--N 1.366 1.483 0 C-N-CA 122.955 2.437 . . . . 0.0 112.041 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.524 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.7 p -95.46 151.52 19.22 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.863 -178.689 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.97 144.25 28.54 Favored Pre-proline 0 C--O 1.235 0.298 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.716 -179.692 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -31.33 5.24 Favored 'Cis proline' 0 C--N 1.367 1.523 0 C-N-CA 123.99 -1.254 . . . . 0.0 113.115 0.142 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -114.44 144.56 32.02 Favored Pre-proline 0 CA--C 1.541 0.617 0 O-C-N 123.487 0.492 . . . . 0.0 111.172 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.417 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.3 Cg_endo -63.5 157.78 49.06 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.877 2.385 . . . . 0.0 113.565 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.524 HG12 ' OG1' ' A' ' 24' ' ' THR . 16.4 mm -124.35 152.59 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.97 -179.795 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.515 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -88.67 118.54 28.41 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.782 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.51 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.78 142.76 9.58 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 116.138 -0.483 . . . . 0.0 113.101 -179.696 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.423 HG13 HD23 ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.475 -0.774 . . . . 0.0 111.228 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 114.384 1.253 . . . . 0.0 114.384 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -98.09 -26.58 14.55 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.552 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.9 p -82.23 155.92 24.65 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 122.705 0.402 . . . . 0.0 111.455 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.596 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.46 120.92 26.5 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.633 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.73 -156.65 0.42 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.565 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.06 112.87 18.83 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 122.68 0.392 . . . . 0.0 111.363 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.38 9.12 39.45 Favored Glycine 0 C--N 1.334 0.472 0 CA-C-N 115.417 -0.811 . . . . 0.0 112.672 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.54 159.8 21.57 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 122.625 0.37 . . . . 0.0 110.519 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.1 p -80.97 135.19 35.83 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.586 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.421 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.69 36.18 2.62 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.2 -11.5 52.3 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.798 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.03 -38.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 O-C-N 123.423 0.452 . . . . 0.0 110.135 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -132.81 152.29 79.6 Favored Pre-proline 0 CA--C 1.538 0.515 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.422 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.14 -168.42 0.29 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.541 2.827 . . . . 0.0 112.85 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.9 m -83.93 175.84 9.3 Favored 'General case' 0 CA--C 1.538 0.481 0 O-C-N 123.156 0.285 . . . . 0.0 110.547 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.0 m -117.75 -55.88 2.24 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.53 12.62 6.66 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -178.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.83 35.83 7.57 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.359 -0.448 . . . . 0.0 112.41 -179.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.512 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -81.95 171.54 14.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.134 0.574 . . . . 0.0 111.197 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -117.08 144.07 25.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.456 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 m -80.8 102.1 9.78 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.32 178.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.6 m-85 -79.99 140.97 54.17 Favored Pre-proline 0 N--CA 1.456 -0.163 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.36 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.91 64.41 1.89 Allowed 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 122.957 2.438 . . . . 0.0 112.098 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.521 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.0 p -95.19 150.98 19.62 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.937 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.26 144.09 28.26 Favored Pre-proline 0 C--O 1.234 0.25 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.738 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.563 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.76 -35.17 2.97 Favored 'Cis proline' 0 C--N 1.366 1.487 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.226 0.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.563 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.66 144.96 31.32 Favored Pre-proline 0 CA--C 1.542 0.654 0 O-C-N 123.258 0.348 . . . . 0.0 111.194 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.6 Cg_endo -64.25 157.54 53.47 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.784 2.323 . . . . 0.0 113.374 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.521 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.4 mm -124.06 152.88 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.979 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.421 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.83 118.85 28.83 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.788 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.512 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.88 145.62 13.31 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 116.195 -0.457 . . . . 0.0 113.368 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.448 -0.787 . . . . 0.0 111.046 179.503 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 114.409 1.263 . . . . 0.0 114.409 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 94.1 m95 -105.39 -35.58 7.46 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.417 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.5 p -82.75 155.89 24.02 Favored 'General case' 0 N--CA 1.466 0.331 0 O-C-N 123.559 0.537 . . . . 0.0 111.536 -179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.604 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.75 120.69 26.34 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.647 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.64 -156.8 0.42 Allowed 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.54 -178.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -80.82 112.85 18.59 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.682 0.393 . . . . 0.0 111.407 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.42 9.06 39.5 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.585 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.5 159.71 21.67 Favored 'General case' 0 C--O 1.235 0.301 0 C-N-CA 122.592 0.357 . . . . 0.0 110.438 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.8 p -80.88 135.27 35.89 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.555 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.423 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.96 36.43 2.57 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.863 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.25 -11.77 51.43 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.868 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -123.95 -38.46 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 123.384 0.428 . . . . 0.0 110.234 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -132.6 152.46 80.0 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.396 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.19 -168.57 0.3 Allowed 'Trans proline' 0 C--N 1.367 1.545 0 C-N-CA 123.507 2.805 . . . . 0.0 112.937 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.604 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.1 m -83.75 175.9 9.34 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 123.148 0.28 . . . . 0.0 110.567 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.1 m -117.65 -55.9 2.25 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.913 0.709 . . . . 0.0 112.913 -178.058 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.59 12.58 6.81 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 -178.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.77 36.03 7.51 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 121.449 -0.405 . . . . 0.0 112.337 -179.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.507 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -81.99 171.38 14.47 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.19 0.596 . . . . 0.0 111.196 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.86 144.16 25.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.484 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.5 m -80.94 102.13 9.92 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.382 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -79.99 140.9 54.1 Favored Pre-proline 0 CA--C 1.529 0.165 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.39 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 64.45 1.85 Allowed 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.961 2.44 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.7 p -95.27 151.14 19.5 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.893 -178.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.46 144.05 28.22 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.769 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.562 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.77 -35.17 2.98 Favored 'Cis proline' 0 C--N 1.367 1.506 0 C-N-CA 124.085 -1.214 . . . . 0.0 113.253 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.562 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.69 144.92 31.25 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.291 0.37 . . . . 0.0 111.217 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.1 Cg_endo -64.1 157.34 53.9 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.904 2.403 . . . . 0.0 113.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.2 mm -123.92 152.88 29.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.068 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.81 118.92 28.85 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.781 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.507 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.75 145.66 13.43 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 116.109 -0.496 . . . . 0.0 113.3 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.078 -0.963 . . . . 0.0 111.055 179.446 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 114.816 1.413 . . . . 0.0 114.816 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 96.7 m95 -118.49 -33.2 4.39 Favored 'General case' 0 N--CA 1.466 0.372 0 O-C-N 123.449 0.468 . . . . 0.0 111.44 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.1 p -81.88 156.28 24.9 Favored 'General case' 0 N--CA 1.467 0.38 0 O-C-N 123.413 0.446 . . . . 0.0 111.46 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.588 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.98 119.79 25.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.81 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.77 -156.28 0.38 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.456 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.34 112.77 18.94 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 122.597 0.359 . . . . 0.0 111.375 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.98 8.15 39.82 Favored Glycine 0 CA--C 1.522 0.488 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.637 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.75 159.58 21.24 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 122.604 0.362 . . . . 0.0 110.562 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.0 p -80.02 131.21 35.74 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.787 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.551 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -100.6 29.83 4.26 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.911 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.405 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -85.39 -10.48 56.2 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.741 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.405 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.96 -37.68 1.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.006 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -137.05 152.87 74.65 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.19 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.39 -172.72 0.56 Allowed 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 123.313 2.676 . . . . 0.0 112.757 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.588 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 48.4 m -80.9 175.41 10.71 Favored 'General case' 0 CA--C 1.539 0.526 0 O-C-N 123.026 0.204 . . . . 0.0 110.472 179.063 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 34.8 m -117.2 -56.01 2.28 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.91 13.07 6.35 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.18 36.7 7.47 Favored Glycine 0 C--N 1.34 0.769 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.418 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.52 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.6 mt -82.24 170.41 15.45 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.157 0.583 . . . . 0.0 111.222 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -115.48 144.44 23.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.588 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.8 m -80.87 102.74 10.25 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.276 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -80.78 140.61 50.87 Favored Pre-proline 0 CA--C 1.53 0.184 0 CA-C-N 115.296 -0.866 . . . . 0.0 111.439 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.73 64.61 1.78 Allowed 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.885 2.39 . . . . 0.0 112.175 179.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.526 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.8 p -95.31 152.33 18.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.983 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.29 144.26 28.83 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.64 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.543 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.6 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.476 0 C-N-CA 124.152 -1.187 . . . . 0.0 113.273 -0.078 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.543 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.93 145.38 32.29 Favored Pre-proline 0 CA--C 1.541 0.599 0 O-C-N 123.365 0.416 . . . . 0.0 111.203 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.422 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.67 156.96 54.26 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 122.884 2.389 . . . . 0.0 113.428 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.526 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.2 mm -123.12 153.46 28.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.979 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.37 119.16 29.59 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.792 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.52 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.44 145.78 13.52 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.261 -0.495 . . . . 0.0 113.256 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.127 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.134 179.386 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.782 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -99.91 -16.42 18.0 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.73 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.4 p -81.39 157.25 25.05 Favored 'General case' 0 C--N 1.343 0.321 0 C-N-CA 122.747 0.419 . . . . 0.0 111.506 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.6 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.86 119.94 25.91 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.844 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.46 -156.43 0.4 Allowed 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.418 -178.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.2 112.42 18.51 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.687 0.395 . . . . 0.0 111.233 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.88 36.8 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -116.94 158.95 23.2 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.646 0.379 . . . . 0.0 110.582 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.4 p -80.13 131.75 35.8 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.855 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.5 p -100.76 31.11 3.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.89 179.758 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.43 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.26 -11.54 52.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.781 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.43 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.4 -37.77 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.134 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -136.6 152.97 75.59 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.13 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -69.35 -172.31 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.561 0 C-N-CA 123.345 2.696 . . . . 0.0 112.646 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.6 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 54.6 m -81.46 174.93 10.98 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 123.017 0.198 . . . . 0.0 110.487 179.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.5 m -115.87 -55.59 2.4 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -84.64 11.81 8.26 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.67 35.29 7.91 Favored Glycine 0 C--N 1.339 0.732 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.348 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.545 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -80.01 166.95 21.06 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.164 0.586 . . . . 0.0 111.488 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.34 144.41 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.188 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.7 m -82.27 104.03 12.29 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.241 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -80.85 140.27 50.47 Favored Pre-proline 0 CA--C 1.53 0.19 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.13 65.16 2.02 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 122.904 2.402 . . . . 0.0 112.103 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.49 151.62 19.14 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.798 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.22 144.31 28.71 Favored Pre-proline 0 CA--C 1.532 0.282 0 O-C-N 123.511 0.507 . . . . 0.0 111.626 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -32.01 4.77 Favored 'Cis proline' 0 C--N 1.367 1.53 0 C-N-CA 124.13 -1.196 . . . . 0.0 113.179 0.044 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -113.98 144.33 31.34 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.025 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.9 Cg_endo -63.45 157.41 50.85 Favored 'Trans proline' 0 C--N 1.375 1.97 0 C-N-CA 123.0 2.467 . . . . 0.0 113.803 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.73 154.4 27.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.92 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.54 119.26 30.66 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.851 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.545 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.68 144.28 10.95 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.112 -0.495 . . . . 0.0 113.003 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.41 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.251 1.145 0 CA-C-O 118.474 -0.774 . . . . 0.0 111.244 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.799 0 N-CA-C 114.944 1.461 . . . . 0.0 114.944 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 m95 -122.7 -35.54 3.05 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.433 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.7 p -81.6 157.61 24.65 Favored 'General case' 0 N--CA 1.466 0.328 0 O-C-N 123.535 0.522 . . . . 0.0 111.524 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.621 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.36 116.84 24.78 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.826 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLU . . . . . 0.553 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.67 -154.46 0.29 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.155 -179.269 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -79.83 106.44 11.86 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.973 0.416 . . . . 0.0 111.053 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.55 9.98 24.19 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.326 -0.852 . . . . 0.0 112.407 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.553 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.9 mt-10 -112.34 156.48 22.38 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.608 0.363 . . . . 0.0 110.525 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -82.64 128.5 34.39 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.889 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.6 p -96.77 33.33 1.88 Allowed 'General case' 0 C--O 1.238 0.486 0 CA-C-O 121.295 0.569 . . . . 0.0 110.9 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -89.85 -10.83 43.88 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.407 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.8 p -123.9 -39.12 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.031 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 25.6 m-85 -134.86 152.63 77.76 Favored Pre-proline 0 CA--C 1.538 0.494 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.177 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.55 -171.76 0.49 Allowed 'Trans proline' 0 C--N 1.367 1.544 0 C-N-CA 123.308 2.672 . . . . 0.0 112.689 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.4 m -81.87 174.84 10.92 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 110.324 -0.25 . . . . 0.0 110.324 178.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 40.9 m -114.29 -55.28 2.51 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 -178.009 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.45 12.2 10.79 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.82 36.86 7.59 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.514 -0.374 . . . . 0.0 112.263 -179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.609 HD22 ' HA2' ' A' ' 31' ' ' GLY . 3.1 mt -79.96 166.85 21.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 123.254 0.622 . . . . 0.0 111.597 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.8 mt -107.7 144.85 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.195 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.9 m -82.52 104.65 12.96 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.162 178.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -81.25 139.93 48.87 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.554 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.1 65.24 2.0 Allowed 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.929 2.42 . . . . 0.0 112.079 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 43.8 p -95.53 151.73 19.05 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.875 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.39 144.3 28.72 Favored Pre-proline 0 CA--C 1.532 0.269 0 O-C-N 123.57 0.544 . . . . 0.0 111.563 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.58 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.367 1.519 0 C-N-CA 124.145 -1.189 . . . . 0.0 113.166 0.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -113.73 144.07 30.73 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.145 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.46 157.23 51.88 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.048 2.499 . . . . 0.0 113.717 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.9 mm -122.38 154.39 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.904 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -90.67 119.39 30.87 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.791 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.609 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.77 144.65 11.17 Favored Glycine 0 C--N 1.338 0.675 0 CA-C-N 116.101 -0.5 . . . . 0.0 113.044 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.484 HG13 HD23 ' A' ' 19' ' ' LEU . 1.1 m . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.079 -0.962 . . . . 0.0 111.199 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 114.417 1.266 . . . . 0.0 114.417 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 8.0 m-90 -89.32 -35.63 16.0 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.344 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.0 p -82.57 157.24 23.57 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.476 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.61 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.79 119.03 24.84 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.8 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -88.24 -155.96 0.34 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.466 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.55 112.99 19.28 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 122.708 0.403 . . . . 0.0 111.256 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.26 7.1 41.08 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-N 115.528 -0.76 . . . . 0.0 112.733 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.12 159.25 21.1 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.561 0.345 . . . . 0.0 110.504 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 54.7 p -79.94 131.63 35.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.843 -179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -100.73 31.23 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.865 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.428 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.58 -11.46 51.44 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.759 179.982 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.428 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.24 -37.68 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.051 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -136.76 153.1 75.46 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.123 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.53 -172.1 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.572 0 C-N-CA 123.295 2.663 . . . . 0.0 112.539 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.61 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.6 m -81.52 175.14 10.78 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 110.49 -0.189 . . . . 0.0 110.49 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.4 m -115.85 -55.3 2.43 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.21 12.36 8.14 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.15 35.36 8.16 Favored Glycine 0 C--N 1.339 0.748 0 C-N-CA 121.516 -0.374 . . . . 0.0 112.383 -179.602 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.552 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -79.91 167.0 21.07 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.231 0.612 . . . . 0.0 111.576 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.46 144.33 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.268 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.8 m -82.09 104.03 12.14 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.253 178.679 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -81.3 140.43 48.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.501 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -70.26 64.83 2.1 Favored 'Trans proline' 0 C--N 1.364 1.393 0 C-N-CA 122.999 2.466 . . . . 0.0 112.054 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.526 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.4 p -95.31 152.52 18.31 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.897 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.52 144.18 28.72 Favored Pre-proline 0 C--O 1.236 0.374 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.565 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.3 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.485 0 C-N-CA 124.064 -1.223 . . . . 0.0 113.238 -0.019 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.02 145.37 32.3 Favored Pre-proline 0 CA--C 1.542 0.661 0 O-C-N 123.29 0.369 . . . . 0.0 111.197 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.422 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.1 Cg_endo -63.67 156.79 55.24 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.943 2.429 . . . . 0.0 113.419 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.526 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.8 mm -122.52 153.79 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.96 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -89.92 119.16 30.05 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.939 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.552 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.35 144.04 10.73 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.985 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.41 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.073 -0.965 . . . . 0.0 111.127 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.778 0 N-CA-C 114.427 1.269 . . . . 0.0 114.427 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -103.21 -18.95 14.68 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.609 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p -81.73 157.2 24.64 Favored 'General case' 0 C--N 1.344 0.354 0 O-C-N 123.344 0.402 . . . . 0.0 111.385 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.635 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.89 116.48 24.16 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.878 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLU . . . . . 0.553 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.14 -154.32 0.27 Allowed 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.181 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -79.82 106.86 12.15 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.082 0.468 . . . . 0.0 111.187 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.74 9.9 25.82 Favored Glycine 0 C--N 1.336 0.541 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.55 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.553 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.0 mt-10 -111.72 156.8 21.32 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 122.649 0.379 . . . . 0.0 110.499 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.4 p -82.88 132.05 35.17 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.752 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.427 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.2 p -102.05 38.1 1.72 Allowed 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.58 0.55 . . . . 0.0 111.18 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -91.46 -11.0 38.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.38 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.9 p -124.72 -39.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.934 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 27.2 m-85 -132.16 152.01 79.39 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 123.538 0.524 . . . . 0.0 111.51 179.367 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.5 -169.07 0.34 Allowed 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.577 2.851 . . . . 0.0 112.75 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 49.4 m -83.53 175.13 10.01 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 123.119 0.262 . . . . 0.0 110.376 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.9 m -114.84 -55.26 2.5 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.102 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 12.36 9.9 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.96 36.14 7.87 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 121.422 -0.418 . . . . 0.0 112.39 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.608 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.9 mt -79.93 168.13 19.62 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.331 0.653 . . . . 0.0 111.541 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -109.85 144.66 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.224 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.1 m -82.37 103.86 12.24 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.173 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -80.69 140.46 51.18 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.492 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -70.37 64.84 2.16 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.924 2.416 . . . . 0.0 111.978 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.5 p -95.0 150.43 20.17 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.963 -178.825 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -105.46 144.19 28.32 Favored Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.589 0.555 . . . . 0.0 111.724 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.87 -31.4 5.16 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.219 0.001 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -113.7 143.9 30.39 Favored Pre-proline 0 CA--C 1.541 0.621 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.199 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.6 Cg_endo -64.09 157.59 52.53 Favored 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 123.016 2.477 . . . . 0.0 113.514 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.97 154.09 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.973 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.427 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.0 m -90.08 119.02 30.06 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.608 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.91 144.68 11.37 Favored Glycine 0 C--N 1.337 0.599 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.013 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.474 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.452 -0.785 . . . . 0.0 111.122 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.793 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 93.0 m95 -100.14 -34.34 10.09 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.363 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.3 p -80.95 156.34 26.02 Favored 'General case' 0 N--CA 1.467 0.389 0 O-C-N 123.435 0.46 . . . . 0.0 111.621 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.612 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.69 118.52 24.46 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.789 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.23 -156.78 0.38 Allowed 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.406 -178.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -80.74 112.03 17.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.641 0.376 . . . . 0.0 111.387 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.94 8.14 37.15 Favored Glycine 0 C--N 1.334 0.471 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.62 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -115.98 158.69 22.69 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 122.623 0.369 . . . . 0.0 110.535 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.0 p -80.11 131.67 35.79 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.808 -179.428 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.6 p -100.6 31.13 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.893 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.3 -11.38 52.37 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.749 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.6 -38.08 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.137 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -136.2 152.86 76.04 Favored Pre-proline 0 CA--C 1.538 0.481 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.145 179.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.07 -172.04 0.47 Allowed 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 123.349 2.699 . . . . 0.0 112.605 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.612 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -81.64 175.78 10.2 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 123.123 0.264 . . . . 0.0 110.406 178.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 42.3 m -114.9 -55.99 2.42 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -87.47 13.18 10.55 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.87 35.98 6.97 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.395 -0.431 . . . . 0.0 112.625 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.552 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -80.19 166.36 21.51 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.018 0.527 . . . . 0.0 111.447 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.86 143.96 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.223 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.5 m -82.13 103.55 11.82 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.238 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.8 m-85 -80.19 140.33 53.06 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.509 -179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 65.01 2.07 Favored 'Trans proline' 0 C--N 1.365 1.424 0 C-N-CA 123.055 2.503 . . . . 0.0 112.142 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.33 151.55 19.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.894 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.65 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.56 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.366 1.477 0 C-N-CA 124.055 -1.227 . . . . 0.0 113.088 0.081 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -113.87 144.24 31.12 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.09 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.0 Cg_endo -63.34 157.62 49.28 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.023 2.482 . . . . 0.0 113.751 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.96 153.93 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.902 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.15 119.25 30.32 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.883 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.552 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.9 143.93 10.51 Favored Glycine 0 C--N 1.339 0.695 0 CA-C-N 116.071 -0.513 . . . . 0.0 113.088 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.415 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.135 -0.936 . . . . 0.0 111.142 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -98.11 -20.29 17.42 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.597 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p -81.39 157.33 25.03 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 122.709 0.404 . . . . 0.0 111.468 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.599 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.67 120.25 26.17 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.742 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.68 -156.34 0.4 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.389 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.23 112.6 18.71 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.897 0.379 . . . . 0.0 111.373 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.31 8.8 37.63 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.566 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -116.97 158.97 23.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 122.622 0.369 . . . . 0.0 110.524 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.4 p -80.03 131.94 35.89 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.819 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -100.96 31.16 3.71 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.854 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.417 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.41 -11.21 52.57 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.721 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.417 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.6 p -121.52 -37.89 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.07 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -136.72 152.95 75.36 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.179 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.23 -172.17 0.5 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 123.342 2.695 . . . . 0.0 112.574 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.599 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -81.61 175.15 10.73 Favored 'General case' 0 CA--C 1.539 0.535 0 O-C-N 123.044 0.215 . . . . 0.0 110.449 179.075 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.8 m -116.02 -55.43 2.41 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -177.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -85.11 12.87 6.96 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -178.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.33 8.73 Favored Glycine 0 C--N 1.341 0.851 0 C-N-CA 121.478 -0.392 . . . . 0.0 112.413 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.55 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -79.98 166.77 21.26 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.22 0.608 . . . . 0.0 111.484 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.09 144.36 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.239 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.5 m -82.3 103.93 12.24 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.5 m-85 -80.76 140.28 50.8 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.46 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.17 65.07 2.05 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.94 2.427 . . . . 0.0 112.056 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.41 151.49 19.23 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.878 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.339 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.746 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.52 -32.28 4.6 Favored 'Cis proline' 0 C--N 1.366 1.475 0 C-N-CA 124.046 -1.231 . . . . 0.0 113.142 0.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.76 144.23 31.05 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.43 157.42 50.73 Favored 'Trans proline' 0 C--N 1.375 1.931 0 C-N-CA 123.004 2.47 . . . . 0.0 113.809 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.7 mm -122.81 154.33 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.857 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -90.59 119.36 30.78 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.877 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.55 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.76 144.01 10.63 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 116.041 -0.527 . . . . 0.0 113.014 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.411 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.424 -0.798 . . . . 0.0 111.23 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -98.14 -18.7 18.34 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.697 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p -82.65 156.14 24.02 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 122.754 0.422 . . . . 0.0 111.46 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.19 119.95 25.63 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.71 179.685 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -89.14 -156.3 0.39 Allowed 'General case' 0 CA--C 1.544 0.713 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.665 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -81.21 113.04 19.08 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 122.651 0.38 . . . . 0.0 111.384 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.76 8.36 40.01 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.334 -0.848 . . . . 0.0 112.604 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -116.16 159.67 21.45 Favored 'General case' 0 C--O 1.236 0.395 0 C-N-CA 122.493 0.317 . . . . 0.0 110.555 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.8 p -81.02 134.74 35.73 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.702 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.457 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -105.41 37.41 2.21 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.758 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -87.31 -13.36 43.83 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.885 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 p -122.43 -38.43 1.37 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 O-C-N 123.506 0.504 . . . . 0.0 110.111 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -132.26 152.42 80.08 Favored Pre-proline 0 CA--C 1.538 0.511 0 O-C-N 123.609 0.568 . . . . 0.0 111.462 179.512 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.21 -168.35 0.29 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 123.426 2.751 . . . . 0.0 112.777 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.626 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -84.09 175.6 9.39 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 123.048 0.218 . . . . 0.0 110.502 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.9 m -116.53 -55.34 2.38 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -178.016 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -84.77 12.26 7.62 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.5 34.74 8.34 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.461 -0.399 . . . . 0.0 112.359 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.539 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -80.04 167.79 19.98 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.223 0.609 . . . . 0.0 111.426 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.91 144.21 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.252 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.9 m -82.22 103.26 11.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.166 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.9 m-85 -80.34 140.83 52.69 Favored Pre-proline 0 CA--C 1.53 0.195 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.511 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.33 64.58 2.14 Favored 'Trans proline' 0 C--N 1.364 1.389 0 C-N-CA 122.955 2.437 . . . . 0.0 111.997 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.522 ' OG1' HG12 ' A' ' 29' ' ' ILE . 47.7 p -95.02 151.65 18.99 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.964 -178.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.76 143.95 28.09 Favored Pre-proline 0 C--O 1.234 0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.674 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -76.36 -36.61 2.44 Favored 'Cis proline' 0 C--N 1.365 1.435 0 C-N-CA 124.079 -1.217 . . . . 0.0 113.162 0.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -109.67 145.91 32.94 Favored Pre-proline 0 CA--C 1.54 0.559 0 O-C-N 123.342 0.401 . . . . 0.0 111.131 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.4 Cg_endo -64.47 157.64 53.84 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.842 2.362 . . . . 0.0 113.351 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.522 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.1 mm -123.71 153.55 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.969 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.457 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.54 118.95 29.55 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.929 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.539 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.8 144.1 10.89 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 116.042 -0.526 . . . . 0.0 113.092 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.407 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.19 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.795 0 N-CA-C 114.319 1.229 . . . . 0.0 114.319 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.8 m95 -139.57 96.33 3.07 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.848 179.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p -156.08 160.68 40.18 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.963 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.573 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.78 120.16 27.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.524 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.08 -156.12 0.38 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.526 -178.818 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.12 113.49 19.32 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.78 0.432 . . . . 0.0 111.242 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.82 7.23 42.1 Favored Glycine 0 C--N 1.334 0.419 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.588 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.72 159.31 20.69 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.741 0.416 . . . . 0.0 110.579 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 65.1 p -79.98 131.44 35.81 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.781 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.576 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.47 28.7 5.3 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.971 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.4 -12.18 56.75 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.705 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.445 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.5 p -121.35 -41.06 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.348 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -130.26 153.53 81.24 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.306 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.7 -174.71 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.202 2.601 . . . . 0.0 112.42 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.07 175.22 10.83 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 110.53 -0.174 . . . . 0.0 110.53 179.114 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.5 m -115.15 -54.88 2.52 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.31 12.95 8.9 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.68 8.65 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.415 -0.421 . . . . 0.0 112.366 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.571 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -79.93 166.56 21.51 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.265 0.626 . . . . 0.0 111.565 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.6 144.29 17.37 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.155 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.8 m -82.21 103.98 12.2 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.214 178.741 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.64 140.18 51.23 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.535 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.33 65.23 2.14 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.965 2.443 . . . . 0.0 112.093 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.29 152.9 17.97 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.963 -178.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -107.05 144.23 28.7 Favored Pre-proline 0 C--O 1.236 0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.73 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.42 -32.05 4.77 Favored 'Cis proline' 0 C--N 1.365 1.419 0 C-N-CA 124.084 -1.215 . . . . 0.0 113.196 0.047 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.27 144.49 31.8 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.089 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.2 Cg_endo -63.21 157.52 49.27 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 123.02 2.48 . . . . 0.0 113.75 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.89 154.38 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.864 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.42 119.5 30.76 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.948 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.571 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.44 144.32 10.86 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 116.083 -0.508 . . . . 0.0 113.117 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.434 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.065 -0.969 . . . . 0.0 111.108 179.633 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.828 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 82.3 m95 -139.42 96.47 3.1 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.348 0.594 . . . . 0.0 109.934 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.7 p -155.95 161.07 40.57 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.906 179.706 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.9 120.03 27.74 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.0 -156.11 0.37 Allowed 'General case' 0 CA--C 1.543 0.696 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.533 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.09 113.47 19.29 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.986 0.422 . . . . 0.0 111.238 -179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.04 6.94 41.99 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.546 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.56 159.39 20.47 Favored 'General case' 0 C--O 1.234 0.275 0 C-N-CA 122.547 0.339 . . . . 0.0 110.481 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.2 p -79.94 131.27 35.79 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.811 -179.321 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.578 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.11 28.62 5.2 Favored 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.969 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.446 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.59 -12.1 56.5 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.661 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.446 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.38 -41.31 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.217 -179.614 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -130.26 153.44 81.23 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.326 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.62 -174.82 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.472 0 C-N-CA 123.202 2.601 . . . . 0.0 112.348 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -79.87 175.28 10.77 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -115.16 -54.86 2.52 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -178.019 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.55 13.08 9.05 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.26 35.88 8.53 Favored Glycine 0 C--N 1.34 0.764 0 C-N-CA 121.495 -0.384 . . . . 0.0 112.293 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.576 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.97 166.58 21.45 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.159 0.584 . . . . 0.0 111.649 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -108.4 144.36 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.141 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.2 m -82.24 103.89 12.16 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -80.38 140.13 52.22 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.538 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.24 65.22 2.09 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.05 2.5 . . . . 0.0 112.079 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.36 152.74 18.13 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.889 -178.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -107.0 144.23 28.68 Favored Pre-proline 0 C--O 1.234 0.268 0 O-C-N 123.541 0.526 . . . . 0.0 111.683 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.55 -31.93 4.84 Favored 'Cis proline' 0 C--N 1.367 1.505 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.22 0.06 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.15 144.6 31.95 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.525 0.516 . . . . 0.0 111.127 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.2 Cg_endo -63.28 157.53 49.53 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.962 2.441 . . . . 0.0 113.793 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.83 154.31 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.871 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.31 119.44 30.61 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.91 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.576 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.56 144.36 10.88 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 116.114 -0.494 . . . . 0.0 113.016 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.433 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.126 -0.94 . . . . 0.0 111.257 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.875 0 N-CA-C 114.357 1.243 . . . . 0.0 114.357 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.5 m95 -139.39 96.51 3.11 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.928 179.649 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p -156.13 160.89 40.31 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.88 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.57 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.92 120.37 28.12 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.465 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.26 -155.96 0.37 Allowed 'General case' 0 CA--C 1.545 0.768 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.622 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.37 113.65 19.6 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.312 0.382 . . . . 0.0 111.225 -179.506 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.78 7.31 42.06 Favored Glycine 0 CA--C 1.521 0.453 0 CA-C-N 115.378 -0.828 . . . . 0.0 112.511 -179.579 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -114.95 159.51 20.65 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 122.62 0.368 . . . . 0.0 110.526 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.4 p -80.1 131.44 35.75 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.804 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.575 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.41 28.66 5.31 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.033 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.446 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.43 -12.05 56.84 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.712 179.971 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.446 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.46 -41.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 O-C-N 123.583 0.552 . . . . 0.0 110.298 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -130.41 153.45 81.34 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -70.69 -174.65 1.14 Allowed 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 123.188 2.592 . . . . 0.0 112.357 179.183 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.06 175.21 10.84 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.6 m -115.29 -54.84 2.51 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 112.906 0.706 . . . . 0.0 112.906 -178.006 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -86.11 12.73 9.01 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.62 8.56 Favored Glycine 0 C--N 1.34 0.792 0 C-N-CA 121.517 -0.373 . . . . 0.0 112.291 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.569 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -79.9 166.61 21.48 Favored 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 123.254 0.621 . . . . 0.0 111.51 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.57 144.42 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.175 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.6 m -82.38 103.97 12.34 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.155 178.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -80.68 140.17 51.08 Favored Pre-proline 0 CA--C 1.53 0.199 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.32 65.25 2.13 Favored 'Trans proline' 0 C--N 1.366 1.455 0 C-N-CA 122.975 2.45 . . . . 0.0 111.993 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.3 152.49 18.33 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.9 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.84 144.29 28.77 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.688 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -31.85 4.88 Favored 'Cis proline' 0 C--N 1.367 1.521 0 C-N-CA 124.024 -1.24 . . . . 0.0 113.116 0.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.31 144.6 32.03 Favored Pre-proline 0 CA--C 1.542 0.665 0 O-C-N 123.481 0.488 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.25 157.51 49.52 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 122.894 2.396 . . . . 0.0 113.845 -179.499 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.93 154.37 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.819 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.575 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.42 30.62 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.901 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.569 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.35 144.24 10.78 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 116.048 -0.524 . . . . 0.0 113.001 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.429 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.252 1.236 0 CA-C-O 118.375 -0.822 . . . . 0.0 111.189 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 114.431 1.271 . . . . 0.0 114.431 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -139.49 96.42 3.09 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.931 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p -155.96 160.59 40.21 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.943 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.571 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.59 119.49 26.9 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.539 179.304 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.06 -156.2 0.35 Allowed 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.634 -178.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.27 113.63 19.53 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 122.765 0.426 . . . . 0.0 111.315 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.4 5.43 42.86 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.624 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.37 159.5 19.37 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.526 0.331 . . . . 0.0 110.52 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.9 131.67 35.9 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.805 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.19 4.84 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.002 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.447 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -84.02 -12.36 55.33 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.584 -0.734 . . . . 0.0 111.704 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.447 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.7 p -120.96 -41.01 1.79 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.268 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -130.59 153.5 81.49 Favored Pre-proline 0 CA--C 1.536 0.44 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.305 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.8 -174.48 1.12 Allowed 'Trans proline' 0 C--N 1.365 1.436 0 C-N-CA 123.167 2.578 . . . . 0.0 112.35 179.175 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.571 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.0 175.38 10.69 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.135 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -115.06 -54.69 2.54 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.69 13.07 9.3 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.71 8.62 Favored Glycine 0 C--N 1.341 0.831 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.34 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.579 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.83 166.81 21.32 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.187 0.595 . . . . 0.0 111.577 -179.453 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.54 144.4 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.195 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.8 m -82.43 104.11 12.47 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.162 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.06 140.33 49.71 Favored Pre-proline 0 CA--C 1.53 0.188 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.514 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.32 64.87 2.14 Favored 'Trans proline' 0 C--N 1.366 1.464 0 C-N-CA 122.995 2.463 . . . . 0.0 112.063 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.527 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.8 p -95.17 152.74 18.09 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.982 -178.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.68 144.16 28.73 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.57 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.539 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.31 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.025 -1.239 . . . . 0.0 113.22 0.003 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.539 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.07 145.54 32.67 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 123.34 0.4 . . . . 0.0 111.197 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.418 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 27.9 Cg_endo -63.58 156.8 54.77 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 122.988 2.459 . . . . 0.0 113.465 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.527 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -122.67 153.9 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.868 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.46 30.22 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.579 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.26 144.35 10.93 Favored Glycine 0 C--N 1.341 0.81 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.979 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.445 HG13 HD23 ' A' ' 19' ' ' LEU . 1.1 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.049 -0.977 . . . . 0.0 111.192 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.811 0 N-CA-C 114.333 1.234 . . . . 0.0 114.333 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -139.68 96.56 3.1 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.895 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 p -156.79 161.71 39.75 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.879 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.38 121.32 28.78 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.417 179.265 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -89.59 -156.58 0.41 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.636 -178.734 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.59 113.59 19.71 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 122.742 0.417 . . . . 0.0 111.295 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.73 7.4 42.01 Favored Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.565 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -115.05 160.34 19.75 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 122.548 0.339 . . . . 0.0 110.444 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.4 p -79.86 135.36 36.43 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.525 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.519 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -107.59 34.86 3.31 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.148 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -86.59 -14.89 41.49 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.761 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 p -118.76 -41.53 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 O-C-N 123.399 0.437 . . . . 0.0 110.2 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -127.68 153.6 77.76 Favored Pre-proline 0 CA--C 1.537 0.474 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.34 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.69 -170.25 0.51 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 123.298 2.665 . . . . 0.0 112.384 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.567 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -83.25 175.78 9.66 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.81 -54.57 2.49 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 112.875 0.695 . . . . 0.0 112.875 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 13.14 8.3 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.23 35.17 8.99 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.486 -0.388 . . . . 0.0 112.382 -179.541 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.573 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.6 mt -80.05 167.47 20.38 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.169 0.587 . . . . 0.0 111.489 -179.378 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.07 144.14 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.277 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.8 m -82.06 103.58 11.79 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.236 178.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -80.82 140.62 50.72 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.285 -0.87 . . . . 0.0 111.49 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.45 64.86 2.21 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.92 2.413 . . . . 0.0 112.045 179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.524 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.0 p -95.02 151.01 19.54 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.948 -178.786 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.74 144.4 28.79 Favored Pre-proline 0 C--O 1.234 0.279 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.692 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.67 -30.99 5.47 Favored 'Cis proline' 0 C--N 1.366 1.499 0 C-N-CA 124.053 -1.228 . . . . 0.0 113.161 0.048 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -114.64 144.4 31.8 Favored Pre-proline 0 CA--C 1.542 0.659 0 O-C-N 123.509 0.506 . . . . 0.0 111.118 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.76 157.61 51.04 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.865 2.377 . . . . 0.0 113.572 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.524 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.0 mm -124.39 153.66 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.943 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.519 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.1 m -89.41 119.13 29.6 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.804 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.573 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.61 144.45 11.16 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.078 -0.51 . . . . 0.0 113.016 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.424 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.083 -0.96 . . . . 0.0 111.265 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.822 0 N-CA-C 114.408 1.262 . . . . 0.0 114.408 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 82.3 m95 -139.56 96.54 3.1 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.928 179.679 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p -155.79 160.31 40.15 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.949 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.549 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.6 120.76 27.4 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.511 179.146 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLU . . . . . 0.508 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 12.0 pt-20 -89.11 -155.87 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.609 -178.786 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.508 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.65 113.74 19.86 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.961 0.41 . . . . 0.0 111.316 -179.548 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.48 7.19 43.14 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.635 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.78 159.97 19.97 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 122.538 0.335 . . . . 0.0 110.395 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 59.1 p -79.97 131.31 35.79 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.798 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.559 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 32.0 p -101.33 27.49 6.18 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.042 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -82.46 -11.36 58.56 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.685 179.95 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.8 p -121.8 -40.75 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.268 -179.618 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -130.8 153.47 81.64 Favored Pre-proline 0 CA--C 1.536 0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.377 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.92 -174.74 1.21 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.245 2.63 . . . . 0.0 112.297 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.5 m -80.01 175.53 10.55 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 110.508 -0.182 . . . . 0.0 110.508 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.4 m -116.71 -55.51 2.36 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -177.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.23 13.78 7.46 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.625 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.51 37.04 7.69 Favored Glycine 0 C--N 1.339 0.716 0 C-N-CA 121.43 -0.414 . . . . 0.0 112.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.533 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -82.28 169.65 16.28 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.239 0.616 . . . . 0.0 111.131 -179.531 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -114.81 144.22 22.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.54 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 m -80.61 102.88 10.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.379 178.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -80.74 140.49 50.98 Favored Pre-proline 0 N--CA 1.457 -0.111 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.415 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.7 64.64 1.77 Allowed 'Trans proline' 0 C--N 1.364 1.376 0 C-N-CA 123.009 2.473 . . . . 0.0 112.22 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.527 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.7 p -95.47 152.46 18.39 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.971 -178.848 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.42 144.13 28.59 Favored Pre-proline 0 C--O 1.235 0.341 0 O-C-N 123.506 0.504 . . . . 0.0 111.632 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.543 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.47 -35.52 2.85 Favored 'Cis proline' 0 C--N 1.368 1.557 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.266 0.129 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.543 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -111.05 145.39 32.34 Favored Pre-proline 0 CA--C 1.542 0.649 0 O-C-N 123.299 0.374 . . . . 0.0 111.166 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.419 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.1 Cg_endo -63.71 156.91 54.64 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 122.9 2.4 . . . . 0.0 113.365 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.527 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -123.12 153.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.977 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -88.85 119.21 29.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.72 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.533 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.01 146.08 13.96 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.342 -0.456 . . . . 0.0 113.323 -179.742 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.4 HG13 ' HA ' ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.414 -0.803 . . . . 0.0 111.08 179.437 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 114.461 1.282 . . . . 0.0 114.461 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -139.54 96.48 3.09 Favored 'General case' 0 C--O 1.237 0.401 0 O-C-N 123.619 0.574 . . . . 0.0 109.903 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p -156.05 161.55 40.41 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.146 -0.933 . . . . 0.0 110.917 179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.503 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.57 121.89 28.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.691 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.34 -155.7 0.33 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.484 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.554 ' HG2' HD21 ' A' ' 19' ' ' LEU . 2.3 mt-10 -83.03 115.82 22.02 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 122.605 0.362 . . . . 0.0 110.509 -179.252 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.65 6.63 49.7 Favored Glycine 0 CA--C 1.523 0.539 0 CA-C-N 115.468 -0.787 . . . . 0.0 112.69 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -113.35 160.05 18.78 Favored 'General case' 0 C--O 1.234 0.266 0 C-N-CA 122.494 0.318 . . . . 0.0 110.54 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.3 p -79.81 132.03 36.03 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.992 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.581 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -101.99 29.15 5.2 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.033 179.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.471 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.8 -13.58 53.46 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.713 179.97 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.471 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.3 p -119.99 -41.18 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.165 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -130.47 153.38 81.36 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.291 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.12 -174.52 1.2 Allowed 'Trans proline' 0 C--N 1.365 1.442 0 C-N-CA 123.307 2.671 . . . . 0.0 112.31 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 58.7 m -79.91 176.22 9.93 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.1 m -117.72 -55.68 2.26 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -178.048 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.8 12.85 8.21 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.24 36.1 7.74 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 121.439 -0.41 . . . . 0.0 112.356 -179.63 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.554 HD21 ' HG2' ' A' ' 6' ' ' GLU . 2.5 mt -80.12 166.25 21.67 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.13 0.572 . . . . 0.0 111.464 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -109.4 143.53 19.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.097 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.9 m -81.67 103.65 11.52 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.4 m-85 -80.52 140.18 51.71 Favored Pre-proline 0 CA--C 1.529 0.167 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.542 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.3 65.31 2.12 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.998 2.466 . . . . 0.0 112.007 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.517 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.64 152.04 18.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.927 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.49 144.22 28.57 Favored Pre-proline 0 C--O 1.234 0.249 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.673 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -32.06 4.73 Favored 'Cis proline' 0 C--N 1.366 1.493 0 C-N-CA 124.074 -1.219 . . . . 0.0 113.083 0.164 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.96 144.46 31.6 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.502 0.501 . . . . 0.0 111.101 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.34 157.74 48.66 Favored 'Trans proline' 0 C--N 1.375 1.932 0 C-N-CA 122.938 2.425 . . . . 0.0 113.85 -179.499 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.517 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.15 152.88 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.967 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.581 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.13 118.78 29.08 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.703 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.512 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.35 142.53 9.29 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 116.206 -0.452 . . . . 0.0 113.182 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.425 HG13 HD23 ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.289 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.845 0 N-CA-C 114.37 1.248 . . . . 0.0 114.37 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.9 m95 -139.47 96.29 3.07 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.906 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.8 p -156.06 160.42 39.97 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.959 179.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.71 119.47 26.97 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.486 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLU . . . . . 0.507 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 11.9 pt-20 -88.07 -156.22 0.35 Allowed 'General case' 0 CA--C 1.545 0.77 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.598 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.507 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.35 113.8 19.69 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 122.714 0.406 . . . . 0.0 111.287 -179.572 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.23 5.53 43.24 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.435 -0.802 . . . . 0.0 112.628 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.39 159.47 19.41 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.638 0.375 . . . . 0.0 110.454 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.92 131.68 35.89 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.866 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.04 4.92 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.98 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.95 -12.35 55.47 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.702 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.451 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.12 -40.83 1.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.262 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -130.66 153.43 81.52 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 123.682 0.614 . . . . 0.0 111.317 179.578 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -70.61 -174.46 1.08 Allowed 'Trans proline' 0 C--N 1.365 1.417 0 C-N-CA 123.277 2.651 . . . . 0.0 112.331 179.15 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -80.06 175.39 10.68 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.03 -54.59 2.55 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.821 0.675 . . . . 0.0 112.821 -177.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.77 12.91 9.76 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.36 35.81 8.51 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.509 -0.377 . . . . 0.0 112.335 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.583 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.89 166.89 21.2 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.208 0.603 . . . . 0.0 111.62 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.55 144.41 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.204 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.3 m -82.28 104.11 12.36 Favored 'General case' 0 C--O 1.239 0.525 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.206 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.22 140.33 49.13 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.506 -179.597 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.21 64.9 2.07 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 123.003 2.469 . . . . 0.0 112.028 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.53 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.2 152.73 18.1 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.032 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.64 144.19 28.78 Favored Pre-proline 0 C--O 1.234 0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.634 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.539 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.25 -35.51 2.86 Favored 'Cis proline' 0 C--N 1.367 1.552 0 C-N-CA 123.986 -1.256 . . . . 0.0 113.333 -0.088 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.539 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.15 145.53 32.67 Favored Pre-proline 0 CA--C 1.543 0.677 0 O-C-N 123.303 0.377 . . . . 0.0 111.211 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.3 Cg_endo -63.65 156.71 55.6 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.867 2.378 . . . . 0.0 113.489 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.53 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.2 mm -122.42 153.92 27.16 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.002 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.38 30.15 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.896 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.583 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.2 144.35 10.94 Favored Glycine 0 C--N 1.338 0.688 0 CA-C-N 116.167 -0.469 . . . . 0.0 113.096 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.443 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.146 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.789 0 N-CA-C 114.373 1.249 . . . . 0.0 114.373 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.3 m95 -139.52 96.39 3.08 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.912 179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.1 p -156.11 160.81 40.26 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.985 179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.569 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.8 120.43 28.09 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.528 179.269 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.28 -156.09 0.38 Allowed 'General case' 0 CA--C 1.544 0.72 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.62 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.29 113.69 19.57 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.948 0.404 . . . . 0.0 111.29 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.85 7.08 42.3 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.492 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.77 159.4 20.64 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 122.71 0.404 . . . . 0.0 110.479 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.6 p -79.98 131.43 35.81 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.053 -0.522 . . . . 0.0 111.856 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.576 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 30.9 p -101.47 28.69 5.31 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.004 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.447 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.46 -11.94 56.92 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.663 179.926 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.447 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.57 -41.17 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 O-C-N 123.543 0.527 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -130.24 153.58 81.23 Favored Pre-proline 0 CA--C 1.536 0.425 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.285 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.79 -174.74 1.18 Allowed 'Trans proline' 0 C--N 1.365 1.437 0 C-N-CA 123.214 2.61 . . . . 0.0 112.338 179.157 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.569 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.07 175.2 10.86 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 110.579 -0.156 . . . . 0.0 110.579 179.089 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 53.4 m -115.31 -54.81 2.51 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -177.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -86.33 13.85 7.49 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.2 35.78 9.4 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 121.428 -0.415 . . . . 0.0 112.47 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.573 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -80.03 166.63 21.37 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 123.163 0.585 . . . . 0.0 111.602 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.41 144.36 17.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.211 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.1 m -82.28 104.05 12.31 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.272 178.7 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.68 140.21 51.1 Favored Pre-proline 0 CA--C 1.531 0.222 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.484 -179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.31 65.21 2.12 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.964 2.443 . . . . 0.0 112.101 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.27 152.56 18.27 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.899 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.86 144.21 28.62 Favored Pre-proline 0 C--O 1.233 0.233 0 O-C-N 123.512 0.507 . . . . 0.0 111.645 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.47 -32.08 4.74 Favored 'Cis proline' 0 C--N 1.368 1.578 0 C-N-CA 123.961 -1.266 . . . . 0.0 113.137 0.061 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.12 144.49 31.73 Favored Pre-proline 0 CA--C 1.542 0.652 0 O-C-N 123.515 0.509 . . . . 0.0 111.099 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.5 Cg_endo -63.21 157.47 49.55 Favored 'Trans proline' 0 C--N 1.374 1.871 0 C-N-CA 123.015 2.476 . . . . 0.0 113.859 -179.455 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.98 154.41 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.863 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.55 30.73 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.873 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.573 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.48 144.27 10.79 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 116.013 -0.54 . . . . 0.0 113.046 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.433 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.094 -0.955 . . . . 0.0 111.182 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 114.35 1.241 . . . . 0.0 114.35 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -139.76 96.71 3.12 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.833 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p -156.9 162.42 39.65 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.721 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.73 122.74 30.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.659 179.298 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.62 -155.74 0.34 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.556 -178.877 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.552 ' HG2' HD21 ' A' ' 19' ' ' LEU . 2.3 mt-10 -83.59 116.26 22.52 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 120.926 0.393 . . . . 0.0 110.527 -179.313 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.14 6.4 51.62 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.71 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -112.93 160.81 17.69 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.562 0.345 . . . . 0.0 110.646 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.8 p -79.72 136.18 36.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.677 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.515 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.7 p -108.38 34.48 3.61 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.18 -179.785 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -86.67 -15.35 39.89 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.753 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.4 p -118.06 -41.59 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 O-C-N 123.42 0.45 . . . . 0.0 110.086 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.3 m-85 -128.14 153.58 78.64 Favored Pre-proline 0 CA--C 1.537 0.464 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.189 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.22 -171.19 0.66 Allowed 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 123.31 2.674 . . . . 0.0 112.424 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 59.4 m -82.05 176.79 9.24 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 123.132 0.27 . . . . 0.0 110.402 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.3 m -118.23 -55.46 2.23 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.1 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -85.73 13.0 7.78 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.772 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.2 35.57 8.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.432 -0.413 . . . . 0.0 112.391 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.552 HD21 ' HG2' ' A' ' 6' ' ' GLU . 2.3 mt -80.07 166.68 21.29 Favored 'General case' 0 C--O 1.236 0.379 0 C-N-CA 123.178 0.591 . . . . 0.0 111.51 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -110.48 143.33 20.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.091 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.7 m -81.37 103.3 11.03 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.223 178.702 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -80.45 140.42 52.06 Favored Pre-proline 0 CA--C 1.529 0.153 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.546 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.38 65.09 2.17 Favored 'Trans proline' 0 C--N 1.366 1.483 0 C-N-CA 122.955 2.437 . . . . 0.0 112.041 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.524 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.7 p -95.46 151.52 19.22 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.863 -178.689 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.97 144.25 28.54 Favored Pre-proline 0 C--O 1.235 0.298 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.716 -179.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -31.33 5.24 Favored 'Cis proline' 0 C--N 1.367 1.523 0 C-N-CA 123.99 -1.254 . . . . 0.0 113.115 0.142 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -114.44 144.56 32.02 Favored Pre-proline 0 CA--C 1.541 0.617 0 O-C-N 123.487 0.492 . . . . 0.0 111.172 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.417 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.3 Cg_endo -63.5 157.78 49.06 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.877 2.385 . . . . 0.0 113.565 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.524 HG12 ' OG1' ' A' ' 24' ' ' THR . 16.4 mm -124.35 152.59 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.97 -179.795 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.515 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -88.67 118.54 28.41 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.782 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.51 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.78 142.76 9.58 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 116.138 -0.483 . . . . 0.0 113.101 -179.696 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.423 HG13 HD23 ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.475 -0.774 . . . . 0.0 111.228 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.9 p . . . . . 0 N--CA 1.466 0.333 0 CA-C-O 120.699 0.285 . . . . 0.0 111.455 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.596 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.46 120.92 26.5 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.633 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.73 -156.65 0.42 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.565 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.06 112.87 18.83 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 122.68 0.392 . . . . 0.0 111.363 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.38 9.12 39.45 Favored Glycine 0 C--N 1.334 0.472 0 CA-C-N 115.417 -0.811 . . . . 0.0 112.672 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.54 159.8 21.57 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 122.625 0.37 . . . . 0.0 110.519 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.1 p -80.97 135.19 35.83 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.586 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.421 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.69 36.18 2.62 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.2 -11.5 52.3 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.798 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.03 -38.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 O-C-N 123.423 0.452 . . . . 0.0 110.135 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -132.81 152.29 79.6 Favored Pre-proline 0 CA--C 1.538 0.515 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.422 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.14 -168.42 0.29 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.541 2.827 . . . . 0.0 112.85 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.9 m -83.93 175.84 9.3 Favored 'General case' 0 CA--C 1.538 0.481 0 O-C-N 123.156 0.285 . . . . 0.0 110.547 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.0 m -117.75 -55.88 2.24 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.53 12.62 6.66 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -178.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.83 35.83 7.57 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.359 -0.448 . . . . 0.0 112.41 -179.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.512 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -81.95 171.54 14.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.134 0.574 . . . . 0.0 111.197 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -117.08 144.07 25.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.456 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 m -80.8 102.1 9.78 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.32 178.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.6 m-85 -79.99 140.97 54.17 Favored Pre-proline 0 N--CA 1.456 -0.163 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.36 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.91 64.41 1.89 Allowed 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 122.957 2.438 . . . . 0.0 112.098 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.521 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.0 p -95.19 150.98 19.62 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.937 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.26 144.09 28.26 Favored Pre-proline 0 C--O 1.234 0.25 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.738 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.563 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.76 -35.17 2.97 Favored 'Cis proline' 0 C--N 1.366 1.487 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.226 0.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.563 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.66 144.96 31.32 Favored Pre-proline 0 CA--C 1.542 0.654 0 O-C-N 123.258 0.348 . . . . 0.0 111.194 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.6 Cg_endo -64.25 157.54 53.47 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.784 2.323 . . . . 0.0 113.374 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.521 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.4 mm -124.06 152.88 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.979 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.421 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.83 118.85 28.83 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.788 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.512 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.88 145.62 13.31 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 116.195 -0.457 . . . . 0.0 113.368 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.448 -0.787 . . . . 0.0 111.046 179.503 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.5 p . . . . . 0 N--CA 1.466 0.331 0 CA-C-O 120.665 0.269 . . . . 0.0 111.536 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.604 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.75 120.69 26.34 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.647 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.64 -156.8 0.42 Allowed 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.54 -178.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -80.82 112.85 18.59 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.682 0.393 . . . . 0.0 111.407 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.42 9.06 39.5 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.585 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.5 159.71 21.67 Favored 'General case' 0 C--O 1.235 0.301 0 C-N-CA 122.592 0.357 . . . . 0.0 110.438 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.8 p -80.88 135.27 35.89 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.555 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.423 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.96 36.43 2.57 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.863 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.25 -11.77 51.43 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.868 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -123.95 -38.46 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 123.384 0.428 . . . . 0.0 110.234 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -132.6 152.46 80.0 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.396 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.19 -168.57 0.3 Allowed 'Trans proline' 0 C--N 1.367 1.545 0 C-N-CA 123.507 2.805 . . . . 0.0 112.937 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.604 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.1 m -83.75 175.9 9.34 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 123.148 0.28 . . . . 0.0 110.567 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.1 m -117.65 -55.9 2.25 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.913 0.709 . . . . 0.0 112.913 -178.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.59 12.58 6.81 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 -178.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.77 36.03 7.51 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 121.449 -0.405 . . . . 0.0 112.337 -179.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.507 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -81.99 171.38 14.47 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.19 0.596 . . . . 0.0 111.196 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.86 144.16 25.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.484 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.5 m -80.94 102.13 9.92 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.382 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -79.99 140.9 54.1 Favored Pre-proline 0 CA--C 1.529 0.165 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.39 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 64.45 1.85 Allowed 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.961 2.44 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.7 p -95.27 151.14 19.5 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.893 -178.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.46 144.05 28.22 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.769 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.562 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.77 -35.17 2.98 Favored 'Cis proline' 0 C--N 1.367 1.506 0 C-N-CA 124.085 -1.214 . . . . 0.0 113.253 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.562 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.69 144.92 31.25 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.291 0.37 . . . . 0.0 111.217 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.1 Cg_endo -64.1 157.34 53.9 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.904 2.403 . . . . 0.0 113.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.2 mm -123.92 152.88 29.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.068 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.81 118.92 28.85 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.781 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.507 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.75 145.66 13.43 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 116.109 -0.496 . . . . 0.0 113.3 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.078 -0.963 . . . . 0.0 111.055 179.446 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.1 p . . . . . 0 N--CA 1.467 0.38 0 CA-C-O 120.74 0.305 . . . . 0.0 111.46 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.588 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.98 119.79 25.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.81 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.77 -156.28 0.38 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.456 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.34 112.77 18.94 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 122.597 0.359 . . . . 0.0 111.375 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.98 8.15 39.82 Favored Glycine 0 CA--C 1.522 0.488 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.637 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.75 159.58 21.24 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 122.604 0.362 . . . . 0.0 110.562 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.0 p -80.02 131.21 35.74 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.787 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.551 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -100.6 29.83 4.26 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.911 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.405 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -85.39 -10.48 56.2 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.741 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.405 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.96 -37.68 1.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.006 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -137.05 152.87 74.65 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.19 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.39 -172.72 0.56 Allowed 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 123.313 2.676 . . . . 0.0 112.757 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.588 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 48.4 m -80.9 175.41 10.71 Favored 'General case' 0 CA--C 1.539 0.526 0 O-C-N 123.026 0.204 . . . . 0.0 110.472 179.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 34.8 m -117.2 -56.01 2.28 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.91 13.07 6.35 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.18 36.7 7.47 Favored Glycine 0 C--N 1.34 0.769 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.418 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.52 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.6 mt -82.24 170.41 15.45 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.157 0.583 . . . . 0.0 111.222 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -115.48 144.44 23.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.588 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.8 m -80.87 102.74 10.25 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.276 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -80.78 140.61 50.87 Favored Pre-proline 0 CA--C 1.53 0.184 0 CA-C-N 115.296 -0.866 . . . . 0.0 111.439 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.73 64.61 1.78 Allowed 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.885 2.39 . . . . 0.0 112.175 179.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.526 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.8 p -95.31 152.33 18.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.983 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.29 144.26 28.83 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.64 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.543 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.6 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.476 0 C-N-CA 124.152 -1.187 . . . . 0.0 113.273 -0.078 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.543 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.93 145.38 32.29 Favored Pre-proline 0 CA--C 1.541 0.599 0 O-C-N 123.365 0.416 . . . . 0.0 111.203 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.422 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.67 156.96 54.26 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 122.884 2.389 . . . . 0.0 113.428 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.526 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.2 mm -123.12 153.46 28.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.979 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.37 119.16 29.59 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.792 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.52 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.44 145.78 13.52 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.261 -0.495 . . . . 0.0 113.256 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.127 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.134 179.386 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.4 p . . . . . 0 C--O 1.235 0.317 0 CA-C-O 120.677 0.275 . . . . 0.0 111.506 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.6 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.86 119.94 25.91 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.844 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.46 -156.43 0.4 Allowed 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.418 -178.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.2 112.42 18.51 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.687 0.395 . . . . 0.0 111.233 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.88 36.8 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -116.94 158.95 23.2 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.646 0.379 . . . . 0.0 110.582 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.4 p -80.13 131.75 35.8 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.855 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.5 p -100.76 31.11 3.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.89 179.758 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.43 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.26 -11.54 52.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.781 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.43 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.4 -37.77 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.134 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -136.6 152.97 75.59 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.13 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -69.35 -172.31 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.561 0 C-N-CA 123.345 2.696 . . . . 0.0 112.646 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.6 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 54.6 m -81.46 174.93 10.98 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 123.017 0.198 . . . . 0.0 110.487 179.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.5 m -115.87 -55.59 2.4 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -84.64 11.81 8.26 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.67 35.29 7.91 Favored Glycine 0 C--N 1.339 0.732 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.348 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.545 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -80.01 166.95 21.06 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.164 0.586 . . . . 0.0 111.488 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.34 144.41 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.188 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.7 m -82.27 104.03 12.29 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.241 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -80.85 140.27 50.47 Favored Pre-proline 0 CA--C 1.53 0.19 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.13 65.16 2.02 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 122.904 2.402 . . . . 0.0 112.103 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.49 151.62 19.14 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.798 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.22 144.31 28.71 Favored Pre-proline 0 CA--C 1.532 0.282 0 O-C-N 123.511 0.507 . . . . 0.0 111.626 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -32.01 4.77 Favored 'Cis proline' 0 C--N 1.367 1.53 0 C-N-CA 124.13 -1.196 . . . . 0.0 113.179 0.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -113.98 144.33 31.34 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.025 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.9 Cg_endo -63.45 157.41 50.85 Favored 'Trans proline' 0 C--N 1.375 1.97 0 C-N-CA 123.0 2.467 . . . . 0.0 113.803 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.73 154.4 27.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.92 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.54 119.26 30.66 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.851 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.545 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.68 144.28 10.95 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.112 -0.495 . . . . 0.0 113.003 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.41 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.251 1.145 0 CA-C-O 118.474 -0.774 . . . . 0.0 111.244 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.7 p . . . . . 0 N--CA 1.466 0.328 0 CA-C-O 120.821 0.344 . . . . 0.0 111.524 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.621 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.36 116.84 24.78 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.826 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . 0.553 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.67 -154.46 0.29 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.155 -179.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -79.83 106.44 11.86 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.973 0.416 . . . . 0.0 111.053 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.55 9.98 24.19 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.326 -0.852 . . . . 0.0 112.407 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.553 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.9 mt-10 -112.34 156.48 22.38 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.608 0.363 . . . . 0.0 110.525 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -82.64 128.5 34.39 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.889 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.6 p -96.77 33.33 1.88 Allowed 'General case' 0 C--O 1.238 0.486 0 CA-C-O 121.295 0.569 . . . . 0.0 110.9 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -89.85 -10.83 43.88 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.407 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.8 p -123.9 -39.12 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.031 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 25.6 m-85 -134.86 152.63 77.76 Favored Pre-proline 0 CA--C 1.538 0.494 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.177 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.55 -171.76 0.49 Allowed 'Trans proline' 0 C--N 1.367 1.544 0 C-N-CA 123.308 2.672 . . . . 0.0 112.689 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.4 m -81.87 174.84 10.92 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 110.324 -0.25 . . . . 0.0 110.324 178.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 40.9 m -114.29 -55.28 2.51 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 -178.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.45 12.2 10.79 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.82 36.86 7.59 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.514 -0.374 . . . . 0.0 112.263 -179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.609 HD22 ' HA2' ' A' ' 31' ' ' GLY . 3.1 mt -79.96 166.85 21.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 123.254 0.622 . . . . 0.0 111.597 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.8 mt -107.7 144.85 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.195 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.9 m -82.52 104.65 12.96 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.162 178.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -81.25 139.93 48.87 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.554 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.1 65.24 2.0 Allowed 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.929 2.42 . . . . 0.0 112.079 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 43.8 p -95.53 151.73 19.05 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.875 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.39 144.3 28.72 Favored Pre-proline 0 CA--C 1.532 0.269 0 O-C-N 123.57 0.544 . . . . 0.0 111.563 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.58 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.367 1.519 0 C-N-CA 124.145 -1.189 . . . . 0.0 113.166 0.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -113.73 144.07 30.73 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.145 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.46 157.23 51.88 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.048 2.499 . . . . 0.0 113.717 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.9 mm -122.38 154.39 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.904 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -90.67 119.39 30.87 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.791 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.609 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.77 144.65 11.17 Favored Glycine 0 C--N 1.338 0.675 0 CA-C-N 116.101 -0.5 . . . . 0.0 113.044 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.484 HG13 HD23 ' A' ' 19' ' ' LEU . 1.1 m . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.079 -0.962 . . . . 0.0 111.199 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.0 p . . . . . 0 N--CA 1.465 0.298 0 CA-C-O 120.726 0.298 . . . . 0.0 111.476 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.61 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.79 119.03 24.84 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.8 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -88.24 -155.96 0.34 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.466 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.55 112.99 19.28 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 122.708 0.403 . . . . 0.0 111.256 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.26 7.1 41.08 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-N 115.528 -0.76 . . . . 0.0 112.733 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.12 159.25 21.1 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.561 0.345 . . . . 0.0 110.504 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 54.7 p -79.94 131.63 35.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.843 -179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -100.73 31.23 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.865 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.428 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.58 -11.46 51.44 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.759 179.982 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.428 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.24 -37.68 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.051 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -136.76 153.1 75.46 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.123 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.53 -172.1 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.572 0 C-N-CA 123.295 2.663 . . . . 0.0 112.539 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.61 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.6 m -81.52 175.14 10.78 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 110.49 -0.189 . . . . 0.0 110.49 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.4 m -115.85 -55.3 2.43 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.21 12.36 8.14 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.15 35.36 8.16 Favored Glycine 0 C--N 1.339 0.748 0 C-N-CA 121.516 -0.374 . . . . 0.0 112.383 -179.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.552 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -79.91 167.0 21.07 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.231 0.612 . . . . 0.0 111.576 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.46 144.33 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.268 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.8 m -82.09 104.03 12.14 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.253 178.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -81.3 140.43 48.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.501 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -70.26 64.83 2.1 Favored 'Trans proline' 0 C--N 1.364 1.393 0 C-N-CA 122.999 2.466 . . . . 0.0 112.054 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.526 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.4 p -95.31 152.52 18.31 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.897 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.52 144.18 28.72 Favored Pre-proline 0 C--O 1.236 0.374 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.565 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.3 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.485 0 C-N-CA 124.064 -1.223 . . . . 0.0 113.238 -0.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.02 145.37 32.3 Favored Pre-proline 0 CA--C 1.542 0.661 0 O-C-N 123.29 0.369 . . . . 0.0 111.197 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.422 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.1 Cg_endo -63.67 156.79 55.24 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.943 2.429 . . . . 0.0 113.419 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.526 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.8 mm -122.52 153.79 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.96 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -89.92 119.16 30.05 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.939 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.552 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.35 144.04 10.73 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.985 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.41 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.073 -0.965 . . . . 0.0 111.127 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p . . . . . 0 C--O 1.235 0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.385 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.635 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.89 116.48 24.16 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.878 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . 0.553 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.14 -154.32 0.27 Allowed 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.181 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -79.82 106.86 12.15 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.082 0.468 . . . . 0.0 111.187 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.74 9.9 25.82 Favored Glycine 0 C--N 1.336 0.541 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.55 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.553 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.0 mt-10 -111.72 156.8 21.32 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 122.649 0.379 . . . . 0.0 110.499 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.4 p -82.88 132.05 35.17 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.752 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.427 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.2 p -102.05 38.1 1.72 Allowed 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.58 0.55 . . . . 0.0 111.18 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -91.46 -11.0 38.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.38 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.9 p -124.72 -39.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.934 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 27.2 m-85 -132.16 152.01 79.39 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 123.538 0.524 . . . . 0.0 111.51 179.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.5 -169.07 0.34 Allowed 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.577 2.851 . . . . 0.0 112.75 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 49.4 m -83.53 175.13 10.01 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 123.119 0.262 . . . . 0.0 110.376 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.9 m -114.84 -55.26 2.5 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.102 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 12.36 9.9 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.96 36.14 7.87 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 121.422 -0.418 . . . . 0.0 112.39 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.608 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.9 mt -79.93 168.13 19.62 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.331 0.653 . . . . 0.0 111.541 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -109.85 144.66 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.224 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.1 m -82.37 103.86 12.24 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.173 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -80.69 140.46 51.18 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.492 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -70.37 64.84 2.16 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.924 2.416 . . . . 0.0 111.978 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.5 p -95.0 150.43 20.17 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.963 -178.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -105.46 144.19 28.32 Favored Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.589 0.555 . . . . 0.0 111.724 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.87 -31.4 5.16 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.219 0.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -113.7 143.9 30.39 Favored Pre-proline 0 CA--C 1.541 0.621 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.199 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.6 Cg_endo -64.09 157.59 52.53 Favored 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 123.016 2.477 . . . . 0.0 113.514 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.97 154.09 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.973 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.427 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.0 m -90.08 119.02 30.06 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.608 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.91 144.68 11.37 Favored Glycine 0 C--N 1.337 0.599 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.013 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.474 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.452 -0.785 . . . . 0.0 111.122 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.3 p . . . . . 0 N--CA 1.467 0.389 0 CA-C-O 120.667 0.27 . . . . 0.0 111.621 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.612 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.69 118.52 24.46 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.789 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.23 -156.78 0.38 Allowed 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.406 -178.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -80.74 112.03 17.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.641 0.376 . . . . 0.0 111.387 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.94 8.14 37.15 Favored Glycine 0 C--N 1.334 0.471 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.62 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -115.98 158.69 22.69 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 122.623 0.369 . . . . 0.0 110.535 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.0 p -80.11 131.67 35.79 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.808 -179.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.6 p -100.6 31.13 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.893 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.3 -11.38 52.37 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.749 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.6 -38.08 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.137 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -136.2 152.86 76.04 Favored Pre-proline 0 CA--C 1.538 0.481 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.145 179.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.07 -172.04 0.47 Allowed 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 123.349 2.699 . . . . 0.0 112.605 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.612 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -81.64 175.78 10.2 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 123.123 0.264 . . . . 0.0 110.406 178.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 42.3 m -114.9 -55.99 2.42 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -87.47 13.18 10.55 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.87 35.98 6.97 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.395 -0.431 . . . . 0.0 112.625 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.552 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -80.19 166.36 21.51 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.018 0.527 . . . . 0.0 111.447 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.86 143.96 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.223 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.5 m -82.13 103.55 11.82 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.238 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.8 m-85 -80.19 140.33 53.06 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.509 -179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 65.01 2.07 Favored 'Trans proline' 0 C--N 1.365 1.424 0 C-N-CA 123.055 2.503 . . . . 0.0 112.142 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.33 151.55 19.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.894 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.65 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.56 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.366 1.477 0 C-N-CA 124.055 -1.227 . . . . 0.0 113.088 0.081 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -113.87 144.24 31.12 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.09 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.0 Cg_endo -63.34 157.62 49.28 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.023 2.482 . . . . 0.0 113.751 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.96 153.93 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.902 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.15 119.25 30.32 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.883 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.552 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.9 143.93 10.51 Favored Glycine 0 C--N 1.339 0.695 0 CA-C-N 116.071 -0.513 . . . . 0.0 113.088 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.415 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.135 -0.936 . . . . 0.0 111.142 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.467 0.392 0 CA-C-O 120.712 0.291 . . . . 0.0 111.468 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.599 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.67 120.25 26.17 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.742 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.68 -156.34 0.4 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.389 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.23 112.6 18.71 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.897 0.379 . . . . 0.0 111.373 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.31 8.8 37.63 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.566 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -116.97 158.97 23.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 122.622 0.369 . . . . 0.0 110.524 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.4 p -80.03 131.94 35.89 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.819 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -100.96 31.16 3.71 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.854 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.417 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.41 -11.21 52.57 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.721 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.417 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.6 p -121.52 -37.89 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.07 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -136.72 152.95 75.36 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.179 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.23 -172.17 0.5 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 123.342 2.695 . . . . 0.0 112.574 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.599 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -81.61 175.15 10.73 Favored 'General case' 0 CA--C 1.539 0.535 0 O-C-N 123.044 0.215 . . . . 0.0 110.449 179.075 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.8 m -116.02 -55.43 2.41 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -177.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -85.11 12.87 6.96 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -178.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.33 8.73 Favored Glycine 0 C--N 1.341 0.851 0 C-N-CA 121.478 -0.392 . . . . 0.0 112.413 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.55 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -79.98 166.77 21.26 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.22 0.608 . . . . 0.0 111.484 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.09 144.36 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.239 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.5 m -82.3 103.93 12.24 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.5 m-85 -80.76 140.28 50.8 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.46 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.17 65.07 2.05 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.94 2.427 . . . . 0.0 112.056 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.41 151.49 19.23 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.878 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.339 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.746 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.52 -32.28 4.6 Favored 'Cis proline' 0 C--N 1.366 1.475 0 C-N-CA 124.046 -1.231 . . . . 0.0 113.142 0.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.76 144.23 31.05 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.43 157.42 50.73 Favored 'Trans proline' 0 C--N 1.375 1.931 0 C-N-CA 123.004 2.47 . . . . 0.0 113.809 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.7 mm -122.81 154.33 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.857 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -90.59 119.36 30.78 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.877 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.55 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.76 144.01 10.63 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 116.041 -0.527 . . . . 0.0 113.014 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.411 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.424 -0.798 . . . . 0.0 111.23 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p . . . . . 0 C--O 1.235 0.332 0 CA-C-O 120.691 0.281 . . . . 0.0 111.46 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.19 119.95 25.63 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.71 179.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -89.14 -156.3 0.39 Allowed 'General case' 0 CA--C 1.544 0.713 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.665 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -81.21 113.04 19.08 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 122.651 0.38 . . . . 0.0 111.384 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.76 8.36 40.01 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.334 -0.848 . . . . 0.0 112.604 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -116.16 159.67 21.45 Favored 'General case' 0 C--O 1.236 0.395 0 C-N-CA 122.493 0.317 . . . . 0.0 110.555 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.8 p -81.02 134.74 35.73 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.702 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.457 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -105.41 37.41 2.21 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.758 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -87.31 -13.36 43.83 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.885 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 p -122.43 -38.43 1.37 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 O-C-N 123.506 0.504 . . . . 0.0 110.111 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -132.26 152.42 80.08 Favored Pre-proline 0 CA--C 1.538 0.511 0 O-C-N 123.609 0.568 . . . . 0.0 111.462 179.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.21 -168.35 0.29 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 123.426 2.751 . . . . 0.0 112.777 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.626 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -84.09 175.6 9.39 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 123.048 0.218 . . . . 0.0 110.502 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.9 m -116.53 -55.34 2.38 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -178.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -84.77 12.26 7.62 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.5 34.74 8.34 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.461 -0.399 . . . . 0.0 112.359 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.539 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -80.04 167.79 19.98 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.223 0.609 . . . . 0.0 111.426 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.91 144.21 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.252 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.9 m -82.22 103.26 11.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.166 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.9 m-85 -80.34 140.83 52.69 Favored Pre-proline 0 CA--C 1.53 0.195 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.511 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.33 64.58 2.14 Favored 'Trans proline' 0 C--N 1.364 1.389 0 C-N-CA 122.955 2.437 . . . . 0.0 111.997 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.522 ' OG1' HG12 ' A' ' 29' ' ' ILE . 47.7 p -95.02 151.65 18.99 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.964 -178.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.76 143.95 28.09 Favored Pre-proline 0 C--O 1.234 0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.674 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -76.36 -36.61 2.44 Favored 'Cis proline' 0 C--N 1.365 1.435 0 C-N-CA 124.079 -1.217 . . . . 0.0 113.162 0.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -109.67 145.91 32.94 Favored Pre-proline 0 CA--C 1.54 0.559 0 O-C-N 123.342 0.401 . . . . 0.0 111.131 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.4 Cg_endo -64.47 157.64 53.84 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.842 2.362 . . . . 0.0 113.351 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.522 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.1 mm -123.71 153.55 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.969 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.457 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.54 118.95 29.55 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.929 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.539 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.8 144.1 10.89 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 116.042 -0.526 . . . . 0.0 113.092 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.407 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.19 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.47 0.527 0 CA-C-O 120.707 0.289 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.573 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.78 120.16 27.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.524 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.08 -156.12 0.38 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.526 -178.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.12 113.49 19.32 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.78 0.432 . . . . 0.0 111.242 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.82 7.23 42.1 Favored Glycine 0 C--N 1.334 0.419 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.588 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.72 159.31 20.69 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.741 0.416 . . . . 0.0 110.579 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 65.1 p -79.98 131.44 35.81 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.781 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.576 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.47 28.7 5.3 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.971 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.4 -12.18 56.75 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.705 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.445 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.5 p -121.35 -41.06 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.348 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -130.26 153.53 81.24 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.306 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.7 -174.71 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.202 2.601 . . . . 0.0 112.42 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.07 175.22 10.83 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 110.53 -0.174 . . . . 0.0 110.53 179.114 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.5 m -115.15 -54.88 2.52 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.31 12.95 8.9 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.68 8.65 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.415 -0.421 . . . . 0.0 112.366 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.571 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -79.93 166.56 21.51 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.265 0.626 . . . . 0.0 111.565 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.6 144.29 17.37 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.155 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.8 m -82.21 103.98 12.2 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.214 178.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.64 140.18 51.23 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.535 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.33 65.23 2.14 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.965 2.443 . . . . 0.0 112.093 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.29 152.9 17.97 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.963 -178.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -107.05 144.23 28.7 Favored Pre-proline 0 C--O 1.236 0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.73 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.42 -32.05 4.77 Favored 'Cis proline' 0 C--N 1.365 1.419 0 C-N-CA 124.084 -1.215 . . . . 0.0 113.196 0.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.27 144.49 31.8 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.089 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.2 Cg_endo -63.21 157.52 49.27 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 123.02 2.48 . . . . 0.0 113.75 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.89 154.38 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.864 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.42 119.5 30.76 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.948 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.571 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.44 144.32 10.86 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 116.083 -0.508 . . . . 0.0 113.117 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.434 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.065 -0.969 . . . . 0.0 111.108 179.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.7 p . . . . . 0 N--CA 1.471 0.584 0 CA-C-O 120.681 0.277 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.9 120.03 27.74 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.0 -156.11 0.37 Allowed 'General case' 0 CA--C 1.543 0.696 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.533 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.09 113.47 19.29 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.986 0.422 . . . . 0.0 111.238 -179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.04 6.94 41.99 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.546 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.56 159.39 20.47 Favored 'General case' 0 C--O 1.234 0.275 0 C-N-CA 122.547 0.339 . . . . 0.0 110.481 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.2 p -79.94 131.27 35.79 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.811 -179.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.578 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.11 28.62 5.2 Favored 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.969 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.446 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.59 -12.1 56.5 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.661 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.446 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.38 -41.31 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.217 -179.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -130.26 153.44 81.23 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.326 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.62 -174.82 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.472 0 C-N-CA 123.202 2.601 . . . . 0.0 112.348 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -79.87 175.28 10.77 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -115.16 -54.86 2.52 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -178.019 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.55 13.08 9.05 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.26 35.88 8.53 Favored Glycine 0 C--N 1.34 0.764 0 C-N-CA 121.495 -0.384 . . . . 0.0 112.293 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.576 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.97 166.58 21.45 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.159 0.584 . . . . 0.0 111.649 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -108.4 144.36 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.141 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.2 m -82.24 103.89 12.16 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -80.38 140.13 52.22 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.538 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.24 65.22 2.09 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.05 2.5 . . . . 0.0 112.079 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.36 152.74 18.13 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.889 -178.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -107.0 144.23 28.68 Favored Pre-proline 0 C--O 1.234 0.268 0 O-C-N 123.541 0.526 . . . . 0.0 111.683 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.55 -31.93 4.84 Favored 'Cis proline' 0 C--N 1.367 1.505 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.22 0.06 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.15 144.6 31.95 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.525 0.516 . . . . 0.0 111.127 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.2 Cg_endo -63.28 157.53 49.53 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.962 2.441 . . . . 0.0 113.793 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.83 154.31 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.871 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.31 119.44 30.61 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.91 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.576 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.56 144.36 10.88 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 116.114 -0.494 . . . . 0.0 113.016 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.433 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.126 -0.94 . . . . 0.0 111.257 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.469 0.505 0 CA-C-O 120.666 0.27 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.57 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.92 120.37 28.12 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.465 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.26 -155.96 0.37 Allowed 'General case' 0 CA--C 1.545 0.768 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.622 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.37 113.65 19.6 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.312 0.382 . . . . 0.0 111.225 -179.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.78 7.31 42.06 Favored Glycine 0 CA--C 1.521 0.453 0 CA-C-N 115.378 -0.828 . . . . 0.0 112.511 -179.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -114.95 159.51 20.65 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 122.62 0.368 . . . . 0.0 110.526 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.4 p -80.1 131.44 35.75 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.804 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.575 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.41 28.66 5.31 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.033 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.446 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.43 -12.05 56.84 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.712 179.971 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.446 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.46 -41.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 O-C-N 123.583 0.552 . . . . 0.0 110.298 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -130.41 153.45 81.34 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -70.69 -174.65 1.14 Allowed 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 123.188 2.592 . . . . 0.0 112.357 179.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.06 175.21 10.84 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.6 m -115.29 -54.84 2.51 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 112.906 0.706 . . . . 0.0 112.906 -178.006 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -86.11 12.73 9.01 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.62 8.56 Favored Glycine 0 C--N 1.34 0.792 0 C-N-CA 121.517 -0.373 . . . . 0.0 112.291 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.569 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -79.9 166.61 21.48 Favored 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 123.254 0.621 . . . . 0.0 111.51 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.57 144.42 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.175 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.6 m -82.38 103.97 12.34 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.155 178.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -80.68 140.17 51.08 Favored Pre-proline 0 CA--C 1.53 0.199 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.32 65.25 2.13 Favored 'Trans proline' 0 C--N 1.366 1.455 0 C-N-CA 122.975 2.45 . . . . 0.0 111.993 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.3 152.49 18.33 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.9 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.84 144.29 28.77 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.688 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -31.85 4.88 Favored 'Cis proline' 0 C--N 1.367 1.521 0 C-N-CA 124.024 -1.24 . . . . 0.0 113.116 0.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.31 144.6 32.03 Favored Pre-proline 0 CA--C 1.542 0.665 0 O-C-N 123.481 0.488 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.25 157.51 49.52 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 122.894 2.396 . . . . 0.0 113.845 -179.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.93 154.37 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.819 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.575 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.42 30.62 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.901 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.569 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.35 144.24 10.78 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 116.048 -0.524 . . . . 0.0 113.001 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.429 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.252 1.236 0 CA-C-O 118.375 -0.822 . . . . 0.0 111.189 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p . . . . . 0 N--CA 1.47 0.555 0 CA-C-O 120.698 0.285 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.571 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.59 119.49 26.9 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.539 179.304 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.06 -156.2 0.35 Allowed 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.634 -178.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.27 113.63 19.53 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 122.765 0.426 . . . . 0.0 111.315 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.4 5.43 42.86 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.624 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.37 159.5 19.37 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.526 0.331 . . . . 0.0 110.52 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.9 131.67 35.9 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.805 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.19 4.84 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.002 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.447 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -84.02 -12.36 55.33 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.584 -0.734 . . . . 0.0 111.704 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.447 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.7 p -120.96 -41.01 1.79 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.268 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -130.59 153.5 81.49 Favored Pre-proline 0 CA--C 1.536 0.44 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.305 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.8 -174.48 1.12 Allowed 'Trans proline' 0 C--N 1.365 1.436 0 C-N-CA 123.167 2.578 . . . . 0.0 112.35 179.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.571 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.0 175.38 10.69 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.135 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -115.06 -54.69 2.54 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.69 13.07 9.3 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.71 8.62 Favored Glycine 0 C--N 1.341 0.831 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.34 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.579 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.83 166.81 21.32 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.187 0.595 . . . . 0.0 111.577 -179.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.54 144.4 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.195 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.8 m -82.43 104.11 12.47 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.162 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.06 140.33 49.71 Favored Pre-proline 0 CA--C 1.53 0.188 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.514 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.32 64.87 2.14 Favored 'Trans proline' 0 C--N 1.366 1.464 0 C-N-CA 122.995 2.463 . . . . 0.0 112.063 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.527 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.8 p -95.17 152.74 18.09 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.982 -178.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.68 144.16 28.73 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.57 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.539 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.31 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.025 -1.239 . . . . 0.0 113.22 0.003 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.539 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.07 145.54 32.67 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 123.34 0.4 . . . . 0.0 111.197 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.418 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 27.9 Cg_endo -63.58 156.8 54.77 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 122.988 2.459 . . . . 0.0 113.465 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.527 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -122.67 153.9 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.868 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.46 30.22 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.579 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.26 144.35 10.93 Favored Glycine 0 C--N 1.341 0.81 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.979 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.445 HG13 HD23 ' A' ' 19' ' ' LEU . 1.1 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.049 -0.977 . . . . 0.0 111.192 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 p . . . . . 0 N--CA 1.469 0.485 0 CA-C-O 120.643 0.258 . . . . 0.0 110.879 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.38 121.32 28.78 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.417 179.265 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -89.59 -156.58 0.41 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.636 -178.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.59 113.59 19.71 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 122.742 0.417 . . . . 0.0 111.295 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.73 7.4 42.01 Favored Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.565 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -115.05 160.34 19.75 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 122.548 0.339 . . . . 0.0 110.444 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.4 p -79.86 135.36 36.43 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.525 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.519 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -107.59 34.86 3.31 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.148 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -86.59 -14.89 41.49 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.761 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 p -118.76 -41.53 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 O-C-N 123.399 0.437 . . . . 0.0 110.2 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -127.68 153.6 77.76 Favored Pre-proline 0 CA--C 1.537 0.474 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.34 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.69 -170.25 0.51 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 123.298 2.665 . . . . 0.0 112.384 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.567 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -83.25 175.78 9.66 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.81 -54.57 2.49 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 112.875 0.695 . . . . 0.0 112.875 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 13.14 8.3 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.23 35.17 8.99 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.486 -0.388 . . . . 0.0 112.382 -179.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.573 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.6 mt -80.05 167.47 20.38 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.169 0.587 . . . . 0.0 111.489 -179.378 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.07 144.14 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.277 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.8 m -82.06 103.58 11.79 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.236 178.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -80.82 140.62 50.72 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.285 -0.87 . . . . 0.0 111.49 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.45 64.86 2.21 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.92 2.413 . . . . 0.0 112.045 179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.524 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.0 p -95.02 151.01 19.54 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.948 -178.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.74 144.4 28.79 Favored Pre-proline 0 C--O 1.234 0.279 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.692 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.67 -30.99 5.47 Favored 'Cis proline' 0 C--N 1.366 1.499 0 C-N-CA 124.053 -1.228 . . . . 0.0 113.161 0.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -114.64 144.4 31.8 Favored Pre-proline 0 CA--C 1.542 0.659 0 O-C-N 123.509 0.506 . . . . 0.0 111.118 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.76 157.61 51.04 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.865 2.377 . . . . 0.0 113.572 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.524 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.0 mm -124.39 153.66 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.943 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.519 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.1 m -89.41 119.13 29.6 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.804 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.573 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.61 144.45 11.16 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.078 -0.51 . . . . 0.0 113.016 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.424 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.083 -0.96 . . . . 0.0 111.265 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p . . . . . 0 N--CA 1.47 0.546 0 CA-C-O 120.6 0.238 . . . . 0.0 110.949 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.549 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.6 120.76 27.4 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.511 179.146 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . 0.508 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 12.0 pt-20 -89.11 -155.87 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.609 -178.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.508 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.65 113.74 19.86 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.961 0.41 . . . . 0.0 111.316 -179.548 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.48 7.19 43.14 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.635 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.78 159.97 19.97 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 122.538 0.335 . . . . 0.0 110.395 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 59.1 p -79.97 131.31 35.79 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.798 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.559 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 32.0 p -101.33 27.49 6.18 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.042 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -82.46 -11.36 58.56 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.685 179.95 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.8 p -121.8 -40.75 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.268 -179.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -130.8 153.47 81.64 Favored Pre-proline 0 CA--C 1.536 0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.377 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.92 -174.74 1.21 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.245 2.63 . . . . 0.0 112.297 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.5 m -80.01 175.53 10.55 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 110.508 -0.182 . . . . 0.0 110.508 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.4 m -116.71 -55.51 2.36 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -177.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.23 13.78 7.46 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.51 37.04 7.69 Favored Glycine 0 C--N 1.339 0.716 0 C-N-CA 121.43 -0.414 . . . . 0.0 112.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.533 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -82.28 169.65 16.28 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.239 0.616 . . . . 0.0 111.131 -179.531 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -114.81 144.22 22.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.54 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 m -80.61 102.88 10.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.379 178.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -80.74 140.49 50.98 Favored Pre-proline 0 N--CA 1.457 -0.111 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.415 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.7 64.64 1.77 Allowed 'Trans proline' 0 C--N 1.364 1.376 0 C-N-CA 123.009 2.473 . . . . 0.0 112.22 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.527 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.7 p -95.47 152.46 18.39 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.971 -178.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.42 144.13 28.59 Favored Pre-proline 0 C--O 1.235 0.341 0 O-C-N 123.506 0.504 . . . . 0.0 111.632 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.543 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.47 -35.52 2.85 Favored 'Cis proline' 0 C--N 1.368 1.557 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.266 0.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.543 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -111.05 145.39 32.34 Favored Pre-proline 0 CA--C 1.542 0.649 0 O-C-N 123.299 0.374 . . . . 0.0 111.166 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.419 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.1 Cg_endo -63.71 156.91 54.64 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 122.9 2.4 . . . . 0.0 113.365 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.527 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -123.12 153.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.977 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -88.85 119.21 29.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.72 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.533 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.01 146.08 13.96 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.342 -0.456 . . . . 0.0 113.323 -179.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.4 HG13 ' HA ' ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.414 -0.803 . . . . 0.0 111.08 179.437 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.469 0.489 0 CA-C-O 120.658 0.266 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.503 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.57 121.89 28.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.691 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.34 -155.7 0.33 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.484 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.554 ' HG2' HD21 ' A' ' 19' ' ' LEU . 2.3 mt-10 -83.03 115.82 22.02 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 122.605 0.362 . . . . 0.0 110.509 -179.252 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.65 6.63 49.7 Favored Glycine 0 CA--C 1.523 0.539 0 CA-C-N 115.468 -0.787 . . . . 0.0 112.69 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -113.35 160.05 18.78 Favored 'General case' 0 C--O 1.234 0.266 0 C-N-CA 122.494 0.318 . . . . 0.0 110.54 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.3 p -79.81 132.03 36.03 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.992 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.581 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -101.99 29.15 5.2 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.033 179.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.471 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.8 -13.58 53.46 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.713 179.97 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.471 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.3 p -119.99 -41.18 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.165 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -130.47 153.38 81.36 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.291 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.12 -174.52 1.2 Allowed 'Trans proline' 0 C--N 1.365 1.442 0 C-N-CA 123.307 2.671 . . . . 0.0 112.31 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 58.7 m -79.91 176.22 9.93 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.1 m -117.72 -55.68 2.26 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -178.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.8 12.85 8.21 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.24 36.1 7.74 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 121.439 -0.41 . . . . 0.0 112.356 -179.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.554 HD21 ' HG2' ' A' ' 6' ' ' GLU . 2.5 mt -80.12 166.25 21.67 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.13 0.572 . . . . 0.0 111.464 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -109.4 143.53 19.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.097 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.9 m -81.67 103.65 11.52 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.4 m-85 -80.52 140.18 51.71 Favored Pre-proline 0 CA--C 1.529 0.167 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.542 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.3 65.31 2.12 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.998 2.466 . . . . 0.0 112.007 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.517 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.64 152.04 18.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.927 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.49 144.22 28.57 Favored Pre-proline 0 C--O 1.234 0.249 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.673 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -32.06 4.73 Favored 'Cis proline' 0 C--N 1.366 1.493 0 C-N-CA 124.074 -1.219 . . . . 0.0 113.083 0.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.96 144.46 31.6 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.502 0.501 . . . . 0.0 111.101 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.34 157.74 48.66 Favored 'Trans proline' 0 C--N 1.375 1.932 0 C-N-CA 122.938 2.425 . . . . 0.0 113.85 -179.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.517 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.15 152.88 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.967 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.581 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.13 118.78 29.08 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.703 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.512 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.35 142.53 9.29 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 116.206 -0.452 . . . . 0.0 113.182 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.425 HG13 HD23 ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.289 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.8 p . . . . . 0 N--CA 1.469 0.515 0 CA-C-O 120.715 0.293 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.71 119.47 26.97 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.486 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . 0.507 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 11.9 pt-20 -88.07 -156.22 0.35 Allowed 'General case' 0 CA--C 1.545 0.77 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.598 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.507 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.35 113.8 19.69 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 122.714 0.406 . . . . 0.0 111.287 -179.572 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.23 5.53 43.24 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.435 -0.802 . . . . 0.0 112.628 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.39 159.47 19.41 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.638 0.375 . . . . 0.0 110.454 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.92 131.68 35.89 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.866 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.04 4.92 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.98 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.95 -12.35 55.47 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.702 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.451 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.12 -40.83 1.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.262 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -130.66 153.43 81.52 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 123.682 0.614 . . . . 0.0 111.317 179.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -70.61 -174.46 1.08 Allowed 'Trans proline' 0 C--N 1.365 1.417 0 C-N-CA 123.277 2.651 . . . . 0.0 112.331 179.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -80.06 175.39 10.68 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.03 -54.59 2.55 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.821 0.675 . . . . 0.0 112.821 -177.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.77 12.91 9.76 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.36 35.81 8.51 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.509 -0.377 . . . . 0.0 112.335 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.583 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.89 166.89 21.2 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.208 0.603 . . . . 0.0 111.62 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.55 144.41 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.204 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.3 m -82.28 104.11 12.36 Favored 'General case' 0 C--O 1.239 0.525 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.206 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.22 140.33 49.13 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.506 -179.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.21 64.9 2.07 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 123.003 2.469 . . . . 0.0 112.028 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.53 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.2 152.73 18.1 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.032 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.64 144.19 28.78 Favored Pre-proline 0 C--O 1.234 0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.634 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.539 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.25 -35.51 2.86 Favored 'Cis proline' 0 C--N 1.367 1.552 0 C-N-CA 123.986 -1.256 . . . . 0.0 113.333 -0.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.539 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.15 145.53 32.67 Favored Pre-proline 0 CA--C 1.543 0.677 0 O-C-N 123.303 0.377 . . . . 0.0 111.211 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.3 Cg_endo -63.65 156.71 55.6 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.867 2.378 . . . . 0.0 113.489 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.53 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.2 mm -122.42 153.92 27.16 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.002 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.38 30.15 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.896 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.583 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.2 144.35 10.94 Favored Glycine 0 C--N 1.338 0.688 0 CA-C-N 116.167 -0.469 . . . . 0.0 113.096 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.443 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.146 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.1 p . . . . . 0 N--CA 1.469 0.52 0 CA-C-O 120.629 0.252 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.569 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.8 120.43 28.09 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.528 179.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.28 -156.09 0.38 Allowed 'General case' 0 CA--C 1.544 0.72 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.62 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.29 113.69 19.57 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.948 0.404 . . . . 0.0 111.29 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.85 7.08 42.3 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.492 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.77 159.4 20.64 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 122.71 0.404 . . . . 0.0 110.479 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.6 p -79.98 131.43 35.81 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.053 -0.522 . . . . 0.0 111.856 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.576 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 30.9 p -101.47 28.69 5.31 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.004 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.447 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.46 -11.94 56.92 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.663 179.926 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.447 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.57 -41.17 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 O-C-N 123.543 0.527 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -130.24 153.58 81.23 Favored Pre-proline 0 CA--C 1.536 0.425 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.285 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.79 -174.74 1.18 Allowed 'Trans proline' 0 C--N 1.365 1.437 0 C-N-CA 123.214 2.61 . . . . 0.0 112.338 179.157 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.569 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.07 175.2 10.86 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 110.579 -0.156 . . . . 0.0 110.579 179.089 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 53.4 m -115.31 -54.81 2.51 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -177.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -86.33 13.85 7.49 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.2 35.78 9.4 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 121.428 -0.415 . . . . 0.0 112.47 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.573 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -80.03 166.63 21.37 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 123.163 0.585 . . . . 0.0 111.602 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.41 144.36 17.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.211 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.1 m -82.28 104.05 12.31 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.272 178.7 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.68 140.21 51.1 Favored Pre-proline 0 CA--C 1.531 0.222 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.484 -179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.31 65.21 2.12 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.964 2.443 . . . . 0.0 112.101 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.27 152.56 18.27 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.899 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.86 144.21 28.62 Favored Pre-proline 0 C--O 1.233 0.233 0 O-C-N 123.512 0.507 . . . . 0.0 111.645 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.47 -32.08 4.74 Favored 'Cis proline' 0 C--N 1.368 1.578 0 C-N-CA 123.961 -1.266 . . . . 0.0 113.137 0.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.12 144.49 31.73 Favored Pre-proline 0 CA--C 1.542 0.652 0 O-C-N 123.515 0.509 . . . . 0.0 111.099 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.5 Cg_endo -63.21 157.47 49.55 Favored 'Trans proline' 0 C--N 1.374 1.871 0 C-N-CA 123.015 2.476 . . . . 0.0 113.859 -179.455 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.98 154.41 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.863 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.55 30.73 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.873 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.573 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.48 144.27 10.79 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 116.013 -0.54 . . . . 0.0 113.046 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.433 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.094 -0.955 . . . . 0.0 111.182 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p . . . . . 0 N--CA 1.469 0.512 0 CA-C-O 120.671 0.272 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.73 122.74 30.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.659 179.298 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.62 -155.74 0.34 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.556 -178.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.552 ' HG2' HD21 ' A' ' 19' ' ' LEU . 2.3 mt-10 -83.59 116.26 22.52 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 120.926 0.393 . . . . 0.0 110.527 -179.313 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.14 6.4 51.62 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.71 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -112.93 160.81 17.69 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.562 0.345 . . . . 0.0 110.646 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.8 p -79.72 136.18 36.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.677 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.515 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.7 p -108.38 34.48 3.61 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.18 -179.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -86.67 -15.35 39.89 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.753 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.4 p -118.06 -41.59 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 O-C-N 123.42 0.45 . . . . 0.0 110.086 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.3 m-85 -128.14 153.58 78.64 Favored Pre-proline 0 CA--C 1.537 0.464 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.189 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.22 -171.19 0.66 Allowed 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 123.31 2.674 . . . . 0.0 112.424 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 59.4 m -82.05 176.79 9.24 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 123.132 0.27 . . . . 0.0 110.402 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.3 m -118.23 -55.46 2.23 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.1 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -85.73 13.0 7.78 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.2 35.57 8.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.432 -0.413 . . . . 0.0 112.391 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.552 HD21 ' HG2' ' A' ' 6' ' ' GLU . 2.3 mt -80.07 166.68 21.29 Favored 'General case' 0 C--O 1.236 0.379 0 C-N-CA 123.178 0.591 . . . . 0.0 111.51 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -110.48 143.33 20.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.091 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.7 m -81.37 103.3 11.03 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.223 178.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -80.45 140.42 52.06 Favored Pre-proline 0 CA--C 1.529 0.153 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.546 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.38 65.09 2.17 Favored 'Trans proline' 0 C--N 1.366 1.483 0 C-N-CA 122.955 2.437 . . . . 0.0 112.041 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.524 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.7 p -95.46 151.52 19.22 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.863 -178.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.97 144.25 28.54 Favored Pre-proline 0 C--O 1.235 0.298 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.716 -179.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -31.33 5.24 Favored 'Cis proline' 0 C--N 1.367 1.523 0 C-N-CA 123.99 -1.254 . . . . 0.0 113.115 0.142 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -114.44 144.56 32.02 Favored Pre-proline 0 CA--C 1.541 0.617 0 O-C-N 123.487 0.492 . . . . 0.0 111.172 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.417 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.3 Cg_endo -63.5 157.78 49.06 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.877 2.385 . . . . 0.0 113.565 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.524 HG12 ' OG1' ' A' ' 24' ' ' THR . 16.4 mm -124.35 152.59 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.97 -179.795 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.515 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -88.67 118.54 28.41 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.782 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.51 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.78 142.76 9.58 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 116.138 -0.483 . . . . 0.0 113.101 -179.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.423 HG13 HD23 ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.475 -0.774 . . . . 0.0 111.228 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 114.384 1.253 . . . . 0.0 114.384 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -98.09 -26.58 14.55 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.552 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.9 p -82.23 155.92 24.65 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 122.705 0.402 . . . . 0.0 111.455 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.596 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.46 120.92 26.5 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.633 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.73 -156.65 0.42 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.565 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.06 112.87 18.83 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 122.68 0.392 . . . . 0.0 111.363 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.38 9.12 39.45 Favored Glycine 0 C--N 1.334 0.472 0 CA-C-N 115.417 -0.811 . . . . 0.0 112.672 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.54 159.8 21.57 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 122.625 0.37 . . . . 0.0 110.519 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.1 p -80.97 135.19 35.83 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.586 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.421 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.69 36.18 2.62 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.2 -11.5 52.3 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.798 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.03 -38.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 O-C-N 123.423 0.452 . . . . 0.0 110.135 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -132.81 152.29 79.6 Favored Pre-proline 0 CA--C 1.538 0.515 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.422 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.14 -168.42 0.29 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.541 2.827 . . . . 0.0 112.85 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.9 m -83.93 175.84 9.3 Favored 'General case' 0 CA--C 1.538 0.481 0 O-C-N 123.156 0.285 . . . . 0.0 110.547 179.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.0 m -117.75 -55.88 2.24 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.53 12.62 6.66 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -178.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.83 35.83 7.57 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.359 -0.448 . . . . 0.0 112.41 -179.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.512 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -81.95 171.54 14.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.134 0.574 . . . . 0.0 111.197 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -117.08 144.07 25.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.456 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 40.2 m -80.8 102.1 9.78 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.32 178.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.6 m-85 -79.99 140.97 54.17 Favored Pre-proline 0 N--CA 1.456 -0.163 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.36 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.91 64.41 1.89 Allowed 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 122.957 2.438 . . . . 0.0 112.098 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.521 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.0 p -95.19 150.98 19.62 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.937 -178.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.26 144.09 28.26 Favored Pre-proline 0 C--O 1.234 0.25 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.738 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.563 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.76 -35.17 2.97 Favored 'Cis proline' 0 C--N 1.366 1.487 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.226 0.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.563 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.66 144.96 31.32 Favored Pre-proline 0 CA--C 1.542 0.654 0 O-C-N 123.258 0.348 . . . . 0.0 111.194 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.6 Cg_endo -64.25 157.54 53.47 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.784 2.323 . . . . 0.0 113.374 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.521 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.4 mm -124.06 152.88 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.979 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.421 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.83 118.85 28.83 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.788 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.512 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.88 145.62 13.31 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 116.195 -0.457 . . . . 0.0 113.368 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.092 0 CA-C-O 118.448 -0.787 . . . . 0.0 111.046 179.503 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 114.409 1.263 . . . . 0.0 114.409 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 94.1 m95 -105.39 -35.58 7.46 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.417 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.5 p -82.75 155.89 24.02 Favored 'General case' 0 N--CA 1.466 0.331 0 O-C-N 123.559 0.537 . . . . 0.0 111.536 -179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.604 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.75 120.69 26.34 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.647 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.64 -156.8 0.42 Allowed 'General case' 0 CA--C 1.543 0.697 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.54 -178.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -80.82 112.85 18.59 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.682 0.393 . . . . 0.0 111.407 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.42 9.06 39.5 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.585 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -116.5 159.71 21.67 Favored 'General case' 0 C--O 1.235 0.301 0 C-N-CA 122.592 0.357 . . . . 0.0 110.438 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.8 p -80.88 135.27 35.89 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.555 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.423 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -105.96 36.43 2.57 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.863 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -86.25 -11.77 51.43 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.868 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -123.95 -38.46 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 123.384 0.428 . . . . 0.0 110.234 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -132.6 152.46 80.0 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.396 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.19 -168.57 0.3 Allowed 'Trans proline' 0 C--N 1.367 1.545 0 C-N-CA 123.507 2.805 . . . . 0.0 112.937 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.604 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 50.1 m -83.75 175.9 9.34 Favored 'General case' 0 CA--C 1.538 0.482 0 O-C-N 123.148 0.28 . . . . 0.0 110.567 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.1 m -117.65 -55.9 2.25 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.913 0.709 . . . . 0.0 112.913 -178.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.59 12.58 6.81 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 112.524 0.564 . . . . 0.0 112.524 -178.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.77 36.03 7.51 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 121.449 -0.405 . . . . 0.0 112.337 -179.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.507 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -81.99 171.38 14.47 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.19 0.596 . . . . 0.0 111.196 -179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.86 144.16 25.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.484 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.5 m -80.94 102.13 9.92 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.382 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -79.99 140.9 54.1 Favored Pre-proline 0 CA--C 1.529 0.165 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.39 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 64.45 1.85 Allowed 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.961 2.44 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 49.7 p -95.27 151.14 19.5 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.893 -178.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.46 144.05 28.22 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.769 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.562 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.7 Cg_exo -76.77 -35.17 2.98 Favored 'Cis proline' 0 C--N 1.367 1.506 0 C-N-CA 124.085 -1.214 . . . . 0.0 113.253 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.562 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.69 144.92 31.25 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.291 0.37 . . . . 0.0 111.217 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.1 Cg_endo -64.1 157.34 53.9 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.904 2.403 . . . . 0.0 113.343 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.2 mm -123.92 152.88 29.65 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.068 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -88.81 118.92 28.85 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.781 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.507 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.75 145.66 13.43 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 116.109 -0.496 . . . . 0.0 113.3 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.078 -0.963 . . . . 0.0 111.055 179.446 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 114.816 1.413 . . . . 0.0 114.816 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 96.7 m95 -118.49 -33.2 4.39 Favored 'General case' 0 N--CA 1.466 0.372 0 O-C-N 123.449 0.468 . . . . 0.0 111.44 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.1 p -81.88 156.28 24.9 Favored 'General case' 0 N--CA 1.467 0.38 0 O-C-N 123.413 0.446 . . . . 0.0 111.46 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.588 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -83.98 119.79 25.34 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.81 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.77 -156.28 0.38 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.456 -178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.34 112.77 18.94 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 122.597 0.359 . . . . 0.0 111.375 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.98 8.15 39.82 Favored Glycine 0 CA--C 1.522 0.488 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.637 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.75 159.58 21.24 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 122.604 0.362 . . . . 0.0 110.562 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 55.0 p -80.02 131.21 35.74 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.787 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.551 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -100.6 29.83 4.26 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.911 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.405 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -85.39 -10.48 56.2 Favored 'General case' 0 CA--C 1.539 0.531 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.741 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.405 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.96 -37.68 1.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.006 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -137.05 152.87 74.65 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.19 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.39 -172.72 0.56 Allowed 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 123.313 2.676 . . . . 0.0 112.757 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.588 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 48.4 m -80.9 175.41 10.71 Favored 'General case' 0 CA--C 1.539 0.526 0 O-C-N 123.026 0.204 . . . . 0.0 110.472 179.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 34.8 m -117.2 -56.01 2.28 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.91 13.07 6.35 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -178.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.18 36.7 7.47 Favored Glycine 0 C--N 1.34 0.769 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.418 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.52 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.6 mt -82.24 170.41 15.45 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.157 0.583 . . . . 0.0 111.222 -179.629 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -115.48 144.44 23.06 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.588 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 39.8 m -80.87 102.74 10.25 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.276 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -80.78 140.61 50.87 Favored Pre-proline 0 CA--C 1.53 0.184 0 CA-C-N 115.296 -0.866 . . . . 0.0 111.439 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -69.73 64.61 1.78 Allowed 'Trans proline' 0 C--N 1.364 1.368 0 C-N-CA 122.885 2.39 . . . . 0.0 112.175 179.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.526 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.8 p -95.31 152.33 18.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.983 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.29 144.26 28.83 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.64 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.543 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.6 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.476 0 C-N-CA 124.152 -1.187 . . . . 0.0 113.273 -0.078 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.543 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -110.93 145.38 32.29 Favored Pre-proline 0 CA--C 1.541 0.599 0 O-C-N 123.365 0.416 . . . . 0.0 111.203 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.422 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.67 156.96 54.26 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 122.884 2.389 . . . . 0.0 113.428 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.526 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.2 mm -123.12 153.46 28.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.979 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.37 119.16 29.59 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.792 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.52 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.44 145.78 13.52 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.261 -0.495 . . . . 0.0 113.256 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 1.2 m . . . . . 0 C--O 1.25 1.127 0 CA-C-O 118.125 -0.94 . . . . 0.0 111.134 179.386 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.782 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -99.91 -16.42 18.0 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.73 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.4 p -81.39 157.25 25.05 Favored 'General case' 0 C--N 1.343 0.321 0 C-N-CA 122.747 0.419 . . . . 0.0 111.506 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.6 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.86 119.94 25.91 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.844 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -89.46 -156.43 0.4 Allowed 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.418 -178.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.2 112.42 18.51 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.687 0.395 . . . . 0.0 111.233 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.88 36.8 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -116.94 158.95 23.2 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.646 0.379 . . . . 0.0 110.582 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.4 p -80.13 131.75 35.8 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.855 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.5 p -100.76 31.11 3.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.89 179.758 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.43 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.26 -11.54 52.03 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.781 -179.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.43 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.4 -37.77 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.134 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -136.6 152.97 75.59 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.13 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -69.35 -172.31 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.561 0 C-N-CA 123.345 2.696 . . . . 0.0 112.646 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.6 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 54.6 m -81.46 174.93 10.98 Favored 'General case' 0 CA--C 1.537 0.447 0 O-C-N 123.017 0.198 . . . . 0.0 110.487 179.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.5 m -115.87 -55.59 2.4 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.794 0.665 . . . . 0.0 112.794 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -84.64 11.81 8.26 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.67 35.29 7.91 Favored Glycine 0 C--N 1.339 0.732 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.348 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.545 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -80.01 166.95 21.06 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.164 0.586 . . . . 0.0 111.488 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.34 144.41 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.188 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.7 m -82.27 104.03 12.29 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.241 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -80.85 140.27 50.47 Favored Pre-proline 0 CA--C 1.53 0.19 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.444 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.13 65.16 2.02 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 122.904 2.402 . . . . 0.0 112.103 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.49 151.62 19.14 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.798 -178.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.22 144.31 28.71 Favored Pre-proline 0 CA--C 1.532 0.282 0 O-C-N 123.511 0.507 . . . . 0.0 111.626 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -32.01 4.77 Favored 'Cis proline' 0 C--N 1.367 1.53 0 C-N-CA 124.13 -1.196 . . . . 0.0 113.179 0.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -113.98 144.33 31.34 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.025 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.9 Cg_endo -63.45 157.41 50.85 Favored 'Trans proline' 0 C--N 1.375 1.97 0 C-N-CA 123.0 2.467 . . . . 0.0 113.803 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.73 154.4 27.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.92 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.54 119.26 30.66 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.851 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.545 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.68 144.28 10.95 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.112 -0.495 . . . . 0.0 113.003 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.41 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.251 1.145 0 CA-C-O 118.474 -0.774 . . . . 0.0 111.244 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.799 0 N-CA-C 114.944 1.461 . . . . 0.0 114.944 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 m95 -122.7 -35.54 3.05 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.433 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.7 p -81.6 157.61 24.65 Favored 'General case' 0 N--CA 1.466 0.328 0 O-C-N 123.535 0.522 . . . . 0.0 111.524 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.621 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.36 116.84 24.78 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.826 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . 0.553 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.67 -154.46 0.29 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.155 -179.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -79.83 106.44 11.86 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.973 0.416 . . . . 0.0 111.053 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.55 9.98 24.19 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.326 -0.852 . . . . 0.0 112.407 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.553 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.9 mt-10 -112.34 156.48 22.38 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.608 0.363 . . . . 0.0 110.525 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -82.64 128.5 34.39 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.889 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 28.6 p -96.77 33.33 1.88 Allowed 'General case' 0 C--O 1.238 0.486 0 CA-C-O 121.295 0.569 . . . . 0.0 110.9 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -89.85 -10.83 43.88 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.407 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.8 p -123.9 -39.12 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.031 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 25.6 m-85 -134.86 152.63 77.76 Favored Pre-proline 0 CA--C 1.538 0.494 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.177 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.55 -171.76 0.49 Allowed 'Trans proline' 0 C--N 1.367 1.544 0 C-N-CA 123.308 2.672 . . . . 0.0 112.689 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.621 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.4 m -81.87 174.84 10.92 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 110.324 -0.25 . . . . 0.0 110.324 178.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 40.9 m -114.29 -55.28 2.51 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 -178.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.45 12.2 10.79 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.82 36.86 7.59 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.514 -0.374 . . . . 0.0 112.263 -179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.609 HD22 ' HA2' ' A' ' 31' ' ' GLY . 3.1 mt -79.96 166.85 21.2 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 123.254 0.622 . . . . 0.0 111.597 -179.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.8 mt -107.7 144.85 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.195 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.9 m -82.52 104.65 12.96 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.162 178.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -81.25 139.93 48.87 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.554 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.1 65.24 2.0 Allowed 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.929 2.42 . . . . 0.0 112.079 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.511 ' OG1' HG12 ' A' ' 29' ' ' ILE . 43.8 p -95.53 151.73 19.05 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.875 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.39 144.3 28.72 Favored Pre-proline 0 CA--C 1.532 0.269 0 O-C-N 123.57 0.544 . . . . 0.0 111.563 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.58 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.367 1.519 0 C-N-CA 124.145 -1.189 . . . . 0.0 113.166 0.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -113.73 144.07 30.73 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.145 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.46 157.23 51.88 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.048 2.499 . . . . 0.0 113.717 -179.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.511 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.9 mm -122.38 154.39 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.904 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -90.67 119.39 30.87 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.791 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.609 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.77 144.65 11.17 Favored Glycine 0 C--N 1.338 0.675 0 CA-C-N 116.101 -0.5 . . . . 0.0 113.044 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.484 HG13 HD23 ' A' ' 19' ' ' LEU . 1.1 m . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.079 -0.962 . . . . 0.0 111.199 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 114.417 1.266 . . . . 0.0 114.417 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 8.0 m-90 -89.32 -35.63 16.0 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.344 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.0 p -82.57 157.24 23.57 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.476 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.61 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.79 119.03 24.84 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.8 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -88.24 -155.96 0.34 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.466 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.55 112.99 19.28 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 122.708 0.403 . . . . 0.0 111.256 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.26 7.1 41.08 Favored Glycine 0 CA--C 1.521 0.444 0 CA-C-N 115.528 -0.76 . . . . 0.0 112.733 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -115.12 159.25 21.1 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.561 0.345 . . . . 0.0 110.504 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 54.7 p -79.94 131.63 35.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.843 -179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.566 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -100.73 31.23 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.865 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.428 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.58 -11.46 51.44 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.759 179.982 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.428 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.24 -37.68 1.48 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.051 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -136.76 153.1 75.46 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.123 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.53 -172.1 0.52 Allowed 'Trans proline' 0 C--N 1.368 1.572 0 C-N-CA 123.295 2.663 . . . . 0.0 112.539 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.61 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.6 m -81.52 175.14 10.78 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 110.49 -0.189 . . . . 0.0 110.49 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.4 m -115.85 -55.3 2.43 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.21 12.36 8.14 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.15 35.36 8.16 Favored Glycine 0 C--N 1.339 0.748 0 C-N-CA 121.516 -0.374 . . . . 0.0 112.383 -179.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.552 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -79.91 167.0 21.07 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.231 0.612 . . . . 0.0 111.576 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.46 144.33 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.268 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.8 m -82.09 104.03 12.14 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.253 178.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -81.3 140.43 48.9 Favored Pre-proline 0 CA--C 1.53 0.192 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.501 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -70.26 64.83 2.1 Favored 'Trans proline' 0 C--N 1.364 1.393 0 C-N-CA 122.999 2.466 . . . . 0.0 112.054 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.526 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.4 p -95.31 152.52 18.31 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.897 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.52 144.18 28.72 Favored Pre-proline 0 C--O 1.236 0.374 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.565 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.54 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.3 Cg_exo -76.28 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.366 1.485 0 C-N-CA 124.064 -1.223 . . . . 0.0 113.238 -0.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.54 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.02 145.37 32.3 Favored Pre-proline 0 CA--C 1.542 0.661 0 O-C-N 123.29 0.369 . . . . 0.0 111.197 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.422 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.1 Cg_endo -63.67 156.79 55.24 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.943 2.429 . . . . 0.0 113.419 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.526 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.8 mm -122.52 153.79 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.96 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -89.92 119.16 30.05 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.939 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.552 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.35 144.04 10.73 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.985 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.41 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.073 -0.965 . . . . 0.0 111.127 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.778 0 N-CA-C 114.427 1.269 . . . . 0.0 114.427 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -103.21 -18.95 14.68 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.609 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p -81.73 157.2 24.64 Favored 'General case' 0 C--N 1.344 0.354 0 O-C-N 123.344 0.402 . . . . 0.0 111.385 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.635 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.89 116.48 24.16 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.878 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . 0.553 ' HG2' ' OE1' ' A' ' 8' ' ' GLU . 12.8 pt-20 -88.14 -154.32 0.27 Allowed 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.181 -179.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -79.82 106.86 12.15 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.082 0.468 . . . . 0.0 111.187 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.74 9.9 25.82 Favored Glycine 0 C--N 1.336 0.541 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.55 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.553 ' OE1' ' HG2' ' A' ' 5' ' ' GLU . 31.0 mt-10 -111.72 156.8 21.32 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 122.649 0.379 . . . . 0.0 110.499 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 68.4 p -82.88 132.05 35.17 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.752 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.427 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 29.2 p -102.05 38.1 1.72 Allowed 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.58 0.55 . . . . 0.0 111.18 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -91.46 -11.0 38.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.38 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.9 p -124.72 -39.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.934 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' HA ' ' A' ' 10' ' ' CYS . 27.2 m-85 -132.16 152.01 79.39 Favored Pre-proline 0 CA--C 1.537 0.454 0 O-C-N 123.538 0.524 . . . . 0.0 111.51 179.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.5 -169.07 0.34 Allowed 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.577 2.851 . . . . 0.0 112.75 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 49.4 m -83.53 175.13 10.01 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 123.119 0.262 . . . . 0.0 110.376 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.9 m -114.84 -55.26 2.5 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.102 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 12.36 9.9 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.96 36.14 7.87 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 121.422 -0.418 . . . . 0.0 112.39 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.608 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.9 mt -79.93 168.13 19.62 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.331 0.653 . . . . 0.0 111.541 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -109.85 144.66 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.224 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.1 m -82.37 103.86 12.24 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.173 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -80.69 140.46 51.18 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.492 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -70.37 64.84 2.16 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.924 2.416 . . . . 0.0 111.978 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.512 ' OG1' HG12 ' A' ' 29' ' ' ILE . 45.5 p -95.0 150.43 20.17 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.963 -178.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -105.46 144.19 28.32 Favored Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.589 0.555 . . . . 0.0 111.724 -179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.87 -31.4 5.16 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.219 0.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -113.7 143.9 30.39 Favored Pre-proline 0 CA--C 1.541 0.621 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.199 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.6 Cg_endo -64.09 157.59 52.53 Favored 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 123.016 2.477 . . . . 0.0 113.514 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.512 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.97 154.09 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.973 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.427 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.0 m -90.08 119.02 30.06 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.608 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.91 144.68 11.37 Favored Glycine 0 C--N 1.337 0.599 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.013 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.474 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.452 -0.785 . . . . 0.0 111.122 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.793 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 93.0 m95 -100.14 -34.34 10.09 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.363 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.3 p -80.95 156.34 26.02 Favored 'General case' 0 N--CA 1.467 0.389 0 O-C-N 123.435 0.46 . . . . 0.0 111.621 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.612 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.69 118.52 24.46 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.789 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.23 -156.78 0.38 Allowed 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.406 -178.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -80.74 112.03 17.74 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.641 0.376 . . . . 0.0 111.387 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.94 8.14 37.15 Favored Glycine 0 C--N 1.334 0.471 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.62 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -115.98 158.69 22.69 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 122.623 0.369 . . . . 0.0 110.535 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.0 p -80.11 131.67 35.79 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.808 -179.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.6 p -100.6 31.13 3.61 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.893 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.3 -11.38 52.37 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.749 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.6 -38.08 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.137 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -136.2 152.86 76.04 Favored Pre-proline 0 CA--C 1.538 0.481 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.145 179.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.07 -172.04 0.47 Allowed 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 123.349 2.699 . . . . 0.0 112.605 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.612 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -81.64 175.78 10.2 Favored 'General case' 0 CA--C 1.539 0.524 0 O-C-N 123.123 0.264 . . . . 0.0 110.406 178.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 42.3 m -114.9 -55.99 2.42 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -87.47 13.18 10.55 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 112.631 0.604 . . . . 0.0 112.631 -178.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.87 35.98 6.97 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.395 -0.431 . . . . 0.0 112.625 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.552 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -80.19 166.36 21.51 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.018 0.527 . . . . 0.0 111.447 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.86 143.96 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.223 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 31.5 m -82.13 103.55 11.82 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.238 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.8 m-85 -80.19 140.33 53.06 Favored Pre-proline 0 CA--C 1.53 0.181 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.509 -179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.2 65.01 2.07 Favored 'Trans proline' 0 C--N 1.365 1.424 0 C-N-CA 123.055 2.503 . . . . 0.0 112.142 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.33 151.55 19.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.894 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.65 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.56 -32.17 4.67 Favored 'Cis proline' 0 C--N 1.366 1.477 0 C-N-CA 124.055 -1.227 . . . . 0.0 113.088 0.081 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -113.87 144.24 31.12 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.09 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.0 Cg_endo -63.34 157.62 49.28 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.023 2.482 . . . . 0.0 113.751 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.96 153.93 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.902 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.8 m -90.15 119.25 30.32 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.883 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.552 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.9 143.93 10.51 Favored Glycine 0 C--N 1.339 0.695 0 CA-C-N 116.071 -0.513 . . . . 0.0 113.088 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.415 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.135 -0.936 . . . . 0.0 111.142 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -98.11 -20.29 17.42 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.597 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p -81.39 157.33 25.03 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 122.709 0.404 . . . . 0.0 111.468 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.599 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.67 120.25 26.17 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.742 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.68 -156.34 0.4 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.389 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -81.23 112.6 18.71 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.897 0.379 . . . . 0.0 111.373 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.31 8.8 37.63 Favored Glycine 0 C--N 1.336 0.53 0 CA-C-N 115.408 -0.815 . . . . 0.0 112.566 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -116.97 158.97 23.21 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 122.622 0.369 . . . . 0.0 110.524 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.4 p -80.03 131.94 35.89 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.819 -179.398 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.4 p -100.96 31.16 3.71 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.854 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.417 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -86.41 -11.21 52.57 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.721 179.985 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.417 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.6 p -121.52 -37.89 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.07 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -136.72 152.95 75.36 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.179 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.23 -172.17 0.5 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 123.342 2.695 . . . . 0.0 112.574 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.599 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -81.61 175.15 10.73 Favored 'General case' 0 CA--C 1.539 0.535 0 O-C-N 123.044 0.215 . . . . 0.0 110.449 179.075 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.8 m -116.02 -55.43 2.41 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -177.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -85.11 12.87 6.96 Favored 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -178.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.33 8.73 Favored Glycine 0 C--N 1.341 0.851 0 C-N-CA 121.478 -0.392 . . . . 0.0 112.413 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.55 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.5 mt -79.98 166.77 21.26 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.22 0.608 . . . . 0.0 111.484 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -109.09 144.36 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.239 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.5 m -82.3 103.93 12.24 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.5 m-85 -80.76 140.28 50.8 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.46 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.17 65.07 2.05 Favored 'Trans proline' 0 C--N 1.365 1.411 0 C-N-CA 122.94 2.427 . . . . 0.0 112.056 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.41 151.49 19.23 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.878 -178.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.1 144.26 28.58 Favored Pre-proline 0 C--O 1.235 0.339 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.746 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.52 -32.28 4.6 Favored 'Cis proline' 0 C--N 1.366 1.475 0 C-N-CA 124.046 -1.231 . . . . 0.0 113.142 0.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.76 144.23 31.05 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.09 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.43 157.42 50.73 Favored 'Trans proline' 0 C--N 1.375 1.931 0 C-N-CA 123.004 2.47 . . . . 0.0 113.809 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.7 mm -122.81 154.33 28.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.857 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -90.59 119.36 30.78 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.877 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.55 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.76 144.01 10.63 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 116.041 -0.527 . . . . 0.0 113.014 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.411 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.424 -0.798 . . . . 0.0 111.23 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -98.14 -18.7 18.34 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.697 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.8 p -82.65 156.14 24.02 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 122.754 0.422 . . . . 0.0 111.46 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -84.19 119.95 25.63 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.71 179.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -89.14 -156.3 0.39 Allowed 'General case' 0 CA--C 1.544 0.713 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.665 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -81.21 113.04 19.08 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 122.651 0.38 . . . . 0.0 111.384 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.76 8.36 40.01 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.334 -0.848 . . . . 0.0 112.604 -179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -116.16 159.67 21.45 Favored 'General case' 0 C--O 1.236 0.395 0 C-N-CA 122.493 0.317 . . . . 0.0 110.555 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.8 p -81.02 134.74 35.73 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.702 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.457 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -105.41 37.41 2.21 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.758 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -87.31 -13.36 43.83 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.885 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.1 p -122.43 -38.43 1.37 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 O-C-N 123.506 0.504 . . . . 0.0 110.111 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -132.26 152.42 80.08 Favored Pre-proline 0 CA--C 1.538 0.511 0 O-C-N 123.609 0.568 . . . . 0.0 111.462 179.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.21 -168.35 0.29 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 123.426 2.751 . . . . 0.0 112.777 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.626 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.8 m -84.09 175.6 9.39 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 123.048 0.218 . . . . 0.0 110.502 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.9 m -116.53 -55.34 2.38 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -178.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -84.77 12.26 7.62 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -178.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.5 34.74 8.34 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.461 -0.399 . . . . 0.0 112.359 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.539 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.4 mt -80.04 167.79 19.98 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 123.223 0.609 . . . . 0.0 111.426 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.91 144.21 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.252 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 32.9 m -82.22 103.26 11.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.166 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.9 m-85 -80.34 140.83 52.69 Favored Pre-proline 0 CA--C 1.53 0.195 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.511 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.33 64.58 2.14 Favored 'Trans proline' 0 C--N 1.364 1.389 0 C-N-CA 122.955 2.437 . . . . 0.0 111.997 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.522 ' OG1' HG12 ' A' ' 29' ' ' ILE . 47.7 p -95.02 151.65 18.99 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.964 -178.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.76 143.95 28.09 Favored Pre-proline 0 C--O 1.234 0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.674 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -76.36 -36.61 2.44 Favored 'Cis proline' 0 C--N 1.365 1.435 0 C-N-CA 124.079 -1.217 . . . . 0.0 113.162 0.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -109.67 145.91 32.94 Favored Pre-proline 0 CA--C 1.54 0.559 0 O-C-N 123.342 0.401 . . . . 0.0 111.131 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 29.4 Cg_endo -64.47 157.64 53.84 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.842 2.362 . . . . 0.0 113.351 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.522 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.1 mm -123.71 153.55 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.969 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.457 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.54 118.95 29.55 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.929 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.539 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.8 144.1 10.89 Favored Glycine 0 C--N 1.338 0.692 0 CA-C-N 116.042 -0.526 . . . . 0.0 113.092 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.407 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.19 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.795 0 N-CA-C 114.319 1.229 . . . . 0.0 114.319 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.8 m95 -139.57 96.33 3.07 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.848 179.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p -156.08 160.68 40.18 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.963 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.573 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.78 120.16 27.78 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.524 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.08 -156.12 0.38 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.526 -178.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.12 113.49 19.32 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.78 0.432 . . . . 0.0 111.242 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.82 7.23 42.1 Favored Glycine 0 C--N 1.334 0.419 0 CA-C-N 115.412 -0.813 . . . . 0.0 112.588 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.72 159.31 20.69 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.741 0.416 . . . . 0.0 110.579 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 65.1 p -79.98 131.44 35.81 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.781 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.576 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.47 28.7 5.3 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.971 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.4 -12.18 56.75 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.705 179.884 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.445 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.5 p -121.35 -41.06 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.348 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -130.26 153.53 81.24 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.306 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.7 -174.71 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.202 2.601 . . . . 0.0 112.42 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.07 175.22 10.83 Favored 'General case' 0 CA--C 1.538 0.516 0 N-CA-C 110.53 -0.174 . . . . 0.0 110.53 179.114 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.5 m -115.15 -54.88 2.52 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.31 12.95 8.9 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.68 8.65 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.415 -0.421 . . . . 0.0 112.366 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.571 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -79.93 166.56 21.51 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.265 0.626 . . . . 0.0 111.565 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.6 144.29 17.37 Favored 'Isoleucine or valine' 0 C--O 1.233 0.214 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.155 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.8 m -82.21 103.98 12.2 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.214 178.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.64 140.18 51.23 Favored Pre-proline 0 CA--C 1.531 0.22 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.535 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.33 65.23 2.14 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.965 2.443 . . . . 0.0 112.093 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.519 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.29 152.9 17.97 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.963 -178.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -107.05 144.23 28.7 Favored Pre-proline 0 C--O 1.236 0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.73 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.42 -32.05 4.77 Favored 'Cis proline' 0 C--N 1.365 1.419 0 C-N-CA 124.084 -1.215 . . . . 0.0 113.196 0.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.27 144.49 31.8 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.089 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.2 Cg_endo -63.21 157.52 49.27 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 123.02 2.48 . . . . 0.0 113.75 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.519 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.89 154.38 28.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.864 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.42 119.5 30.76 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.948 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.571 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.44 144.32 10.86 Favored Glycine 0 C--N 1.337 0.621 0 CA-C-N 116.083 -0.508 . . . . 0.0 113.117 -179.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.434 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.065 -0.969 . . . . 0.0 111.108 179.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.828 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 82.3 m95 -139.42 96.47 3.1 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.348 0.594 . . . . 0.0 109.934 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.7 p -155.95 161.07 40.57 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.906 179.706 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.9 120.03 27.74 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.479 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.0 -156.11 0.37 Allowed 'General case' 0 CA--C 1.543 0.696 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.533 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.09 113.47 19.29 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.986 0.422 . . . . 0.0 111.238 -179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.04 6.94 41.99 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.546 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.56 159.39 20.47 Favored 'General case' 0 C--O 1.234 0.275 0 C-N-CA 122.547 0.339 . . . . 0.0 110.481 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.2 p -79.94 131.27 35.79 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.811 -179.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.578 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.11 28.62 5.2 Favored 'General case' 0 CA--C 1.538 0.508 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.969 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.446 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.59 -12.1 56.5 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.661 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.446 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.38 -41.31 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.217 -179.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -130.26 153.44 81.23 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.326 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.62 -174.82 1.16 Allowed 'Trans proline' 0 C--N 1.366 1.472 0 C-N-CA 123.202 2.601 . . . . 0.0 112.348 179.14 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -79.87 175.28 10.77 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 110.541 -0.17 . . . . 0.0 110.541 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -115.16 -54.86 2.52 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -178.019 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.55 13.08 9.05 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -178.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.26 35.88 8.53 Favored Glycine 0 C--N 1.34 0.764 0 C-N-CA 121.495 -0.384 . . . . 0.0 112.293 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.576 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.97 166.58 21.45 Favored 'General case' 0 N--CA 1.465 0.283 0 C-N-CA 123.159 0.584 . . . . 0.0 111.649 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.7 mt -108.4 144.36 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.141 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.2 m -82.24 103.89 12.16 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.255 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -80.38 140.13 52.22 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.538 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.24 65.22 2.09 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.05 2.5 . . . . 0.0 112.079 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.4 p -95.36 152.74 18.13 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.889 -178.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -107.0 144.23 28.68 Favored Pre-proline 0 C--O 1.234 0.268 0 O-C-N 123.541 0.526 . . . . 0.0 111.683 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.55 -31.93 4.84 Favored 'Cis proline' 0 C--N 1.367 1.505 0 C-N-CA 124.015 -1.244 . . . . 0.0 113.22 0.06 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -114.15 144.6 31.95 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.525 0.516 . . . . 0.0 111.127 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.2 Cg_endo -63.28 157.53 49.53 Favored 'Trans proline' 0 C--N 1.374 1.904 0 C-N-CA 122.962 2.441 . . . . 0.0 113.793 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.83 154.31 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.871 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.5 m -90.31 119.44 30.61 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.91 179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.576 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.56 144.36 10.88 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 116.114 -0.494 . . . . 0.0 113.016 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.433 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.126 -0.94 . . . . 0.0 111.257 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.875 0 N-CA-C 114.357 1.243 . . . . 0.0 114.357 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.5 m95 -139.39 96.51 3.11 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.928 179.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p -156.13 160.89 40.31 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.88 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.57 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.92 120.37 28.12 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.465 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.26 -155.96 0.37 Allowed 'General case' 0 CA--C 1.545 0.768 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.622 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.37 113.65 19.6 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.312 0.382 . . . . 0.0 111.225 -179.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.78 7.31 42.06 Favored Glycine 0 CA--C 1.521 0.453 0 CA-C-N 115.378 -0.828 . . . . 0.0 112.511 -179.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -114.95 159.51 20.65 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 122.62 0.368 . . . . 0.0 110.526 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.4 p -80.1 131.44 35.75 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.804 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.575 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.1 p -101.41 28.66 5.31 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.033 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.446 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.43 -12.05 56.84 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.712 179.971 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.446 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.46 -41.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 O-C-N 123.583 0.552 . . . . 0.0 110.298 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -130.41 153.45 81.34 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -70.69 -174.65 1.14 Allowed 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 123.188 2.592 . . . . 0.0 112.357 179.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.9 m -80.06 175.21 10.84 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 54.6 m -115.29 -54.84 2.51 Favored 'General case' 0 CA--C 1.533 0.309 0 N-CA-C 112.906 0.706 . . . . 0.0 112.906 -178.006 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -86.11 12.73 9.01 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -178.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.43 35.62 8.56 Favored Glycine 0 C--N 1.34 0.792 0 C-N-CA 121.517 -0.373 . . . . 0.0 112.291 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.569 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -79.9 166.61 21.48 Favored 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 123.254 0.621 . . . . 0.0 111.51 -179.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.57 144.42 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.175 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.6 m -82.38 103.97 12.34 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.155 178.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -80.68 140.17 51.08 Favored Pre-proline 0 CA--C 1.53 0.199 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.32 65.25 2.13 Favored 'Trans proline' 0 C--N 1.366 1.455 0 C-N-CA 122.975 2.45 . . . . 0.0 111.993 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.3 152.49 18.33 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.9 -178.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.84 144.29 28.77 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.688 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.61 -31.85 4.88 Favored 'Cis proline' 0 C--N 1.367 1.521 0 C-N-CA 124.024 -1.24 . . . . 0.0 113.116 0.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.31 144.6 32.03 Favored Pre-proline 0 CA--C 1.542 0.665 0 O-C-N 123.481 0.488 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.4 Cg_endo -63.25 157.51 49.52 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 122.894 2.396 . . . . 0.0 113.845 -179.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.6 mm -122.93 154.37 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.819 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.575 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.42 30.62 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.901 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.569 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.35 144.24 10.78 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 116.048 -0.524 . . . . 0.0 113.001 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.429 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.252 1.236 0 CA-C-O 118.375 -0.822 . . . . 0.0 111.189 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 114.431 1.271 . . . . 0.0 114.431 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -139.49 96.42 3.09 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.931 179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p -155.96 160.59 40.21 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.943 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.571 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.59 119.49 26.9 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.539 179.304 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -88.06 -156.2 0.35 Allowed 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.634 -178.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.27 113.63 19.53 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 122.765 0.426 . . . . 0.0 111.315 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.4 5.43 42.86 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.624 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.37 159.5 19.37 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.526 0.331 . . . . 0.0 110.52 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.9 131.67 35.9 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.805 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.19 4.84 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.002 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.447 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -84.02 -12.36 55.33 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.584 -0.734 . . . . 0.0 111.704 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.447 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.7 p -120.96 -41.01 1.79 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.268 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -130.59 153.5 81.49 Favored Pre-proline 0 CA--C 1.536 0.44 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.305 179.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.8 -174.48 1.12 Allowed 'Trans proline' 0 C--N 1.365 1.436 0 C-N-CA 123.167 2.578 . . . . 0.0 112.35 179.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.571 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.0 175.38 10.69 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 110.5 -0.185 . . . . 0.0 110.5 179.135 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -115.06 -54.69 2.54 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.69 13.07 9.3 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.27 35.71 8.62 Favored Glycine 0 C--N 1.341 0.831 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.34 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.579 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.83 166.81 21.32 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.187 0.595 . . . . 0.0 111.577 -179.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.54 144.4 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.195 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.8 m -82.43 104.11 12.47 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.162 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.06 140.33 49.71 Favored Pre-proline 0 CA--C 1.53 0.188 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.514 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.32 64.87 2.14 Favored 'Trans proline' 0 C--N 1.366 1.464 0 C-N-CA 122.995 2.463 . . . . 0.0 112.063 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.527 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.8 p -95.17 152.74 18.09 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.982 -178.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.68 144.16 28.73 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.57 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.539 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.31 -35.66 2.8 Favored 'Cis proline' 0 C--N 1.367 1.525 0 C-N-CA 124.025 -1.239 . . . . 0.0 113.22 0.003 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.539 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.07 145.54 32.67 Favored Pre-proline 0 CA--C 1.542 0.644 0 O-C-N 123.34 0.4 . . . . 0.0 111.197 179.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.418 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 27.9 Cg_endo -63.58 156.8 54.77 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 122.988 2.459 . . . . 0.0 113.465 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.527 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -122.67 153.9 27.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.868 -179.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.46 30.22 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.579 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.26 144.35 10.93 Favored Glycine 0 C--N 1.341 0.81 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.979 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.445 HG13 HD23 ' A' ' 19' ' ' LEU . 1.1 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.049 -0.977 . . . . 0.0 111.192 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.811 0 N-CA-C 114.333 1.234 . . . . 0.0 114.333 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -139.68 96.56 3.1 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.895 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.8 p -156.79 161.71 39.75 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.879 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.38 121.32 28.78 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.417 179.265 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -89.59 -156.58 0.41 Allowed 'General case' 0 CA--C 1.544 0.731 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.636 -178.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.59 113.59 19.71 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 122.742 0.417 . . . . 0.0 111.295 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.73 7.4 42.01 Favored Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.565 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -115.05 160.34 19.75 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 122.548 0.339 . . . . 0.0 110.444 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.4 p -79.86 135.36 36.43 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.525 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.519 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.9 p -107.59 34.86 3.31 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.148 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -86.59 -14.89 41.49 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.761 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 p -118.76 -41.53 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 O-C-N 123.399 0.437 . . . . 0.0 110.2 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -127.68 153.6 77.76 Favored Pre-proline 0 CA--C 1.537 0.474 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.34 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.69 -170.25 0.51 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 123.298 2.665 . . . . 0.0 112.384 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.567 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -83.25 175.78 9.66 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 178.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.81 -54.57 2.49 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 112.875 0.695 . . . . 0.0 112.875 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.16 13.14 8.3 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -178.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.23 35.17 8.99 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.486 -0.388 . . . . 0.0 112.382 -179.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.573 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.6 mt -80.05 167.47 20.38 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 123.169 0.587 . . . . 0.0 111.489 -179.378 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.5 mt -110.07 144.14 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.277 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.8 m -82.06 103.58 11.79 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.236 178.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -80.82 140.62 50.72 Favored Pre-proline 0 CA--C 1.531 0.243 0 CA-C-N 115.285 -0.87 . . . . 0.0 111.49 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.45 64.86 2.21 Favored 'Trans proline' 0 C--N 1.365 1.428 0 C-N-CA 122.92 2.413 . . . . 0.0 112.045 179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.524 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.0 p -95.02 151.01 19.54 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.948 -178.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.74 144.4 28.79 Favored Pre-proline 0 C--O 1.234 0.279 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.692 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.67 -30.99 5.47 Favored 'Cis proline' 0 C--N 1.366 1.499 0 C-N-CA 124.053 -1.228 . . . . 0.0 113.161 0.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -114.64 144.4 31.8 Favored Pre-proline 0 CA--C 1.542 0.659 0 O-C-N 123.509 0.506 . . . . 0.0 111.118 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.76 157.61 51.04 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.865 2.377 . . . . 0.0 113.572 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.524 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.0 mm -124.39 153.66 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.943 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.519 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.1 m -89.41 119.13 29.6 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.804 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.573 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.61 144.45 11.16 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.078 -0.51 . . . . 0.0 113.016 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.424 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.083 -0.96 . . . . 0.0 111.265 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.822 0 N-CA-C 114.408 1.262 . . . . 0.0 114.408 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 82.3 m95 -139.56 96.54 3.1 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.928 179.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.6 p -155.79 160.31 40.15 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.949 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.549 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.6 120.76 27.4 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.511 179.146 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . 0.508 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 12.0 pt-20 -89.11 -155.87 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.609 -178.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.508 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.65 113.74 19.86 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.961 0.41 . . . . 0.0 111.316 -179.548 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.48 7.19 43.14 Favored Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.635 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.78 159.97 19.97 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 122.538 0.335 . . . . 0.0 110.395 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 59.1 p -79.97 131.31 35.79 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.798 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.559 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 32.0 p -101.33 27.49 6.18 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.042 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.425 ' OE1' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -82.46 -11.36 58.56 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.685 179.95 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.425 ' HB ' ' OE1' ' A' ' 11' ' ' GLU . 14.8 p -121.8 -40.75 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.268 -179.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -130.8 153.47 81.64 Favored Pre-proline 0 CA--C 1.536 0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.377 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.92 -174.74 1.21 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.245 2.63 . . . . 0.0 112.297 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 55.5 m -80.01 175.53 10.55 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 110.508 -0.182 . . . . 0.0 110.508 179.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.4 m -116.71 -55.51 2.36 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -177.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -86.23 13.78 7.46 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.51 37.04 7.69 Favored Glycine 0 C--N 1.339 0.716 0 C-N-CA 121.43 -0.414 . . . . 0.0 112.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.533 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -82.28 169.65 16.28 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.239 0.616 . . . . 0.0 111.131 -179.531 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 4.7 mp -114.81 144.22 22.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.54 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 36.4 m -80.61 102.88 10.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.379 178.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -80.74 140.49 50.98 Favored Pre-proline 0 N--CA 1.457 -0.111 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.415 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.7 64.64 1.77 Allowed 'Trans proline' 0 C--N 1.364 1.376 0 C-N-CA 123.009 2.473 . . . . 0.0 112.22 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.527 ' OG1' HG12 ' A' ' 29' ' ' ILE . 46.7 p -95.47 152.46 18.39 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.971 -178.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.42 144.13 28.59 Favored Pre-proline 0 C--O 1.235 0.341 0 O-C-N 123.506 0.504 . . . . 0.0 111.632 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.543 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.47 -35.52 2.85 Favored 'Cis proline' 0 C--N 1.368 1.557 0 C-N-CA 124.092 -1.212 . . . . 0.0 113.266 0.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.543 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.2 pm0 -111.05 145.39 32.34 Favored Pre-proline 0 CA--C 1.542 0.649 0 O-C-N 123.299 0.374 . . . . 0.0 111.166 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.419 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.1 Cg_endo -63.71 156.91 54.64 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 122.9 2.4 . . . . 0.0 113.365 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.527 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.7 mm -123.12 153.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.977 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -88.85 119.21 29.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.72 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.533 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -154.01 146.08 13.96 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.342 -0.456 . . . . 0.0 113.323 -179.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.4 HG13 ' HA ' ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.414 -0.803 . . . . 0.0 111.08 179.437 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 114.461 1.282 . . . . 0.0 114.461 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -139.54 96.48 3.09 Favored 'General case' 0 C--O 1.237 0.401 0 O-C-N 123.619 0.574 . . . . 0.0 109.903 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.9 p -156.05 161.55 40.41 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.146 -0.933 . . . . 0.0 110.917 179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.503 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.57 121.89 28.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.691 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.34 -155.7 0.33 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.484 -178.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.554 ' HG2' HD21 ' A' ' 19' ' ' LEU . 2.3 mt-10 -83.03 115.82 22.02 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 122.605 0.362 . . . . 0.0 110.509 -179.252 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.65 6.63 49.7 Favored Glycine 0 CA--C 1.523 0.539 0 CA-C-N 115.468 -0.787 . . . . 0.0 112.69 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -113.35 160.05 18.78 Favored 'General case' 0 C--O 1.234 0.266 0 C-N-CA 122.494 0.318 . . . . 0.0 110.54 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 67.3 p -79.81 132.03 36.03 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.992 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.581 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.3 p -101.99 29.15 5.2 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.033 179.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.471 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.8 -13.58 53.46 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.713 179.97 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.471 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.3 p -119.99 -41.18 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.165 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -130.47 153.38 81.36 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.291 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.12 -174.52 1.2 Allowed 'Trans proline' 0 C--N 1.365 1.442 0 C-N-CA 123.307 2.671 . . . . 0.0 112.31 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 58.7 m -79.91 176.22 9.93 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 110.455 -0.202 . . . . 0.0 110.455 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.1 m -117.72 -55.68 2.26 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -178.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.8 12.85 8.21 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.24 36.1 7.74 Favored Glycine 0 C--N 1.341 0.817 0 C-N-CA 121.439 -0.41 . . . . 0.0 112.356 -179.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.554 HD21 ' HG2' ' A' ' 6' ' ' GLU . 2.5 mt -80.12 166.25 21.67 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.13 0.572 . . . . 0.0 111.464 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -109.4 143.53 19.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.097 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.9 m -81.67 103.65 11.52 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 178.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.4 m-85 -80.52 140.18 51.71 Favored Pre-proline 0 CA--C 1.529 0.167 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.542 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.3 65.31 2.12 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.998 2.466 . . . . 0.0 112.007 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.517 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.5 p -95.64 152.04 18.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.927 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.49 144.22 28.57 Favored Pre-proline 0 C--O 1.234 0.249 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.673 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -32.06 4.73 Favored 'Cis proline' 0 C--N 1.366 1.493 0 C-N-CA 124.074 -1.219 . . . . 0.0 113.083 0.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -113.96 144.46 31.6 Favored Pre-proline 0 CA--C 1.542 0.646 0 O-C-N 123.502 0.501 . . . . 0.0 111.101 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.423 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.7 Cg_endo -63.34 157.74 48.66 Favored 'Trans proline' 0 C--N 1.375 1.932 0 C-N-CA 122.938 2.425 . . . . 0.0 113.85 -179.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.517 HG12 ' OG1' ' A' ' 24' ' ' THR . 15.7 mm -123.15 152.88 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.967 -179.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.581 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.7 m -89.13 118.78 29.08 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.703 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.512 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -153.35 142.53 9.29 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 116.206 -0.452 . . . . 0.0 113.182 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.425 HG13 HD23 ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.289 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.845 0 N-CA-C 114.37 1.248 . . . . 0.0 114.37 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.9 m95 -139.47 96.29 3.07 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.906 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.8 p -156.06 160.42 39.97 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.959 179.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.71 119.47 26.97 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.486 179.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . 0.507 ' HB2' ' OE2' ' A' ' 6' ' ' GLU . 11.9 pt-20 -88.07 -156.22 0.35 Allowed 'General case' 0 CA--C 1.545 0.77 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.598 -178.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.507 ' OE2' ' HB2' ' A' ' 5' ' ' GLU . 1.2 pm0 -81.35 113.8 19.69 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 122.714 0.406 . . . . 0.0 111.287 -179.572 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 104.23 5.53 43.24 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.435 -0.802 . . . . 0.0 112.628 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -113.39 159.47 19.41 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 122.638 0.375 . . . . 0.0 110.454 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.7 p -79.92 131.68 35.89 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.866 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.2 p -101.19 29.04 4.92 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.98 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.95 -12.35 55.47 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.702 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.451 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.5 p -121.12 -40.83 1.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.262 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -130.66 153.43 81.52 Favored Pre-proline 0 CA--C 1.536 0.415 0 O-C-N 123.682 0.614 . . . . 0.0 111.317 179.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -70.61 -174.46 1.08 Allowed 'Trans proline' 0 C--N 1.365 1.417 0 C-N-CA 123.277 2.651 . . . . 0.0 112.331 179.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.7 m -80.06 175.39 10.68 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 110.527 -0.175 . . . . 0.0 110.527 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.8 m -115.03 -54.59 2.55 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.821 0.675 . . . . 0.0 112.821 -177.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -86.77 12.91 9.76 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.36 35.81 8.51 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.509 -0.377 . . . . 0.0 112.335 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.583 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.8 mt -79.89 166.89 21.2 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.208 0.603 . . . . 0.0 111.62 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.55 144.41 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.204 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 29.3 m -82.28 104.11 12.36 Favored 'General case' 0 C--O 1.239 0.525 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.206 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -81.22 140.33 49.13 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.506 -179.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.21 64.9 2.07 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 123.003 2.469 . . . . 0.0 112.028 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.53 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.7 p -95.2 152.73 18.1 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.032 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.64 144.19 28.78 Favored Pre-proline 0 C--O 1.234 0.276 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.634 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.539 ' HD2' ' OE2' ' A' ' 27' ' ' GLU . 5.5 Cg_exo -76.25 -35.51 2.86 Favored 'Cis proline' 0 C--N 1.367 1.552 0 C-N-CA 123.986 -1.256 . . . . 0.0 113.333 -0.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.539 ' OE2' ' HD2' ' A' ' 26' ' ' PRO . 1.3 pm0 -111.15 145.53 32.67 Favored Pre-proline 0 CA--C 1.543 0.677 0 O-C-N 123.303 0.377 . . . . 0.0 111.211 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.3 Cg_endo -63.65 156.71 55.6 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.867 2.378 . . . . 0.0 113.489 -179.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.53 HG12 ' OG1' ' A' ' 24' ' ' THR . 13.2 mm -122.42 153.92 27.16 Favored 'Isoleucine or valine' 0 C--O 1.238 0.456 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.002 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.3 m -89.81 119.38 30.15 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.896 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.583 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.2 144.35 10.94 Favored Glycine 0 C--N 1.338 0.688 0 CA-C-N 116.167 -0.469 . . . . 0.0 113.096 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.443 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.146 179.606 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.789 0 N-CA-C 114.373 1.249 . . . . 0.0 114.373 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 81.3 m95 -139.52 96.39 3.08 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.912 179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.1 p -156.11 160.81 40.26 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.985 179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.569 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -86.8 120.43 28.09 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.528 179.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -89.28 -156.09 0.38 Allowed 'General case' 0 CA--C 1.544 0.72 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.62 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -81.29 113.69 19.57 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.948 0.404 . . . . 0.0 111.29 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.85 7.08 42.3 Favored Glycine 0 C--N 1.334 0.467 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.492 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -114.77 159.4 20.64 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 122.71 0.404 . . . . 0.0 110.479 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 64.6 p -79.98 131.43 35.81 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.053 -0.522 . . . . 0.0 111.856 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.576 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 30.9 p -101.47 28.69 5.31 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.004 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.447 ' OE2' ' HB ' ' A' ' 12' ' ' VAL . 0.0 OUTLIER -83.46 -11.94 56.92 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.663 179.926 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.447 ' HB ' ' OE2' ' A' ' 11' ' ' GLU . 14.4 p -121.57 -41.17 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 O-C-N 123.543 0.527 . . . . 0.0 110.191 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -130.24 153.58 81.23 Favored Pre-proline 0 CA--C 1.536 0.425 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.285 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.79 -174.74 1.18 Allowed 'Trans proline' 0 C--N 1.365 1.437 0 C-N-CA 123.214 2.61 . . . . 0.0 112.338 179.157 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.569 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 56.8 m -80.07 175.2 10.86 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 110.579 -0.156 . . . . 0.0 110.579 179.089 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 53.4 m -115.31 -54.81 2.51 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 -177.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -86.33 13.85 7.49 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -178.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.2 35.78 9.4 Favored Glycine 0 C--N 1.341 0.833 0 C-N-CA 121.428 -0.415 . . . . 0.0 112.47 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.573 HD22 ' HA2' ' A' ' 31' ' ' GLY . 2.7 mt -80.03 166.63 21.37 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 123.163 0.585 . . . . 0.0 111.602 -179.48 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.41 144.36 17.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.211 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.1 m -82.28 104.05 12.31 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.272 178.7 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -80.68 140.21 51.1 Favored Pre-proline 0 CA--C 1.531 0.222 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.484 -179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.31 65.21 2.12 Favored 'Trans proline' 0 C--N 1.364 1.379 0 C-N-CA 122.964 2.443 . . . . 0.0 112.101 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.518 ' OG1' HG12 ' A' ' 29' ' ' ILE . 44.3 p -95.27 152.56 18.27 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.899 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -106.86 144.21 28.62 Favored Pre-proline 0 C--O 1.233 0.233 0 O-C-N 123.512 0.507 . . . . 0.0 111.645 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.47 -32.08 4.74 Favored 'Cis proline' 0 C--N 1.368 1.578 0 C-N-CA 123.961 -1.266 . . . . 0.0 113.137 0.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -114.12 144.49 31.73 Favored Pre-proline 0 CA--C 1.542 0.652 0 O-C-N 123.515 0.509 . . . . 0.0 111.099 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.5 Cg_endo -63.21 157.47 49.55 Favored 'Trans proline' 0 C--N 1.374 1.871 0 C-N-CA 123.015 2.476 . . . . 0.0 113.859 -179.455 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.518 HG12 ' OG1' ' A' ' 24' ' ' THR . 14.5 mm -122.98 154.41 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.863 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.6 m -90.34 119.55 30.73 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.873 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.573 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -155.48 144.27 10.79 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 116.013 -0.54 . . . . 0.0 113.046 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.433 HG13 HD23 ' A' ' 19' ' ' LEU . 1.2 m . . . . . 0 C--O 1.25 1.109 0 CA-C-O 118.094 -0.955 . . . . 0.0 111.182 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 114.35 1.241 . . . . 0.0 114.35 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -139.76 96.71 3.12 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.833 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p -156.9 162.42 39.65 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.721 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 15' ' ' CYS . . . -85.73 122.74 30.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.659 179.298 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -88.62 -155.74 0.34 Allowed 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.556 -178.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.552 ' HG2' HD21 ' A' ' 19' ' ' LEU . 2.3 mt-10 -83.59 116.26 22.52 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 120.926 0.393 . . . . 0.0 110.527 -179.313 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.14 6.4 51.62 Favored Glycine 0 CA--C 1.522 0.509 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.71 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -112.93 160.81 17.69 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 122.562 0.345 . . . . 0.0 110.646 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 78.8 p -79.72 136.18 36.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.677 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.515 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 31.7 p -108.38 34.48 3.61 Favored 'General case' 0 CA--C 1.539 0.545 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.18 -179.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -86.67 -15.35 39.89 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.753 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.4 p -118.06 -41.59 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 O-C-N 123.42 0.45 . . . . 0.0 110.086 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 22.3 m-85 -128.14 153.58 78.64 Favored Pre-proline 0 CA--C 1.537 0.464 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.189 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.22 -171.19 0.66 Allowed 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 123.31 2.674 . . . . 0.0 112.424 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 59.4 m -82.05 176.79 9.24 Favored 'General case' 0 CA--C 1.54 0.558 0 O-C-N 123.132 0.27 . . . . 0.0 110.402 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 43.3 m -118.23 -55.46 2.23 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.1 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -85.73 13.0 7.78 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -178.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.2 35.57 8.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 121.432 -0.413 . . . . 0.0 112.391 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.552 HD21 ' HG2' ' A' ' 6' ' ' GLU . 2.3 mt -80.07 166.68 21.29 Favored 'General case' 0 C--O 1.236 0.379 0 C-N-CA 123.178 0.591 . . . . 0.0 111.51 -179.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 6.6 mt -110.48 143.33 20.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.091 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 28.7 m -81.37 103.3 11.03 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.223 178.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 36.0 m-85 -80.45 140.42 52.06 Favored Pre-proline 0 CA--C 1.529 0.153 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.546 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.38 65.09 2.17 Favored 'Trans proline' 0 C--N 1.366 1.483 0 C-N-CA 122.955 2.437 . . . . 0.0 112.041 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.524 ' OG1' HG12 ' A' ' 29' ' ' ILE . 48.7 p -95.46 151.52 19.22 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.863 -178.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -105.97 144.25 28.54 Favored Pre-proline 0 C--O 1.235 0.298 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.716 -179.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -77.65 -31.33 5.24 Favored 'Cis proline' 0 C--N 1.367 1.523 0 C-N-CA 123.99 -1.254 . . . . 0.0 113.115 0.142 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -114.44 144.56 32.02 Favored Pre-proline 0 CA--C 1.541 0.617 0 O-C-N 123.487 0.492 . . . . 0.0 111.172 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.417 ' HA ' ' OG1' ' A' ' 24' ' ' THR . 28.3 Cg_endo -63.5 157.78 49.06 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.877 2.385 . . . . 0.0 113.565 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.524 HG12 ' OG1' ' A' ' 24' ' ' THR . 16.4 mm -124.35 152.59 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.97 -179.795 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.515 ' SG ' ' HB3' ' A' ' 10' ' ' CYS . 2.2 m -88.67 118.54 28.41 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.782 179.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.51 ' HA2' HD22 ' A' ' 19' ' ' LEU . . . -152.78 142.76 9.58 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 116.138 -0.483 . . . . 0.0 113.101 -179.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.423 HG13 HD23 ' A' ' 19' ' ' LEU . 1.3 m . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.475 -0.774 . . . . 0.0 111.228 179.617 . . . . . . . . 1 1 . 1 stop_ save_